<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10458847</article-id><article-id pub-id-type="pmcid-ver">PMC10458847.1</article-id><article-id pub-id-type="pmcaid">10458847</article-id><article-id pub-id-type="pmcaiid">10458847</article-id><article-id pub-id-type="pmid">37631328</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics15082114</article-id><article-id pub-id-type="publisher-id">pharmaceutics-15-02114</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="S">Sumin</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="P">Panjae</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8233-5864</contrib-id><name name-style="western"><surname>Choi</surname><given-names initials="HJ">Hyo-Jick</given-names></name><xref rid="c1-pharmaceutics-15-02114" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Lu</surname><given-names initials="W">Wei</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-15-02114">Department of Chemical and Materials Engineering, University of Alberta, Edmonton, AB T6G 1H9, Canada; <email>sumin3@ualberta.ca</email> (S.H.); <email>panjae@ualberta.ca</email> (P.L.)</aff><author-notes><corresp id="c1-pharmaceutics-15-02114"><label>*</label>Correspondence: <email>hyojick@ualberta.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>8</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2023</year></pub-date><volume>15</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">444092</issue-id><elocation-id>2114</elocation-id><history><date date-type="received"><day>13</day><month>7</month><year>2023</year></date><date date-type="rev-recd"><day>07</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>08</day><month>8</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>08</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>27</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-05 18:25:17.050"><day>05</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-15-02114.pdf"/><abstract><p>Given the limitations of conventional invasive vaccines, such as the requirement for a cold chain system and trained personnel, needle-based injuries, and limited immunogenicity, non-invasive vaccines have gained significant attention. Although numerous approaches for formulating and administrating non-invasive vaccines have emerged, each of them faces its own challenges associated with vaccine bioavailability, toxicity, and other issues. To overcome such limitations, researchers have created novel supplementary materials and delivery systems. The goal of this review article is to provide vaccine formulation researchers with the most up-to-date information on vaccine formulation and the immunological mechanisms available, to identify the technical challenges associated with the commercialization of non-invasive vaccines, and to guide future research and development efforts.</p></abstract><kwd-group><kwd>non-invasive</kwd><kwd>vaccines</kwd><kwd>oral</kwd><kwd>intranasal</kwd><kwd>transcutaneous</kwd></kwd-group><funding-group><award-group><funding-source>Natural Sciences and Engineering Research Council of Canada (NSERC)</funding-source><award-id>RGPIN-2018-04314</award-id></award-group><funding-statement>This research was financially supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant [RGPIN-2018-04314]. The funders had no role in the study design, the data collection and analysis, the decision to publish, or the preparation of the manuscript.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-15-02114"><title>1. Introduction</title><p>Vaccine administration methods can be categorized into invasive, minimally invasive, and non-invasive administration, and conventional vaccine administration primarily relies on invasive administration (e.g., intramuscular, subcutaneous, and intradermal) to maximize vaccine bioavailability through site-specific administration. However, such methods of administration have inherent limitations that compromise their utility (<xref rid="pharmaceutics-15-02114-f001" ref-type="fig">Figure 1</xref>). Firstly, liquid formulations used in these methods necessitate a cold chain system, making them susceptible to accidental freezing [<xref rid="B1-pharmaceutics-15-02114" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-15-02114" ref-type="bibr">2</xref>]. Certain temperature ranges can drastically reduce the shelf life of vaccines, with examples including the Pfizer-BioNTech (&lt;6 months at &#8722;60 to &#8722;90 &#176;C and &lt;2 h at 8&#8211;30 &#176;C), ModernaTX (&lt;30 days at 2&#8211;8 &#176;C and &lt;12 h at 8&#8211;25 &#176;C), and Oxford-AstraZeneca (&lt;6 months at 2&#8211;8 &#176;C and &lt;2 h at 8&#8211;25 &#176;C) SARS-CoV-2 vaccines [<xref rid="B3-pharmaceutics-15-02114" ref-type="bibr">3</xref>]. mRNA vaccines are especially easily affected by changes in liquid formulation (i.e., pH, buffers, temperature, amount of oxygen, etc.), which can lead to the degradation of the vaccines through hydrolysis [<xref rid="B4-pharmaceutics-15-02114" ref-type="bibr">4</xref>].</p><p>Second, the use of needle-based delivery of liquid vaccines also presents technical and safety concerns. The variability in adipose tissue thickness among individuals necessitates adjusting the needle length based on body weight and sex. For instance, a needle length of 1 inch is recommended for individuals weighing less than 70 kg, 1&#8211;1.25 inches for men weighing 70&#8211;118 kg and women weighing 70&#8211;90 kg, and 1.5 inches for men weighing over 118 kg and women weighing over 90 kg [<xref rid="B2-pharmaceutics-15-02114" ref-type="bibr">2</xref>,<xref rid="B5-pharmaceutics-15-02114" ref-type="bibr">5</xref>]. Achieving accurate administration requires specialized personnel and proper setups, posing challenges for vaccination in isolated communities and developing countries with limited resources and personnel. Furthermore, needle-based administration carries the risk of needlestick injuries and the transmission of bloodborne pathogens to the injection site (e.g., hepatitis B, hepatitis C, and human immunodeficiency virus (HIV)) [<xref rid="B6-pharmaceutics-15-02114" ref-type="bibr">6</xref>].</p><p>Third, invasive vaccines primarily elicit systemic immune responses in the lower respiratory tract, unlike natural infections that stimulate robust, both systemic and mucosal immunities [<xref rid="B7-pharmaceutics-15-02114" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-15-02114" ref-type="bibr">8</xref>]. While systemic immune responses can provide disease-attenuating or disease-preventing immunity through the production of immunoglobulin G (IgG) [<xref rid="B7-pharmaceutics-15-02114" ref-type="bibr">7</xref>], the limited mucosal immunity in the lower respiratory tract can hinder the elimination of pathogens in the early stages, potentially exacerbating disease severity. On the other hand, minimally invasive and non-invasive vaccines can achieve mucosal vaccination that initiates both robust systemic and mucosal immunities, thereby efficiently preventing pathogens from developing severe disease [<xref rid="B9-pharmaceutics-15-02114" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-15-02114" ref-type="bibr">10</xref>].</p><p>Invasive vaccines have demonstrated high stability and safety when administered correctly, leading to their predominant use in present-day vaccine delivery. However, due to the aforementioned limitations, there is a growing demand for the development of alternative vaccines, and minimally invasive and non-invasive vaccines have been actively researched as promising candidates. The scope of this manuscript primarily revolves around non-invasive vaccines, which have undergone more comprehensive studies and research compared to minimally invasive vaccines. This review aims to shed light on the advantages and challenges of non-invasive vaccine approaches, along with conventional invasive counterparts, while providing valuable insights into their formulation strategies.</p></sec><sec id="sec2-pharmaceutics-15-02114"><title>2. Types of Vaccines and Their Formulation</title><p>Since Louis Pasteur&#8217;s groundbreaking conceptualization of vaccination, significant advancements have been made in the development of vaccines in terms of their stability and effectiveness [<xref rid="B11-pharmaceutics-15-02114" ref-type="bibr">11</xref>]. To date, seven types of vaccines have been developed: live attenuated, inactivated, replicating viral vector, non-replicating viral vector, DNA, RNA, and subunit vaccines. Each vaccine type leverages distinct immunological mechanisms to trigger adaptive immunity upon administration [<xref rid="B12-pharmaceutics-15-02114" ref-type="bibr">12</xref>]. Replicable vaccines, including live attenuated vaccines, replicating viral vector vaccines, and replicating nucleic acid vaccines, enter host cells and replicate virulent molecules, which are subsequently taken up by dendritic cells (DCs). In contrast, non-replicable vaccines, such as non-replicating viral vector vaccines, inactivated vaccines, subunit vaccines, and non-replicating nucleic acid vaccines, are directly phagocytosed by DCs [<xref rid="B12-pharmaceutics-15-02114" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-15-02114" ref-type="bibr">13</xref>]. Replicable vaccines are characterized by prolonged immunogenicity compared to non-replicable vaccines due to their ability to replicate. Whole-particle-based vaccines, such as live attenuated and inactivated vaccines, exhibit the highest immunogenicity compared to other types of vaccines due to the presence of immunostimulant molecules within the particles, effectively inducing immunity similar to that of natural infections [<xref rid="B14-pharmaceutics-15-02114" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-15-02114" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-15-02114" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-15-02114" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-15-02114" ref-type="bibr">18</xref>].</p><p>Following the phagocytosis, DCs carrying vaccine particles migrate to the draining lymph node, where they present peptides derived from the vaccine antigens on the major histocompatibility complex (MHC) class II or MHC class I molecules. MHC II activation stimulates CD4<sup>+</sup> T cells (T helper cells), including T helper (Th) 1 cells and Th2 cells [<xref rid="B19-pharmaceutics-15-02114" ref-type="bibr">19</xref>]. Th1 cells play a role in cell-mediated immunity by secreting interferon-gamma (IFN-&#947;), a proinflammatory cytokine that eliminates external pathogenic particles [<xref rid="B20-pharmaceutics-15-02114" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-15-02114" ref-type="bibr">21</xref>]. Th1 cells also activate CD8<sup>+</sup> T cells (cytotoxic T cells) by interacting with MHC I [<xref rid="B22-pharmaceutics-15-02114" ref-type="bibr">22</xref>]. This interaction leads to the production of granzymes, which induce apoptosis, and the pore-forming protein perforin, which physically damages the target cell membrane, allowing granzymes to enter the cell [<xref rid="B23-pharmaceutics-15-02114" ref-type="bibr">23</xref>]. In contrast, Th2 cells initiate humoral immunity by producing interleukin-4 (IL-4), IL-5, and IL-13, which promote the proliferation and maturation of B cells. Additionally, Th2 cells produce anti-inflammatory IL-10, which modulates the inflammatory responses of Th1 cells (<xref rid="pharmaceutics-15-02114-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B20-pharmaceutics-15-02114" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-15-02114" ref-type="bibr">21</xref>].</p><sec id="sec2dot1-pharmaceutics-15-02114"><title>2.1. Live Attenuated Vaccines</title><p>Live attenuated vaccines (LAVs) consist of live bacteria or virus particles that have been weakened but retain the ability to initiate immune responses. The production of live attenuated vaccines involves either natural or engineered mutations. In natural production, bacteria or viruses are subjected to multiple passages through different species in a process known as serial passage exposure experiments (SPEs) [<xref rid="B24-pharmaceutics-15-02114" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-15-02114" ref-type="bibr">25</xref>]. For example, weakened <italic toggle="yes">Theileria annulata</italic> loses its virulence against its original host, cattle, after undergoing 50&#8211;100 passages of in vitro culturing [<xref rid="B26-pharmaceutics-15-02114" ref-type="bibr">26</xref>]. This loss of virulence is attributed to alterations or selections in gene expression triggered by environmental changes. In the case of viruses, genetic modifications can occur even more rapidly. For example, nucleopolyhedrosis viruses (NPVs) have been shown to lose virulence against three out of their six original hosts after eight passages in <italic toggle="yes">Pseudoplusia includens</italic> [<xref rid="B27-pharmaceutics-15-02114" ref-type="bibr">27</xref>].</p><p>Engineered mutation involves the use of transposon mutagenesis, which facilitates the translocation of repetitive DNA sequences to the host cell nucleus, thereby introducing random mutations in the host gene [<xref rid="B28-pharmaceutics-15-02114" ref-type="bibr">28</xref>]. Another method, gamma rays, is commonly employed to induce DNA strand breaks and oxidative stress in viruses, leading to single base substitutions. However, such mutagenesis techniques often raise safety concerns, including the potential re-emergence of virulence upon repeated exposures to the same host or the restoration of mutated gene sites [<xref rid="B24-pharmaceutics-15-02114" ref-type="bibr">24</xref>]. Historical examples of virulence re-emergence include the poliovirus vaccine in 1964, the yellow fever vaccine in 2008, and the rotavirus vaccine in 2009 [<xref rid="B29-pharmaceutics-15-02114" ref-type="bibr">29</xref>]. As a result, research has been focused on developing methods to prevent pathogens from regaining virulence.</p><p>One strategy to minimize the re-emergence of virulence is to selectively choose variants with high genetic fidelity for vaccine development [<xref rid="B30-pharmaceutics-15-02114" ref-type="bibr">30</xref>]. Another approach is multi-region replacement, often combined with gene targeting methods, which involves increasing the number of mutated regions to decrease the probability of mutations reverting to their original state. For example, codon deoptimization replaces conventional codons with synonymous codons, resulting in the same level of immune responses with reduced virulence and re-emergence [<xref rid="B30-pharmaceutics-15-02114" ref-type="bibr">30</xref>]. Studies have shown that after achieving 97% codon replacement in the contiguous capsid region of polioviruses, the transmission rate in host cells decreased by more than 10-fold [<xref rid="B31-pharmaceutics-15-02114" ref-type="bibr">31</xref>]. Undesirable mutations can be minimized using small interfering RNA (siRNA) and microRNA (miRNA), which target specific genes for degradation and repress the translation of respective proteins. Zinc finger (ZF) domains, which are protein motifs with finger-like protrusions that bind to DNA, can also be utilized to target specific genetic sites. ZF domains are typically engineered to express multiple types of domains, such as restriction enzymes, to suppress gene transcription or replication origin-competing domains to reduce virus replication [<xref rid="B30-pharmaceutics-15-02114" ref-type="bibr">30</xref>].</p></sec><sec id="sec2dot2-pharmaceutics-15-02114"><title>2.2. Inactivated Vaccines</title><p>Inactivated vaccines offer a high level of safety compared to live attenuated vaccines, as they are free of concerns regarding virulence reversion and transmission [<xref rid="B29-pharmaceutics-15-02114" ref-type="bibr">29</xref>]. However, these vaccines tend to have relatively low immunogenicity compared to live attenuated vaccines [<xref rid="B29-pharmaceutics-15-02114" ref-type="bibr">29</xref>]. Therefore, the design of inactivated vaccines must consider two key factors: complete pathogen inactivation and epitope conservation. Meeting the aforementioned requirements requires a comprehensive study of various virus behaviors, including aggregation, protein crosslinking, protein denaturation, and degradation [<xref rid="B32-pharmaceutics-15-02114" ref-type="bibr">32</xref>].</p><p>Delrue (2012) has described the mechanism and chemical reactions involved in different inactivation treatments, such as formaldehyde, glutaraldehyde, 2,2&#8242;-dethiodipyridine, &#946;-propiolactone (BPL), binary ethylene imine, pH, temperature, gamma irradiation, and ultraviolet light [<xref rid="B32-pharmaceutics-15-02114" ref-type="bibr">32</xref>]. Among these treatments, formaldehyde and &#946;-propiolactone (BPL) have been most commonly used in vaccine development for many years [<xref rid="B29-pharmaceutics-15-02114" ref-type="bibr">29</xref>]. Formaldehyde primarily acts by deforming the adenine residues of genes and amino acids through monohydroxymethylation (NH-CH<sub>2</sub>OH), which creates a methylene spacer (-CH<sub>2</sub>-) that bridges two independent molecules. On the other hand, BPL primarily alkylates the guanine residues of genes, thereby disrupting the reading of sequences [<xref rid="B32-pharmaceutics-15-02114" ref-type="bibr">32</xref>]. Unlike formaldehyde, BPL treatments preserve the intact epitopes of antigens, leading to greater immunogenicity [<xref rid="B29-pharmaceutics-15-02114" ref-type="bibr">29</xref>]. Currently, three inactivated vaccines for SARS-CoV-2 have received FDA approval [<xref rid="B33-pharmaceutics-15-02114" ref-type="bibr">33</xref>]. All three vaccines (Coronavac&#8212;Sinovac, Covaxin (BBV152)&#8212;Bharat Biotech International, and COVID-19 vaccine (Vero cell)&#8212;Sinopharm) employ BPL for the inactivation of the whole SARS-CoV-2 virus [<xref rid="B34-pharmaceutics-15-02114" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-15-02114" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-15-02114" ref-type="bibr">36</xref>]. However, inactivated vaccines face limitations, as they may exhibit poor clearance of unnecessary viral molecules from the human body, which could interact with and harm host cells. Additionally, the process of culturing whole viruses is considered time-consuming compared to gene-based vaccines that can be rapidly amplified [<xref rid="B19-pharmaceutics-15-02114" ref-type="bibr">19</xref>]. Consequently, there has been a significant shift in the industry towards simpler vaccine forms, such as recombinant DNA and protein subunits [<xref rid="B37-pharmaceutics-15-02114" ref-type="bibr">37</xref>].</p></sec><sec id="sec2dot3-pharmaceutics-15-02114"><title>2.3. Replicating and Non-Replicating Viral Vector Vaccines</title><p>Replicating and non-replicating viral vector vaccines have been developed to minimize the insertion of pathogenic molecules into the human body. These vaccines utilize different types of vectors to deliver the desired viral genes. Replicating viral vector vaccines employ various vectors such as adenovirus, measles virus, poxviruses, and vesicular stomatitis virus, while non-replicating viral vector vaccines use adenovirus, adeno-associated virus, alphavirus, herpesvirus, and poxviruses [<xref rid="B17-pharmaceutics-15-02114" ref-type="bibr">17</xref>]. The selection of these vectors is based on their genetic safety, high immunogenicity, and low likelihood of pre-existing immunity in hosts [<xref rid="B38-pharmaceutics-15-02114" ref-type="bibr">38</xref>].</p><p>The main distinction between replicating and non-replicating viral vectors lies in their ability to replicate genes within hosts, and non-replicating viral vectors are engineered to lack gene-replicating sites [<xref rid="B39-pharmaceutics-15-02114" ref-type="bibr">39</xref>]. As an example, non-replicating adenovirus vectors (such as adenovirus serotype 5, 26, 35) have undergone modifications where the replicating site, Early region 1 (E1), is removed and replaced with an expression cassette that contains a highly active promoter responsible for expressing the inserted foreign gene [<xref rid="B40-pharmaceutics-15-02114" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-15-02114" ref-type="bibr">41</xref>]. Similarly, vesicular stomatitis virus (VSV) vectors lack the glycoprotein (G) responsible for attaching to host cells, rendering them unable to infect host cells [<xref rid="B38-pharmaceutics-15-02114" ref-type="bibr">38</xref>]. Integrase-defective lentiviral vectors (IDLVs) serve as another example of non-replicating viral vectors that lack genes inducing pathogenicity, including replicating genes such as Tat, Rev, Nef, Vif, Vpr, Vpu, Vpx, dUTPase, and open reading frames (ORFs) [<xref rid="B42-pharmaceutics-15-02114" ref-type="bibr">42</xref>]. However, non-replicating viral vectors require relatively high doses or frequent revaccination due to their inability to replicate [<xref rid="B38-pharmaceutics-15-02114" ref-type="bibr">38</xref>]. Furthermore, these vectors have the potential to induce mutagenesis in wild-type viruses [<xref rid="B43-pharmaceutics-15-02114" ref-type="bibr">43</xref>]. In contrast, replicating viral vectors can generate long-lasting immunity even with smaller doses due to their replicability. The replicating viral vectors elicit immune responses similar to natural infections, triggering the production of cytokines and other stimulatory factors that can act as adjuvants [<xref rid="B38-pharmaceutics-15-02114" ref-type="bibr">38</xref>]. As a result, extensive research has been dedicated to developing replicating viral vector vaccines against diverse viruses (e.g., influenza, HIV, hepatitis B virus) [<xref rid="B44-pharmaceutics-15-02114" ref-type="bibr">44</xref>]. However, replicating viral vector vaccines raise immune-related safety concerns, particularly in immunocompromised patients. Additionally, the presence of gene-replicating sites in these vectors limits their capacity to accommodate the insertion of small-sized genes (e.g., 7&#8211;9 kb for non-replicating adenovirus vectors and 3&#8211;4 kb for replicating adenovirus vectors) [<xref rid="B17-pharmaceutics-15-02114" ref-type="bibr">17</xref>].</p></sec><sec id="sec2dot4-pharmaceutics-15-02114"><title>2.4. DNA Vaccines</title><p>The production of DNA vaccines mostly involves genetic modifications of plasmids derived from <italic toggle="yes">Escherichia coli</italic>. Subsequently, the modified plasmids are cultivated under fermentation conditions in an anaerobic condition using glycerol, yeast extract, and MgSO<sub>4</sub> as carbon, nitrogen, and trace metal sources, respectively. The replicated plasmids can be used directly as genetic vectors after undergoing lysis and purification [<xref rid="B45-pharmaceutics-15-02114" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-15-02114" ref-type="bibr">46</xref>]. Conventionally, non-live and non-replicating plasmids have been considered prototypical platforms for DNA vaccines; however, due to their low immunogenicity, replicating DNA vaccines have been considered a potential alternative. In general, replicating DNA vaccines are manufactured by combining eukaryotic promoters (e.g., human cytomegalovirus (CMV) immediate promoters and enhancers) and replicon sequences of alphaviruses [<xref rid="B14-pharmaceutics-15-02114" ref-type="bibr">14</xref>,<xref rid="B47-pharmaceutics-15-02114" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-15-02114" ref-type="bibr">48</xref>]. Furthermore, incorporating additional gene inserts, such as adjuvant coding sequences, has been attempted to enhance the immunogenicity of DNA vaccines [<xref rid="B49-pharmaceutics-15-02114" ref-type="bibr">49</xref>]. For example, incorporating unmethylated CpG motifs into a DNA vaccine has been shown to function as a type of pathogen-associated molecular pattern (PAMP), which can be utilized to boost vaccine-initiated immune responses [<xref rid="B50-pharmaceutics-15-02114" ref-type="bibr">50</xref>].</p><p>Currently, two types of DNA vaccines have been developed: circular vaccines (i.e., minicircle, minivector, miniknot, etc.) and linear vaccines, including immunological-defined gene expression (MIDGE), Micro-Linear vector (MiLV), and Doggybone<sup>TM</sup> DNA, which are covalently closed (<xref rid="pharmaceutics-15-02114-f003" ref-type="fig">Figure 3</xref>). In the case of minicircle (mc) DNA, recombinases are used to separate a plasmid into an mc DNA molecule (containing the genes of interest) and a miniplasmid (containing the bacterial plasmid backbone). This is followed by degradation of the miniplasmid using restriction enzymes [<xref rid="B45-pharmaceutics-15-02114" ref-type="bibr">45</xref>,<xref rid="B51-pharmaceutics-15-02114" ref-type="bibr">51</xref>]. Studies have shown that mc DNA exhibits a significantly higher transfection rate (68%) compared to the parental plasmid (34%) due to its smaller size (3.8 kbp) in contrast to the parental plasmid (8.2 kbp) [<xref rid="B52-pharmaceutics-15-02114" ref-type="bibr">52</xref>]. Minivector DNA is a single-stranded and supercoiled structure of less than 2 kbp in size and less than 4 nm in diameter, and is produced through treatments with recombinases (site-specific cleavage) and topoisomerase IV (separation of the daughter DNA) [<xref rid="B53-pharmaceutics-15-02114" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceutics-15-02114" ref-type="bibr">54</xref>]. The size difference between the miniplasmid and minivector contributes to the ease of the separation process, contributing to the high purity of the minivector DNA [<xref rid="B53-pharmaceutics-15-02114" ref-type="bibr">53</xref>]. A miniknot is an mc DNA strand treated with topoisomerase II, which enhances its physical strength to prevent linearization during processing. However, the use of miniknots is still in a hypothetical stage.</p><p>The MIDGE (2.9 kbp) and MiLV (1.7 kb) vaccines are produced in a similar manner, but they utilize different parental plasmids. This process entails the cleavage of sites containing the genes of interest using a restriction enzyme, followed by the ligation of the sticky ends of the cleaved sites with hairpin oligodeoxynucleotides to stabilize the structure [<xref rid="B43-pharmaceutics-15-02114" ref-type="bibr">43</xref>,<xref rid="B55-pharmaceutics-15-02114" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-15-02114" ref-type="bibr">56</xref>]. The Doggybone<sup>TM</sup> (2.6 kbp) vaccine is also created using plasmids. In this process, plasmids are initially denatured by NaOH, resulting in the production of single-stranded DNA that acts as a template for rolling circle amplification. The amplified single-stranded DNA is then polymerized to form a double-stranded DNA concatemer. This concatemer is subsequently treated with Te1N protelomerase, which recognizes the telomeric ends (Tel-L and Tel-R) and cleaves the linear DNA while covalently closing it. This step removes the bacterial plasmid backbone from the sites containing the genes of interest [<xref rid="B57-pharmaceutics-15-02114" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceutics-15-02114" ref-type="bibr">58</xref>]. However, the yield of mc DNA (0.1&#8211;8.84 mg/L) is generally much lower compared to conventional plasmids (2.2 g/L of fermentation), and other engineered plasmids are also expected to have lower yields due to physical loss and size reduction during processing [<xref rid="B51-pharmaceutics-15-02114" ref-type="bibr">51</xref>]. Additionally, although DNA vaccines have exhibited satisfactory immunogenicity in small animals such as rodents, there is a need for improvement when it comes to large animals and humans [<xref rid="B59-pharmaceutics-15-02114" ref-type="bibr">59</xref>].</p></sec><sec id="sec2dot5-pharmaceutics-15-02114"><title>2.5. mRNA Vaccine</title><p>During the initial stages of nucleic acid-based vaccine development, DNA was considered a preferable option to RNA due to its stability and potential for mass production. However, DNA vaccines have shown limited potency in humans and potential risks of integration of inserted DNA into the host genome [<xref rid="B15-pharmaceutics-15-02114" ref-type="bibr">15</xref>]. In contrast, mRNA vaccines provide certain advantages over DNA vaccines as there is no concern about integration into the host genome. Additionally, since mRNA vaccines are not required to cross the nuclear membrane to initiate the translation process, they tend to have higher immunogenicity than DNA vaccines [<xref rid="B60-pharmaceutics-15-02114" ref-type="bibr">60</xref>]. Consequently, numerous trials have been conducted to develop mRNA vaccines, encompassing both non-replicating and replicating mRNA variants.</p><p>Conventionally, to achieve mass production of mRNA vaccines, mRNA is initially extracted from pathogen particles and converted into complementary DNA (cDNA) through a process called reverse transcription. The cDNA is subsequently inserted into a plasmid and linearized using restriction enzymes to create a 3&#8242; end sequence to achieve similar structure to the original mRNA, followed by transcription of the cDNA in host cells [<xref rid="B61-pharmaceutics-15-02114" ref-type="bibr">61</xref>]. Nowadays, in vitro transcription is also widely used in mRNA mass production, with a simpler procedure that consists of the insertion of the target gene into DNA templates followed by RNA amplification [<xref rid="B62-pharmaceutics-15-02114" ref-type="bibr">62</xref>]. The transcribed mRNA contains specific components. These components include a 5&#8242; cap, which regulates translation along with the poly(A) tail, a 5&#8242; untranslated region that regulates mRNA translation, an open reading frame that represents the gene of interest, a 3&#8242; untranslated region that regulates mRNA translation, and a poly(A) tail that enhances the stability of the mRNA [<xref rid="B63-pharmaceutics-15-02114" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-15-02114" ref-type="bibr">64</xref>,<xref rid="B65-pharmaceutics-15-02114" ref-type="bibr">65</xref>].</p><p>Replicating RNA vaccines are primarily developed from alphaviruses. For this, the nsP1-4 genes from alphaviruses are extracted and incorporated into conventional non-replicating RNA. Once inside the host cells, these genes are translated into nsP1-4 proteins, which then assemble into an RNA-dependent RNA polymerase (RdRp) complex. This RdRp complex initiates the replication process for RNA, allowing for the amplification of the target gene [<xref rid="B66-pharmaceutics-15-02114" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceutics-15-02114" ref-type="bibr">67</xref>].</p><p>In terms of immunogenicity, replicating mRNA vaccines are preferred over non-replicating mRNA vaccines. This preference arises from the fact that replicating mRNA vaccines can replicate and maintain replication sites, thereby potentially enhancing their immunogenicity [<xref rid="B66-pharmaceutics-15-02114" ref-type="bibr">66</xref>].</p><p>mRNA vaccines necessitate the use of delivery vehicles due to their electronegativity and large molecular weight (10<sup>5</sup>&#8211;10<sup>6</sup> Da). The negative charge of mRNA, stemming from its phosphate residues, causes repulsion with the anionic phospholipids in the lipid bilayer membrane of host cells [<xref rid="B68-pharmaceutics-15-02114" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceutics-15-02114" ref-type="bibr">69</xref>]. Furthermore, mRNA is three to four times larger than other molecules that can easily enter host cells, such as small interfering RNAs (14 kDa) and antisense oligonucleotides (4&#8211;10 kDa) [<xref rid="B70-pharmaceutics-15-02114" ref-type="bibr">70</xref>].</p><p>To address this requirement, lipid nanoparticles and polymeric nanoparticles have been extensively investigated as potential delivery vehicles for mRNA. Specifically, cationic lipids have commonly been used for lipid nanoparticles due to their capacity to readily interact with negatively charged mRNA. However, their use has been linked to liver damage and inflammation resulting from interactions with molecules in the body [<xref rid="B68-pharmaceutics-15-02114" ref-type="bibr">68</xref>]. To tackle this issue, ionizable lipids have been developed. These lipids carry a positive charge under acidic conditions but become neutral at physiological pH [<xref rid="B71-pharmaceutics-15-02114" ref-type="bibr">71</xref>]. This ionizable property allows them to associate with mRNA under acidic conditions while reducing toxicity in host cells at neutral pH. To date, five different types of ionizable lipids have been developed: unsaturated ionizable lipids, multi-tail ionizable lipids, ionizable polymer&#8211;lipids, biodegradable ionizable lipids, and branch-tail ionizable lipids [<xref rid="B71-pharmaceutics-15-02114" ref-type="bibr">71</xref>].</p><p>Lipid nanoparticles are typically formulated with various types of lipids, including cholesterol, polyethylene glycol (PEG) lipid, and phospholipids, in varying composition ratios. Each component has a distinct purpose. For instance, cholesterol enhances the integrity and rigidity of the particles, while PEG lipid reduces particle aggregation and enhances interaction with ligands on target cells [<xref rid="B72-pharmaceutics-15-02114" ref-type="bibr">72</xref>]. The properties of phospholipids are determined by lipid saturation. For example, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), which consists of saturated lipids, forms a stable lamellar shape that maintains excellent stability over time. In contrast, unsaturated lipids like 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and dioleoylphosphatidylcholine (DOPE) undergo a transition from a lamellar shape to an inverted conical shape at room temperature due to their lower phase transition temperature, enhancing the efficiency of cargo release from the vehicle [<xref rid="B73-pharmaceutics-15-02114" ref-type="bibr">73</xref>].</p><p>In addition to lipids, polymeric materials have undergone extensive research for efficient delivery of nucleic acids. Cationic polymers such as poly(lysine), poly(ethylene imine) (PEI), and poly(amidoamine) dendrimers exhibit high transfection efficiency but can be cytotoxic as lipid nanoparticles. Therefore, degradable materials like water-soluble lipopolymer (WSLP) are often combined with cationic polymers to reduce toxicity and prevent accumulation [<xref rid="B74-pharmaceutics-15-02114" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceutics-15-02114" ref-type="bibr">75</xref>]. Chitosan, known for its biocompatibility, biodegradability, and low cost, is another promising candidate for mRNA delivery. However, its efficacy is not as pronounced as PEI due to its insolubility at physiological pH [<xref rid="B76-pharmaceutics-15-02114" ref-type="bibr">76</xref>]. To achieve high transfection efficiency and low toxicity, biodegradable polyesters containing cationic side chains have been synthesized, including poly(L-lactide-co-L-lysine), poly(serine ester), poly(4-hydroxy-L-proline ester), and poly [R-(4-aminobutyl)-L-glycolic acid] [<xref rid="B74-pharmaceutics-15-02114" ref-type="bibr">74</xref>].</p></sec><sec id="sec2dot6-pharmaceutics-15-02114"><title>2.6. Subunit Vaccine</title><p>Subunit vaccines have been developed to address safety concerns related to whole-particle-based vaccines. These vaccines can be categorized as protein, polysaccharide, conjugate, virus-like particle (VLP), and toxoid vaccines [<xref rid="B29-pharmaceutics-15-02114" ref-type="bibr">29</xref>,<xref rid="B77-pharmaceutics-15-02114" ref-type="bibr">77</xref>]. The production of protein-based subunit vaccines involves the harvest and purification of antigens from bacteria using recombinant DNA encoding the target protein. This is often followed by coupling with carriers (i.e., liposome, polymeric nanoparticles, etc.) to enhance the antigen&#8217;s stability against environmental changes in the body, such as pH variations and enzymatic activity [<xref rid="B77-pharmaceutics-15-02114" ref-type="bibr">77</xref>].</p><p>Polysaccharide vaccines are derived from bacterial polysaccharide capsules and primarily induce B cell immune responses [<xref rid="B78-pharmaceutics-15-02114" ref-type="bibr">78</xref>]. However, these vaccines are unable to elicit T cell immune responses as polysaccharides are considered T-independent antigens [<xref rid="B79-pharmaceutics-15-02114" ref-type="bibr">79</xref>]. To enhance immunogenicity and promote long-term immunity, polysaccharide vaccines are often combined with immunogenic carrier proteins and form conjugate vaccines [<xref rid="B80-pharmaceutics-15-02114" ref-type="bibr">80</xref>]. Currently, there are five licensed immunogenic carrier proteins: genetically modified cross-reacting material (CRM), tetanus (T) toxoid, diphtheria (D) toxoid, outer membrane protein complex (OMPC), and <italic toggle="yes">Haemophilus influenzae</italic> protein D (HiD) [<xref rid="B81-pharmaceutics-15-02114" ref-type="bibr">81</xref>]. CRM is a toxin isolated from <italic toggle="yes">Corynebacterium diphtheriae</italic> and is often modified through mutations to reduce toxicity [<xref rid="B82-pharmaceutics-15-02114" ref-type="bibr">82</xref>]. T and D toxoids are detoxified toxins obtained from <italic toggle="yes">Clostridium tetani</italic> and <italic toggle="yes">Corynebacterium diphtheriae</italic>, respectively, through formaldehyde treatment [<xref rid="B83-pharmaceutics-15-02114" ref-type="bibr">83</xref>,<xref rid="B84-pharmaceutics-15-02114" ref-type="bibr">84</xref>]. OMPC and HiD are non-toxic proteins derived from the outer membrane of <italic toggle="yes">Neisseria meningitidis</italic> serogroup B and <italic toggle="yes">Haemophilus influenzae</italic>, respectively [<xref rid="B81-pharmaceutics-15-02114" ref-type="bibr">81</xref>,<xref rid="B85-pharmaceutics-15-02114" ref-type="bibr">85</xref>].</p><p>VLPs are composed of self-assembling virus capsid proteins derived from various systems, such as bacteria, yeast, insect cells, plant cells, mammalian cells, and cell-free cultures. These extracted proteins can either self-assemble into single-protein VLPs, combine with other proteins to form multi-protein VLPs, or incorporate antigenic materials to enhance immune responses (chimeric VLPs). Since VLPs mimic the structure of pathogens and contain antigens themselves, they can stimulate immune responses, inducing both humoral and cell-mediated immunity, similar to natural infections [<xref rid="B86-pharmaceutics-15-02114" ref-type="bibr">86</xref>,<xref rid="B87-pharmaceutics-15-02114" ref-type="bibr">87</xref>].</p><p>The production of toxoid vaccines involves harvesting and purifying exotoxins, followed by their inactivation using heat, formaldehyde, or iodoacetamide [<xref rid="B88-pharmaceutics-15-02114" ref-type="bibr">88</xref>,<xref rid="B89-pharmaceutics-15-02114" ref-type="bibr">89</xref>]. Subsequently, protein subunits comprising major domains are used instead of full-length proteins to avoid potential immunostimulatory effects caused by activated CD4<sup>+</sup> T cells and macrophages [<xref rid="B90-pharmaceutics-15-02114" ref-type="bibr">90</xref>]. Toxoid vaccines are effective against pathogens that utilize toxins as their primary infection mechanism, as they stimulate the production of anti-toxoid antibodies that can neutralize pathogenic toxins [<xref rid="B90-pharmaceutics-15-02114" ref-type="bibr">90</xref>].</p><p>Different subunit vaccines can be employed to effectively control infections depending on the type of pathogen. For instance, in the case of SARS-CoV and MERS-CoV, subunit vaccines have targeted the spike (S) proteins, which play a crucial role in infection by binding to host receptors [<xref rid="B91-pharmaceutics-15-02114" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceutics-15-02114" ref-type="bibr">92</xref>,<xref rid="B93-pharmaceutics-15-02114" ref-type="bibr">93</xref>]. As another example, the majority of research for influenza virus subunit vaccines has been performed with the HA protein, due to its high immunogenicity and conservability. As a result, several HA protein vaccines, including Fluvirin (1998), Agriflu (2009), and Flucelvax (2012), have been developed and FDA-approved [<xref rid="B94-pharmaceutics-15-02114" ref-type="bibr">94</xref>]. Apart from HA proteins, another class of membrane proteins known as the extracellular domain of matrix protein 2 (M2e) has been explored for subunit vaccine development against influenza viruses [<xref rid="B95-pharmaceutics-15-02114" ref-type="bibr">95</xref>]. M2e proteins are highly conserved and abundant in the cell membrane across all influenza A virus subtypes, providing cross-protective immunity when included in vaccines. However, M2e proteins have low immunogenicity and often require additional highly immunogenic carriers or adjuvants, posing challenges to the development of M2e vaccines beyond their current research stage [<xref rid="B95-pharmaceutics-15-02114" ref-type="bibr">95</xref>]. In contrast, HA proteins are known to be more immunogenic than M2e proteins, making them an even more appealing candidate for subunit vaccines [<xref rid="B96-pharmaceutics-15-02114" ref-type="bibr">96</xref>].</p></sec><sec id="sec2dot7-pharmaceutics-15-02114"><title>2.7. Adjuvants</title><p>Adjuvants are commonly used alongside vaccines to enhance their performance, including rapid response, long-lasting memory, and reduction in dose [<xref rid="B97-pharmaceutics-15-02114" ref-type="bibr">97</xref>]. While whole-particle-based vaccines usually do not require adjuvants due to the presence of inherent adjuvant molecules, such as lipopolysaccharide, flagellin, and cytosine-phosphate-guanine, adjuvants are primarily used with subunit vaccines, as well as some DNA and mRNA vaccines [<xref rid="B98-pharmaceutics-15-02114" ref-type="bibr">98</xref>]. Delivery vehicles with adjuvanticity have garnered attention as a promising type of adjuvant due to their versatility and ability to be combined with various molecules, such as other adjuvants, anchor proteins, and stabilizers. These delivery vehicles not only facilitate the transportation of the vaccine contents to targeted cells with controlled drug release but also enhance immune responses through a number of mechanisms.</p><p>Different types of delivery vehicles with adjuvanticity are currently under development, as shown in <xref rid="pharmaceutics-15-02114-t001" ref-type="table">Table 1</xref>. Oil-in-water (O/W) emulsions are extensively studied adjuvants, characterized by a simple composition of tween and/or span, as well as a straightforward production process [<xref rid="B99-pharmaceutics-15-02114" ref-type="bibr">99</xref>]. However, O/W emulsions have limitations, such as low thermal stability and relatively large particle sizes (&lt;50&#8211;500 &#181;m in diameter), which restrict their usage [<xref rid="B100-pharmaceutics-15-02114" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceutics-15-02114" ref-type="bibr">101</xref>]. Conversely, inorganic micro/nanoparticles offer high thermal stability and can be flexibly shaped into many different forms. The drug release of inorganic micro/nanoparticles can be regulated by adjusting the amount of reactive moieties involved in degradation processes, such as hydrolysis (silica nanoparticles) and pH sensitivity (calcium phosphate nanoparticles) [<xref rid="B102-pharmaceutics-15-02114" ref-type="bibr">102</xref>]. In comparison to other types of inorganic micro/nanoparticles, gold nanoparticles are known to be inert, enabling them to form stable functionalizations or have multi-layer coatings to enhance the bioavailability and immune responses of vaccines [<xref rid="B103-pharmaceutics-15-02114" ref-type="bibr">103</xref>]. Nevertheless, long-term safety concerns persist with these vehicles due to their high stability [<xref rid="B104-pharmaceutics-15-02114" ref-type="bibr">104</xref>].</p><p>In comparison to inorganic nanoparticles, protein-based nanoparticles (PNPs), commonly derived from animal and plant sources, have garnered attention due to their superior biodegradability, biocompatibility, and safety profiles. PNPs have demonstrated several other advantages, such as a convenient and affordable manufacturing process (attributed to the abundant presence of proteins in nature) and the possibility of modification for controlled delivery and specific targeting [<xref rid="B150-pharmaceutics-15-02114" ref-type="bibr">150</xref>,<xref rid="B151-pharmaceutics-15-02114" ref-type="bibr">151</xref>,<xref rid="B152-pharmaceutics-15-02114" ref-type="bibr">152</xref>]. Some of the most commonly explored protein candidates for PNPs include human serum albumin, gelatin, and zein, while different PNPs exhibit different stability and immunogenicity profiles [<xref rid="B123-pharmaceutics-15-02114" ref-type="bibr">123</xref>,<xref rid="B153-pharmaceutics-15-02114" ref-type="bibr">153</xref>]. However, PNPs are also known for relative disadvantages, including challenges in controlling size and vaccine dose [<xref rid="B153-pharmaceutics-15-02114" ref-type="bibr">153</xref>].</p><p>Lipid-based micro/nanoparticles are currently used as delivery vehicles for various types of commercial vaccines. These vehicles can encapsulate both hydrophilic and lipophilic particles due to their bilayer lipid structure [<xref rid="B154-pharmaceutics-15-02114" ref-type="bibr">154</xref>]. They demonstrate high delivery efficiency, primarily because of their positive charge, which promotes their interaction with negatively charged antigen-presenting cells (APCs) [<xref rid="B109-pharmaceutics-15-02114" ref-type="bibr">109</xref>]. However, it is important to note that this positive charge of lipid-based vehicles can also have side effects, such as destabilization of cell membranes by interacting with negatively charged proteins on the cell membrane [<xref rid="B155-pharmaceutics-15-02114" ref-type="bibr">155</xref>].</p><p>Among the synthetic polymers used for vaccine delivery, poly(lactic-co-glycolic acid) (PLGA) and poly(lactic acid) (PLA) have found widespread application in vaccine delivery systems [<xref rid="B156-pharmaceutics-15-02114" ref-type="bibr">156</xref>]. PLA exhibits a slower degradation rate compared to poly(glycolic acid) (PGA) due to the presence of a methyl group in its backbone, imparting hydrophobicity and reducing hydrolysis reactions [<xref rid="B157-pharmaceutics-15-02114" ref-type="bibr">157</xref>]. Additionally, PLGA, the combined form of PLA and PGA, allows controlled drug release by adjusting the proportion of each polymer [<xref rid="B158-pharmaceutics-15-02114" ref-type="bibr">158</xref>]. However, these synthetic polymers are limited by acidic byproducts, which can cause inflammation. In contrast, biopolymers are naturally occurring materials with relatively low toxicity. For example, acetalated dextran has been extensively used as a biopolymer in vaccine delivery systems due to its biocompatibility and the ease of modulating degradation time by adjusting the proportions of acyclic acetals (lower stability) and cyclic acetals (higher stability) to modulate degradation time [<xref rid="B159-pharmaceutics-15-02114" ref-type="bibr">159</xref>].</p></sec><sec id="sec2dot8-pharmaceutics-15-02114"><title>2.8. Future Prospective</title><p>Whole-particle-based vaccines offer distinct advantages, such as strong immunogenicity and the ability to induce immune responses similar to natural infections. However, their production process is considered time-consuming and energy-intensive, making them cost-ineffective. Additionally, these vaccines can be immunostimulatory as they involve the injection of external materials. To address these challenges, gene- or protein-particle-based vaccines have emerged as alternative options. However, these vaccines often lack sufficient immunogenicity and transfection efficiency [<xref rid="B86-pharmaceutics-15-02114" ref-type="bibr">86</xref>]. As a result, they are often encapsulated or coupled with self-adjuvating delivery vehicles. Nonetheless, these vehicles face limitations in terms of toxicity, stability, and low immunogenicity.</p><p>To overcome these limitations, new technologies have been developed, including various forms of nanomaterials such as hydrogel nanoparticles, carbon nanotubes, and dendrimers [<xref rid="B86-pharmaceutics-15-02114" ref-type="bibr">86</xref>,<xref rid="B160-pharmaceutics-15-02114" ref-type="bibr">160</xref>,<xref rid="B161-pharmaceutics-15-02114" ref-type="bibr">161</xref>]. Moreover, various nanomaterials have demonstrated high efficiency in drug delivery, showing potential for inducing both humoral and cell-mediated immune responses and overcoming the limitations of conventional delivery vehicles [<xref rid="B162-pharmaceutics-15-02114" ref-type="bibr">162</xref>,<xref rid="B163-pharmaceutics-15-02114" ref-type="bibr">163</xref>,<xref rid="B164-pharmaceutics-15-02114" ref-type="bibr">164</xref>,<xref rid="B165-pharmaceutics-15-02114" ref-type="bibr">165</xref>]. For instance, hydrogel nanoparticles and carbon nanotubes can bind to bioactive molecules for long periods, resulting in sustained immunity [<xref rid="B161-pharmaceutics-15-02114" ref-type="bibr">161</xref>]. As another example, cationic dendrimers, which form complexes with nucleic acids, do not destabilize cell membranes like lipid-based vehicles. Furthermore, due to their small sizes (1&#8211;10 nm), they can be encapsulated in other types of vehicles for additional functionalization [<xref rid="B155-pharmaceutics-15-02114" ref-type="bibr">155</xref>].</p><p>To ensure the successful development of novel self-adjuvating carriers, several requirements need to be met, including stability, non-toxicity, biodegradability, immunogenicity, and controlled drug release. Commercializing these innovative technologies requires conducting pre-clinical and clinical research to evaluate their safety profiles. Overall, these emerging advancements in vaccine research are expected to bring about a positive transformation in vaccine development, offering safer and more effective treatment options for disease outbreaks.</p></sec></sec><sec id="sec3-pharmaceutics-15-02114"><title>3. Administration of Non-Invasive Vaccines</title><p>Non-invasive vaccines have gained significant recognition due to the drawbacks associated with conventional needle- and liquid-based vaccines, such as the need for cold chain storage, challenges of self-administration, issues with thermal and long-term stability, risks of needle-mediated infections, and needlestick injuries. Among the major non-invasive vaccine systems, oral, intranasal, and transcutaneous administration have been extensively investigated. These non-invasive approaches offer solutions to various limitations of invasive vaccines. However, the effectiveness of non-invasive vaccines is hindered by their limited bioavailability, as biological barriers prevent their efficient absorption into the body. To overcome this issue and enhance the bioavailability of non-invasive vaccines, diverse formulations tailored to specific administration routes have been developed.</p><sec id="sec3dot1-pharmaceutics-15-02114"><title>3.1. Oral Administration</title><p>Oral vaccination has demonstrated its effectiveness in stimulating both mucosal and systemic immune responses by inducing the production of IgA and IgG antibodies [<xref rid="B166-pharmaceutics-15-02114" ref-type="bibr">166</xref>]. The immune responses are mainly initiated in the intestine, where the majority of vaccine uptake and drug absorption occur [<xref rid="B167-pharmaceutics-15-02114" ref-type="bibr">167</xref>,<xref rid="B168-pharmaceutics-15-02114" ref-type="bibr">168</xref>]. The intestine consists of several layers, including the mucus layer, water layer, epithelial layer, basement membrane/Peyer&#8217;s patches, and lymph nodes [<xref rid="B169-pharmaceutics-15-02114" ref-type="bibr">169</xref>]. The epithelial layer is composed of enterocytes, goblet cells, and microfold cells (M cells), which are joined together by tight junctions that prevent the movement of molecules through paracellular and transcellular routes [<xref rid="B169-pharmaceutics-15-02114" ref-type="bibr">169</xref>,<xref rid="B170-pharmaceutics-15-02114" ref-type="bibr">170</xref>,<xref rid="B171-pharmaceutics-15-02114" ref-type="bibr">171</xref>]. Enterocytes, the most abundant cells in the intestinal epithelium (constituting up to 80% of the local cell population), transport antibodies through transcytosis using the neonatal Fc receptor (FcRn) and form antibody&#8211;antigen complexes [<xref rid="B172-pharmaceutics-15-02114" ref-type="bibr">172</xref>,<xref rid="B173-pharmaceutics-15-02114" ref-type="bibr">173</xref>]. Goblet cells produce mucin, the main component of the mucus layer, which provides physical protection against the uptake of pathogenic particles [<xref rid="B174-pharmaceutics-15-02114" ref-type="bibr">174</xref>]. M cells play a crucial role in initiating immune responses by phagocytosing large particles and endocytosing small particles through specialized receptors like pattern recognition receptors (PRRs) [<xref rid="B170-pharmaceutics-15-02114" ref-type="bibr">170</xref>,<xref rid="B171-pharmaceutics-15-02114" ref-type="bibr">171</xref>]. Pathogen particles phagocytosed by M cells are subsequently taken up by dendritic cells (DC cells) in Peyer&#8217;s patches, leading to the activation of cellular and humoral immunity through the differentiation of T cells and B cells (<xref rid="pharmaceutics-15-02114-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B175-pharmaceutics-15-02114" ref-type="bibr">175</xref>].</p><p>Despite the advantageous characteristics of oral immunization, such as stability, independence from cold chain requirements, and ease of administration and storage, there are technical challenges in controlling the behavior of orally administered vaccines. Factors such as the varying pH levels of gastrointestinal fluids (e.g., stomach: 0.8&#8211;5, duodenum: ~7, jejunum: &#8805;7, ileum: &#8805;7, and colon: 7&#8211;8), osmolality, surface tension, viscosity, temperature, volume, hydrodynamics, composition, gastric emptying rate and force, intestinal transit time, and flow rate can impact the performance of orally administered vaccines [<xref rid="B167-pharmaceutics-15-02114" ref-type="bibr">167</xref>,<xref rid="B176-pharmaceutics-15-02114" ref-type="bibr">176</xref>]. Additionally, the presence of mucosal barriers and biomolecules, such as digestive enzymes, limits the bioavailability and immunogenicity of oral vaccines [<xref rid="B77-pharmaceutics-15-02114" ref-type="bibr">77</xref>]. This low efficiency necessitates higher vaccine doses, which can eventually lead to immune tolerance in the host. Moreover, the primary approach for oral vaccines involves the use of heat-killed or attenuated pathogens, which makes it difficult to effectively activate the immune system due to poor penetration of the mucus layer. There is also a risk of attenuated pathogens regaining their toxicity, as exemplified by the oral polio vaccine (OPV) outbreak that occurred in several countries in 2000, including Egypt, Haiti, the Philippines, and the Dominican Republic. Extensive research has been conducted to address these limitations and optimize the administration of oral vaccines [<xref rid="B177-pharmaceutics-15-02114" ref-type="bibr">177</xref>].</p><sec id="sec3dot1dot1-pharmaceutics-15-02114"><title>3.1.1. pH Sensitivity</title><p>Enhancing the bioavailability of oral vaccines requires them to withstand the low-pH environment of the stomach. To improve vaccine stability, researchers have developed anionic coatings that remain stable under acidic conditions. These coatings consist of anionic polymers containing carboxylic acid groups, which remain unionized in the stomach&#8217;s low pH but become ionized in the higher pH of the intestine [<xref rid="B178-pharmaceutics-15-02114" ref-type="bibr">178</xref>]. One example is Eudragit<sup>&#174;</sup>, anionic polymers composed of poly(methacrylic acid-co-acrylates) with different chemical compositions [<xref rid="B179-pharmaceutics-15-02114" ref-type="bibr">179</xref>]. The pH sensitivity of these polymers can be adjusted by varying the number of active carboxylic groups; higher levels of carboxylic groups result in increased sensitivity to low pH. For instance, Eudragit L100 (EL100) contains 48.3% active carboxylic groups and dissolves above pH 6, while Eudragit S100 (ES100), with 29.2% active groups, dissolves above pH 7 [<xref rid="B179-pharmaceutics-15-02114" ref-type="bibr">179</xref>]. pH sensitivity can also be modified by using ethyl acrylate instead of methyl methacrylate in the polymer formulation, as seen with Eudragit L100-55 (EL100-55), which dissolves at lower pH (&gt;pH 5.5) [<xref rid="B180-pharmaceutics-15-02114" ref-type="bibr">180</xref>]. Cellulose-based materials, such as hydroxypropyl methylcellulose phthalate (HPMC-P), cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose acetate succinate (HPMC-AS), and cellulose acetate trimellitate (CAT), have also been explored [<xref rid="B181-pharmaceutics-15-02114" ref-type="bibr">181</xref>]. Among these, HPMC-P and CAP are most commonly used for enteric coatings and their pH-responsive behavior is based on the carboxylic acid residues that remain unionized in the stomach but become ionized in the intestine [<xref rid="B182-pharmaceutics-15-02114" ref-type="bibr">182</xref>]. However, HPMC-P coating processes involving organic solvents raise concerns about toxicity and safety. Moreover, HPMC-P and CAP have limited thermal stability, restricting their application in capsule production [<xref rid="B183-pharmaceutics-15-02114" ref-type="bibr">183</xref>]. Lastly, alginate, derived from brown algae, such as <italic toggle="yes">Laminaria hyperborea</italic>, <italic toggle="yes">Laminaria digitata</italic>, <italic toggle="yes">Laminaria japonica</italic>, <italic toggle="yes">Ascophyllum nodosum</italic>, and <italic toggle="yes">Macrocystis pyrifera</italic>, has been extensively used to produce coating polymers due to its biocompatibility, low toxicity, and affordability. Alginate&#8217;s anionic property also enables it to resist gastric fluid, making it a promising candidate for coating oral vaccines [<xref rid="B184-pharmaceutics-15-02114" ref-type="bibr">184</xref>,<xref rid="B185-pharmaceutics-15-02114" ref-type="bibr">185</xref>].</p></sec><sec id="sec3dot1dot2-pharmaceutics-15-02114"><title>3.1.2. Mucoadhesive Interaction</title><p>Increasing the bioavailability of oral vaccines requires enhancing mucoadhesion, which prolongs the retention time in the intestine [<xref rid="B186-pharmaceutics-15-02114" ref-type="bibr">186</xref>,<xref rid="B187-pharmaceutics-15-02114" ref-type="bibr">187</xref>,<xref rid="B188-pharmaceutics-15-02114" ref-type="bibr">188</xref>,<xref rid="B189-pharmaceutics-15-02114" ref-type="bibr">189</xref>]. To improve mucoadhesion, it is important to understand the behavior of different mucoadhesive materials. The mucoadhesive materials typically have hydrophilic functional groups (e.g., hydroxyl and carboxyl groups), a large molecular weight, high surface-to-volume ratio, and low cross-linking density to maximize interactions with intestinal mucus [<xref rid="B190-pharmaceutics-15-02114" ref-type="bibr">190</xref>]. Among various natural and synthetic mucoadhesive enhancers, chitosan and carbomer have been widely studied [<xref rid="B191-pharmaceutics-15-02114" ref-type="bibr">191</xref>].</p><p>Chitosan, a natural cationic polymer, interacts with negatively charged sialic groups in mucin through electrostatic attraction. Based on the mucoadhesive effects of chitosan, different chitosan-based conjugates (i.e., chitosan&#8211;cysteine, chitosan&#8211;glutathione, chitosan&#8211;thioglycolic acid, etc.) have been developed for vaccine delivery [<xref rid="B187-pharmaceutics-15-02114" ref-type="bibr">187</xref>,<xref rid="B189-pharmaceutics-15-02114" ref-type="bibr">189</xref>]. However, chitosan has limitations such as high solubility in the stomach. To address this issue, chitosan is often conjugated with alginate for coating purposes. The carboxyl groups of alginate interact with the amino groups of chitosan, resulting in strong electrostatic attraction. This alginate&#8211;chitosan complex shrinks and forms a gel in the low gastric pH, releasing drugs in the neutral pH of the intestine, enabling targeted drug delivery to the colon [<xref rid="B192-pharmaceutics-15-02114" ref-type="bibr">192</xref>]. A similar study has also been performed with BSA to develop the alginate&#8211;chitosan complex as a vaccine delivery carrier, which has demonstrated the efficiency of the complex at a low pH [<xref rid="B193-pharmaceutics-15-02114" ref-type="bibr">193</xref>].</p><p>Carbomer, a carboxyvinyl polymer containing large amounts of carboxylic groups (56&#8211;68%), forms hydrogen bonds with sialic acid and sulfate groups present on mucin glycoproteins&#8217; oligosaccharide chains, thereby increasing mucoadhesive effects [<xref rid="B194-pharmaceutics-15-02114" ref-type="bibr">194</xref>,<xref rid="B195-pharmaceutics-15-02114" ref-type="bibr">195</xref>]. Carbopol<sup>&#174;</sup> 971P, 974P, and 934P are mucoadhesive polymers developed based on carbomer, and their mucoadhesive effects are further improved by combining them with cysteine, which interacts with mucus glycoproteins [<xref rid="B196-pharmaceutics-15-02114" ref-type="bibr">196</xref>].</p><p>Nowadays, nanofibers have also gained attention due to their favorable properties such as high surface-to-volume ratio, high porosity, solubility enhancement, controlled cargo release, and the ability to target various sites (e.g., buccal, vaginal, oral, sublingual, transdermal, gastric, intestinal, colonic, and ocular mucosa). However, across different types of polymers, mucoadhesive effects have intrinsic limitations, including the relatively short adherence time (less than 4&#8211;5 h) for cells to absorb vaccines and the challenge of vaccine penetration through the mucus layer [<xref rid="B197-pharmaceutics-15-02114" ref-type="bibr">197</xref>,<xref rid="B198-pharmaceutics-15-02114" ref-type="bibr">198</xref>].</p></sec><sec id="sec3dot1dot3-pharmaceutics-15-02114"><title>3.1.3. Intestinal Permeability</title><p>To improve the bioavailability of oral vaccines, it is important to enhance their intestinal permeability due to the presence of the mucus layer that acts as a physical barrier [<xref rid="B197-pharmaceutics-15-02114" ref-type="bibr">197</xref>,<xref rid="B199-pharmaceutics-15-02114" ref-type="bibr">199</xref>]. This can be achieved through the use of small-sized particles, non-reactive coatings, or permeation enhancers (<xref rid="pharmaceutics-15-02114-f005" ref-type="fig">Figure 5</xref>). Nanoparticles have been extensively used for this purpose because of their ability to easily couple with functional groups and penetrate the mucus layer. It has been reported that anionic nanoparticles themselves have shown a relaxation effect on tight junctions, thereby enhancing the permeability, possibly due to interactions between the nanoparticles and integrin proteins on epithelial cells and the activation of myosin light chain kinase (MLCK) [<xref rid="B200-pharmaceutics-15-02114" ref-type="bibr">200</xref>]. Furthermore, there have been studies demonstrating the size effect of particles on the penetration of the mucus layer, showing that large particles (1190 nm) experience a 30-fold reduction in particle penetration rate than small particles (510 nm) due to steric obstruction and capture by the mucus mesh (mucus mesh spacing &#8805;500 nm) [<xref rid="B201-pharmaceutics-15-02114" ref-type="bibr">201</xref>,<xref rid="B202-pharmaceutics-15-02114" ref-type="bibr">202</xref>].</p><p>Non-reactive nanoparticles can be created by functionalizing them with poly(ethylene glycol) (PEG) and Pluronic F127 to enhance their permeability. In particular, the development of low-molecular-weight PEG coating was inspired by the penetration of viruses through human mucus, reducing hydrophobic and electrostatic interactions between nanoparticles and the mucus layer through a hydrophilic and neutral-charged coating [<xref rid="B203-pharmaceutics-15-02114" ref-type="bibr">203</xref>]. PEG has been successfully coupled with various types of nanoparticles (e.g., PLGA, poly sebacic acid (PSA), polyethylenimine (PEI), poly-l-lysine (PLL)) and has demonstrated efficient penetration [<xref rid="B204-pharmaceutics-15-02114" ref-type="bibr">204</xref>]. Pluronic F127, a triblock copolymer surfactant with alternating hydrophilic and hydrophobic structures, exhibits a unique arrangement that minimizes its interaction with the mucus layer. Furthermore, its neutral charge allows it to avoid interactions with negatively charged mucins [<xref rid="B205-pharmaceutics-15-02114" ref-type="bibr">205</xref>]. It has been reported that Pluronic F127-coated particles show an 80-fold increase in penetration rate compared to uncoated particles [<xref rid="B186-pharmaceutics-15-02114" ref-type="bibr">186</xref>].</p><p>Chemical or enzymatic treatments, such as disulfide-breaking agents or mucolytic enzymes, have been also performed to enhance the intestinal permeability. Such permeation enhancers are typically incorporated inside or immobilized on nanoparticles to selectively affect certain regions of the mucus layer to maintain the functions of mucus layer against pathogens in non-treated areas [<xref rid="B186-pharmaceutics-15-02114" ref-type="bibr">186</xref>]. N-acetyl-l-cysteine (NAC) is an example of a disulfide-breaking agent that breaks the disulfide bonds of cysteine groups in mucin using free sulfur groups [<xref rid="B206-pharmaceutics-15-02114" ref-type="bibr">206</xref>,<xref rid="B207-pharmaceutics-15-02114" ref-type="bibr">207</xref>]. Cleaving these bonds reduces the elasticity and viscosity of mucus, thereby increasing drug permeability through the epithelial layer [<xref rid="B204-pharmaceutics-15-02114" ref-type="bibr">204</xref>]. Additionally, it is speculated that NAC may enhance the uptake of antigens by loosening the mucus layer at Peyer&#8217;s patches, where antigen uptake primarily occurs [<xref rid="B174-pharmaceutics-15-02114" ref-type="bibr">174</xref>]. Other mucolytic enzymes, such as trypsin, papain, bromelain, and recombinant human DNase (rhDNase), can also contribute to reducing the viscosity of mucus by cleaving the cross-links in mucus glycoproteins [<xref rid="B204-pharmaceutics-15-02114" ref-type="bibr">204</xref>,<xref rid="B206-pharmaceutics-15-02114" ref-type="bibr">206</xref>].</p></sec></sec><sec id="sec3dot2-pharmaceutics-15-02114"><title>3.2. Intranasal Administration</title><p>Intranasal vaccination offers several advantages, including easy accessibility, the potential for herd immunization, and the ability to initiate both mucosal and systemic immune responses, making it a favorable administration route for vaccines [<xref rid="B208-pharmaceutics-15-02114" ref-type="bibr">208</xref>]. Similar to the Peyer&#8217;s patches in the intestinal tract, the nasal-associated lymphoid tissues (NALTs) play a significant role in inducing immunity through intranasal vaccination in rodents. NALTs are regions rich in immune cells (such as T cells, B cells, dendritic cells, macrophages, and M cells) where active immune responses occur [<xref rid="B209-pharmaceutics-15-02114" ref-type="bibr">209</xref>]. The key difference between the Peyer&#8217;s patches and NALTs is that the formation of NALT is triggered after exposure to pathogens, whereas Peyer&#8217;s patches develop before birth. Similar to the NALTs of rodents, Waldeyer&#8217;s rings play a major role in human immune responses upon intranasal administration. Waldeyer&#8217;s rings, including the pharyngeal tonsil, tubal tonsils, palatine tonsils, and lingual tonsils, firstly transfer pathogens to DC cells, initiating mucosal immunity through the differentiation and proliferation of T cells [<xref rid="B209-pharmaceutics-15-02114" ref-type="bibr">209</xref>,<xref rid="B210-pharmaceutics-15-02114" ref-type="bibr">210</xref>]. Like oral vaccination, intranasal vaccination faces challenges from the mucus layer, which can result in mucociliary clearance of vaccine particles and hinder the vaccination process. Therefore, numerous methods have been investigated to enhance the immune response during intranasal vaccination, such as improving mucoadhesive interaction and intestinal permeability, as well as incorporating adjuvants.</p><sec id="sec3dot2dot1-pharmaceutics-15-02114"><title>3.2.1. Liquid Formulation</title><p>Currently, intranasal vaccines are predominantly administered in liquid form due to their effective cell penetration. Liquid formulations allow for even distribution of vaccine components, such as adjuvants and stabilizers [<xref rid="B211-pharmaceutics-15-02114" ref-type="bibr">211</xref>]. Developing a liquid formulation involves considering the properties of the liquid phase (e.g., osmolarity, pH, viscosity, and surface tension), the delivery devices, and the inclusion of stabilizers. In terms of osmolarity, isotonic solutions (~290 osmol/L) are commonly used to achieve optimal osmolarity, as hypotonic solutions are poorly absorbed and hypertonic solutions can cause cell shrinkage upon diffusion [<xref rid="B211-pharmaceutics-15-02114" ref-type="bibr">211</xref>]. The pH of liquid formulations should be maintained between 4.5 and 6.5 to avoid irritation, considering that the nasal mucus layer has a pH of 5.5&#8211;6.5; it has also been observed that lysozymes in the intranasal system are inactivated at neutral pH, which can increase the risk of microbial infection [<xref rid="B212-pharmaceutics-15-02114" ref-type="bibr">212</xref>,<xref rid="B213-pharmaceutics-15-02114" ref-type="bibr">213</xref>]. Increasing the viscosity of nasal mucus is another approach to enhance the immunogenicity of vaccines by prolonging their retention time in the nasal cavity and increasing the dosing volume of the nasal spray over conventional dosing volume (50&#8211;140 &#181;L) [<xref rid="B214-pharmaceutics-15-02114" ref-type="bibr">214</xref>,<xref rid="B215-pharmaceutics-15-02114" ref-type="bibr">215</xref>,<xref rid="B216-pharmaceutics-15-02114" ref-type="bibr">216</xref>]. However, it must be noted that high mucosal viscosity may impede effective diffusion and spreading of the vaccines. Surface tension is another critical factor affecting the behavior of liquid vaccines. Most intranasal vaccines have lower surface tension (30.3&#8211;44.9 dynes/cm) than the nasal mucus layer (&lt;56 dynes/cm). [<xref rid="B217-pharmaceutics-15-02114" ref-type="bibr">217</xref>] The low surface tension of vaccines primarily facilitates better bioavailability by maximizing their spread within the nasal cavity [<xref rid="B218-pharmaceutics-15-02114" ref-type="bibr">218</xref>].</p><p>To enhance the delivery efficiency of intranasal formulations, various devices have been developed, ranging from manual dropping-based devices to multifunctional devices with filters and automatic systems that prevent particle deposition in the lungs and ensure reproducibility [<xref rid="B219-pharmaceutics-15-02114" ref-type="bibr">219</xref>]. Examples of devices used for liquid formulations include AccuSpray (FluMist), Classic Mexican Nebulizer (Measles), Aerovax and OptiMist (influenza), ViaNase (Alzheimer&#8217;s), and MAD and CPSI Cartridge Pump System (adenovirus-based vaccine) [<xref rid="B209-pharmaceutics-15-02114" ref-type="bibr">209</xref>]. Among the different intranasal vaccination methods and devices, AccuSpray (FluMist) is the only one approved by the FDA for human use in the United States [<xref rid="B220-pharmaceutics-15-02114" ref-type="bibr">220</xref>].</p><p>Due to the low stability of liquid formulations, stabilizers are often incorporated. For instance, FluMist contains monosodium glutamate, hydrolyzed porcine gelatin, and sucrose [<xref rid="B221-pharmaceutics-15-02114" ref-type="bibr">221</xref>]. Other commonly used stabilizers in intranasal vaccines include lactose, sorbitol, porcine gelatin, arginine, and tricine [<xref rid="B222-pharmaceutics-15-02114" ref-type="bibr">222</xref>]. These stabilizers can also be used during lyophilization to reduce the glass transition temperature and decrease the lyophilization time [<xref rid="B223-pharmaceutics-15-02114" ref-type="bibr">223</xref>]. Moreover, sugars such as lactose and sucrose do not form sharp ice crystals, unlike water, providing physical protection to vaccines at low temperatures [<xref rid="B224-pharmaceutics-15-02114" ref-type="bibr">224</xref>].</p></sec><sec id="sec3dot2dot2-pharmaceutics-15-02114"><title>3.2.2. Powder Formulation</title><p>Powder formulations can resolve limitations of liquid formulations, such as short residence time in the nasal cavity, low stability in terms of chemical and microbiological factors, short shelf-life, and the requirement for cold chain systems [<xref rid="B209-pharmaceutics-15-02114" ref-type="bibr">209</xref>,<xref rid="B225-pharmaceutics-15-02114" ref-type="bibr">225</xref>]. Dry powder vaccines are primarily manufactured using two methods: spray-drying and freeze-drying. Spray-drying starts with a liquid vaccine being sprayed into a drying chamber, followed by powder separation in a gas stream. On the other hand, freeze-drying involves freezing a liquid vaccine using liquid nitrogen and then subjecting it to lyophilization [<xref rid="B226-pharmaceutics-15-02114" ref-type="bibr">226</xref>]. In terms of formulation process, dry powder vaccines share many similarities with conventional injectable vaccines, as well as antigens and adjuvants. However, one difference is that dry powder vaccines often incorporate bulking agents, stabilizers, and mucoadhesive materials to enhance nasal deposition [<xref rid="B227-pharmaceutics-15-02114" ref-type="bibr">227</xref>]. Bulking agents play an important role as a vaccine carrier, facilitating the attainment of appropriate particle sizes to improve vaccine efficiency. For instance, lactose and mannitol, both FDA-approved inactive ingredients for nasal or respiratory use, are frequently chosen as carriers [<xref rid="B228-pharmaceutics-15-02114" ref-type="bibr">228</xref>]. For a stabilizer of vaccines, mild formaldehyde has also been extensively used as it interacts with the residues of various antigens, such as the N-terminus of amino acids and side chains (i.e., arginine, cysteine, histidine, etc.) [<xref rid="B227-pharmaceutics-15-02114" ref-type="bibr">227</xref>,<xref rid="B229-pharmaceutics-15-02114" ref-type="bibr">229</xref>].</p><p>Dry powder vaccines are typically administered using medical devices like the &#956;coTM system and Opt-powder (influenza), Aktiv-Dry PuffHaler<sup>&#174;</sup> and BD solvent<sup>&#174;</sup> (measles), and Combitips Plus Syringe (meningococcal) [<xref rid="B209-pharmaceutics-15-02114" ref-type="bibr">209</xref>]. While there are several advantageous aspects of powder formulations over liquid counterparts, limitations still exist due to limited research on powder formulation delivery systems and the behavior of dry powder vaccines upon contact with the nasal cavity [<xref rid="B211-pharmaceutics-15-02114" ref-type="bibr">211</xref>,<xref rid="B225-pharmaceutics-15-02114" ref-type="bibr">225</xref>]. This is evident considering that there are no FDA-approved dry powder vaccines currently available.</p></sec></sec><sec id="sec3dot3-pharmaceutics-15-02114"><title>3.3. Transcutaneous Administration</title><p>Transcutaneous immunization (TCI) is a topical vaccination strategy that primarily stimulates systemic immunity, also inducing a moderate level of mucosal immunity with the assistance of an adjuvant [<xref rid="B230-pharmaceutics-15-02114" ref-type="bibr">230</xref>]. TCI specifically targets epidermal cells, located in the middle layer of the skin, which also includes keratinocytes (KCs) and Langerhans cells (LCs). KCs are the predominant cells in the epidermis and play a role in recognizing pathogens through Toll-like receptors (TLRs), triggering innate and adaptive immune responses. LCs, a type of dendritic cells, capture a significant portion of TCI particles and recognize them through the major histocompatibility complex (MHC), activating adaptive immune responses [<xref rid="B231-pharmaceutics-15-02114" ref-type="bibr">231</xref>]. However, for TCI to be effective, it is necessary to penetrate the stratum corneum, the outer layer of the skin consisting of 10&#8211;20 layers of dead skin cells that act as a barrier against external substances [<xref rid="B232-pharmaceutics-15-02114" ref-type="bibr">232</xref>]. Consequently, research has focused on exploring physical and chemical methods to enhance the penetration of the stratum corneum in order to achieve successful TCI.</p><sec id="sec3dot3dot1-pharmaceutics-15-02114"><title>3.3.1. Physical Delivery Systems</title><p>To enhance the penetration of vaccines through the stratum corneum, various methods have been employed, including ultrasound, electroporation, jet injectors, laser-based technologies, and microneedles [<xref rid="B233-pharmaceutics-15-02114" ref-type="bibr">233</xref>]. Ultrasound can be utilized to create cavities in the stratum corneum, increasing vaccine permeability. This process involves the pressure gradient generated by ultrasound, enlarging air pockets in the fibrous tissue to allow the diffusion of vaccines through the cavities [<xref rid="B234-pharmaceutics-15-02114" ref-type="bibr">234</xref>,<xref rid="B235-pharmaceutics-15-02114" ref-type="bibr">235</xref>]. Electroporation, on the other hand, involves applying short high-voltage pulses to the cell membrane, temporarily damaging it and creating transient hydrophilic pores that enhance membrane permeability [<xref rid="B236-pharmaceutics-15-02114" ref-type="bibr">236</xref>]. However, both ultrasound and electroporation require large machines and trained personnel to operate them. As an alternative, jet injectors, which are compact and easy to handle, have been used. These injectors use high-pressure liquid to deliver vaccines through the stratum corneum [<xref rid="B237-pharmaceutics-15-02114" ref-type="bibr">237</xref>,<xref rid="B238-pharmaceutics-15-02114" ref-type="bibr">238</xref>]. Despite the increasing accessibility, jet injectors have drawbacks including pain, bleeding, and edema [<xref rid="B232-pharmaceutics-15-02114" ref-type="bibr">232</xref>].</p><p>Currently, diverse laser-based technologies (e.g., laser ablation, fractional laser technology, and ablative fractional laser technology) have also been developed to enhance stratum corneum penetration for vaccine delivery. Laser ablation is a conventional technology used to remove the entire surface of the skin, whereas fractional laser creates micro-columns in the skin, leaving the surrounding areas intact to minimize skin damage and accelerate the healing process [<xref rid="B239-pharmaceutics-15-02114" ref-type="bibr">239</xref>]. Ablative fractional laser (AFL) is a method that combines the laser ablation and fractional laser technologies, minimizing skin damage and enhancing vaccine permeability by ablating the stratum corneum and forming skin microchannels [<xref rid="B240-pharmaceutics-15-02114" ref-type="bibr">240</xref>].</p><p>Among the available transcutaneous immunization (TCI) methods, microneedles have gained acceptance due to their ease of use, accessibility, and independence from patches. Microneedles are minimally invasive and pain-free, involving small needles that penetrate the stratum corneum [<xref rid="B241-pharmaceutics-15-02114" ref-type="bibr">241</xref>]. There are five categories of microneedles based on their structures: solid, coated, hollow, dissolving, and hydrogel-forming microneedles [<xref rid="B242-pharmaceutics-15-02114" ref-type="bibr">242</xref>,<xref rid="B243-pharmaceutics-15-02114" ref-type="bibr">243</xref>,<xref rid="B244-pharmaceutics-15-02114" ref-type="bibr">244</xref>]. Solid microneedles are used to create microchannels in the skin, allowing for vaccine penetration [<xref rid="B245-pharmaceutics-15-02114" ref-type="bibr">245</xref>]. To date, a variety of materials have been considered candidates for the production of solid microneedles (e.g., silicon, polysilicon, silicon dioxide, silicon nitride, PGA) [<xref rid="B246-pharmaceutics-15-02114" ref-type="bibr">246</xref>]. While solid microneedles offer easy manufacturing and high dose delivery, they are hindered by a slower rate of diffusion when compared to other types of microneedles [<xref rid="B247-pharmaceutics-15-02114" ref-type="bibr">247</xref>,<xref rid="B248-pharmaceutics-15-02114" ref-type="bibr">248</xref>].</p><p>Coated microneedles contain vaccines applied to the needle, enabling diffusion into the epidermis upon injection. However, one limitation is that the coating may cause coated particle loss during manufacturing and handling [<xref rid="B241-pharmaceutics-15-02114" ref-type="bibr">241</xref>,<xref rid="B249-pharmaceutics-15-02114" ref-type="bibr">249</xref>]. As another option, hollow microneedles resemble conventional needle injection-based vaccination, with vaccines contained in the bore of the needle. These microneedles also provide the highest level of particle delivery but can experience blockage by tissues upon contact, although repositioning the bore to the side can address this issue [<xref rid="B241-pharmaceutics-15-02114" ref-type="bibr">241</xref>,<xref rid="B244-pharmaceutics-15-02114" ref-type="bibr">244</xref>].</p><p>Dissolving microneedles are made of water-soluble materials that penetrate and dissolve in the skin simultaneously. For these microneedles, vaccines and the microneedle matrix undergo a mixing process upon manufacturing. Among various candidates for the matrix of dissolving needles (e.g., sodium carboxymethylcellulose, poly(vinylalcohol), poly(vinylpyrrolidone), methylvinylether-co-maleic anhydride), sodium hyaluronate is most commonly used due to its biodegradability and mechanical strength [<xref rid="B250-pharmaceutics-15-02114" ref-type="bibr">250</xref>,<xref rid="B251-pharmaceutics-15-02114" ref-type="bibr">251</xref>]. Remarkably, dissolving microneedles have shown high diffusion efficiency within a patch wearing time of just several minutes, while it could be up to several hours for solid microneedles [<xref rid="B247-pharmaceutics-15-02114" ref-type="bibr">247</xref>].</p><p>Lastly, hydrogel-forming microneedles have emerged as a promising option for their biocompatibility and controllable degradability [<xref rid="B252-pharmaceutics-15-02114" ref-type="bibr">252</xref>]. These microneedles are equipped with hydrogel, capitalizing on its three-dimensional structure that allows for a significant capacity to carry vaccines; however, there is a possibility that vaccines can become trapped within the patch and they require a longer diffusion time of up to several hours [<xref rid="B247-pharmaceutics-15-02114" ref-type="bibr">247</xref>,<xref rid="B253-pharmaceutics-15-02114" ref-type="bibr">253</xref>,<xref rid="B254-pharmaceutics-15-02114" ref-type="bibr">254</xref>]. The mechanism of hydrogel-forming microneedles relies on the absorption of interstitial skin fluid, which causes the hydrogel to swell and burst, triggering the release of the vaccines from the microneedle [<xref rid="B254-pharmaceutics-15-02114" ref-type="bibr">254</xref>,<xref rid="B255-pharmaceutics-15-02114" ref-type="bibr">255</xref>]. The vaccine-release behavior of the hydrogel is directly influenced by the swelling property of the matrix polymer and can be modulated by adjusting the amount of crosslinkers; increasing the percentage of crosslinkers results in a reduced swelling rate in the skin [<xref rid="B252-pharmaceutics-15-02114" ref-type="bibr">252</xref>,<xref rid="B254-pharmaceutics-15-02114" ref-type="bibr">254</xref>]. Last but not least, achieving optimal performance with hydrogel-forming microneedles requires maintaining their hardness in a dry state, while ensuring rapid swelling in the skin [<xref rid="B255-pharmaceutics-15-02114" ref-type="bibr">255</xref>].</p><p>The efficiency of microneedle-based vaccines can be enhanced by using different types of nanoparticles with various strengths. For instance, polymeric nanoparticles offer controlled release and targeted delivery, while lipid-based nanoparticles provide enhanced solubility. Furthermore, inorganic nanoparticles are known to allow controlled release and have consistent pore structures, whereas protein-based nanoparticles enable controlled release and targeted delivery [<xref rid="B256-pharmaceutics-15-02114" ref-type="bibr">256</xref>,<xref rid="B257-pharmaceutics-15-02114" ref-type="bibr">257</xref>]. Currently, lipid-based carriers and polymeric carriers (i.e., poly(vinyl pyrrolidone) (PVP), Poly(vinyl alcohol) (PVA), PLGA, polypropylene sulfide, chitosan, etc.) have been the primary focus of research for vaccine delivery. These carriers have demonstrated enhanced immune responses without requiring the addition of adjuvants [<xref rid="B242-pharmaceutics-15-02114" ref-type="bibr">242</xref>].</p></sec><sec id="sec3dot3dot2-pharmaceutics-15-02114"><title>3.3.2. Chemical Enhancers </title><p>Various chemical substances, including water, dimethylsulphoxide (DMSO), acids, essential oils, and surfactants, have been investigated as potential enhancers for transcutaneous delivery [<xref rid="B258-pharmaceutics-15-02114" ref-type="bibr">258</xref>]. These enhancers act to improve the permeability of vaccines through the skin by targeting different components of the stratum corneum: hydrophilic space (intercellular transport), hydrophilic lipid heads (transcellular transport), and hydrophobic lipid chains (transcellular transport) [<xref rid="B259-pharmaceutics-15-02114" ref-type="bibr">259</xref>]. The hydrophilic space can accommodate solvents (e.g., propylene glycol, ethanol, pyrrolidines, dimethyl sulfoxide) through chemical treatment, allowing the delivery of vaccines and drugs in the stratum corneum, followed by their transport to the epidermis by a chemical gradient [<xref rid="B259-pharmaceutics-15-02114" ref-type="bibr">259</xref>,<xref rid="B260-pharmaceutics-15-02114" ref-type="bibr">260</xref>].</p><p>Water can interact with the hydrophilic heads of the bilipid membrane, increasing the fluidity and permeability of the stratum corneum, and this favorable property has led to the development of hydro patches used for vaccine penetration through the skin [<xref rid="B232-pharmaceutics-15-02114" ref-type="bibr">232</xref>,<xref rid="B261-pharmaceutics-15-02114" ref-type="bibr">261</xref>]. In a similar manner, DMSO ((CH<sub>3</sub>)<sub>2</sub>SO) can also effectively enhance the permeability of the stratum corneum; the oxygen atom present in the sulfoxide group of DMSO interacts with the hydrophilic heads of the bilipid membrane, causing a disruption of the hydrogen bonds between lipid heads. This process leads to a transformation of the gel-like structure in the ceramide bilayer of the stratum corneum into a liquid&#8211;crystalline structure [<xref rid="B262-pharmaceutics-15-02114" ref-type="bibr">262</xref>]. On the other hand, lipophilic agents represented by azone, terpenes, and oleic acids disrupt the structure of lipid tails in the stratum corneum, expanding the membrane and facilitating vaccine diffusion [<xref rid="B263-pharmaceutics-15-02114" ref-type="bibr">263</xref>]. However, these hydrophilic and lipophilic chemical enhancers have limitations in terms of efficiency and safety. Firstly, as the particle delivery into the epidermis is primarily mediated by chemical potential, the effectiveness of these agents diminishes as the concentration gradient decreases. This necessitates the application of mechanical force to enhance the efficiency of delivery. Furthermore, chemical molecules have the potential to affect tissue integrity and cause various forms of irritation, including local inflammation, erythema, swelling, dermatitis, and other related conditions [<xref rid="B258-pharmaceutics-15-02114" ref-type="bibr">258</xref>,<xref rid="B264-pharmaceutics-15-02114" ref-type="bibr">264</xref>].</p></sec></sec><sec id="sec3dot4-pharmaceutics-15-02114"><title>3.4. Adjuvants</title><p>Currently, the majority of FDA-approved non-invasive vaccines utilize whole pathogen particles, such as Adenovirus Type 4 and Type 7 vaccines, VAXCHORA, ROTARIX, RotaTeq, Vivotif, and FluMist [<xref rid="B220-pharmaceutics-15-02114" ref-type="bibr">220</xref>,<xref rid="B265-pharmaceutics-15-02114" ref-type="bibr">265</xref>,<xref rid="B266-pharmaceutics-15-02114" ref-type="bibr">266</xref>,<xref rid="B267-pharmaceutics-15-02114" ref-type="bibr">267</xref>,<xref rid="B268-pharmaceutics-15-02114" ref-type="bibr">268</xref>,<xref rid="B269-pharmaceutics-15-02114" ref-type="bibr">269</xref>]. These vaccines typically do not require additional adjuvants, as the parts of the vaccines (e.g., lipopolysaccharide, flagellin, and cytosine-phosphate-guanine) have inherent adjuvanticity [<xref rid="B98-pharmaceutics-15-02114" ref-type="bibr">98</xref>]. Regardless, there have been attempts to incorporate adjuvants into delivery systems to overcome the low bioavailability of non-invasive vaccinations (<xref rid="pharmaceutics-15-02114-t002" ref-type="table">Table 2</xref>). Among the available adjuvants, aluminum-based adjuvants, including aluminum hydroxide and aluminum phosphate, have been the most widely used for over 80 years with invasive vaccines [<xref rid="B270-pharmaceutics-15-02114" ref-type="bibr">270</xref>]. These adjuvants enhance immune responses by promoting antigen uptake by dendritic cells [<xref rid="B271-pharmaceutics-15-02114" ref-type="bibr">271</xref>]. However, aluminum-based adjuvants have demonstrated lower immunogenicity for non-invasive vaccines compared to other adjuvants, likely due to their large particle size, which interferes with diffusion [<xref rid="B272-pharmaceutics-15-02114" ref-type="bibr">272</xref>,<xref rid="B273-pharmaceutics-15-02114" ref-type="bibr">273</xref>,<xref rid="B274-pharmaceutics-15-02114" ref-type="bibr">274</xref>]. Consequently, efforts have been made to identify suitable adjuvants for non-invasive vaccines.</p><p>One alternative that has been studied is toxin-based adjuvants, such as cholera toxin (CT) and heat-labile enterotoxin (LT). However, their high toxicity raises concerns regarding their use. To mitigate this, mutations at specific amino acid sites of CT and LT have been introduced, resulting in improved efficiency and safety (e.g., double-mutant LT (dmLT) and multiple-mutated CT (mmCT)) [<xref rid="B296-pharmaceutics-15-02114" ref-type="bibr">296</xref>]. These adjuvants are reported to specifically enhance the interleukin-17 (IL-17) response, thereby activating antigen-specific T helper cell responses [<xref rid="B285-pharmaceutics-15-02114" ref-type="bibr">285</xref>,<xref rid="B296-pharmaceutics-15-02114" ref-type="bibr">296</xref>].</p><p>In addition to toxin-based adjuvants, adjuvants based on other biological molecules (e.g., such as polysaccharides, lipids, proteins, and genes) have also been investigated. Polysaccharide-based adjuvants are primarily used to enhance the activity of immune cells, such as macrophages, and induce cytokine-mediated immune responses (e.g., IL-1 and -2 (mannatide), IL-5 and -6 (Advax&#8482;), IL-4 and -13 (chitin)) [<xref rid="B297-pharmaceutics-15-02114" ref-type="bibr">297</xref>,<xref rid="B298-pharmaceutics-15-02114" ref-type="bibr">298</xref>,<xref rid="B299-pharmaceutics-15-02114" ref-type="bibr">299</xref>,<xref rid="B300-pharmaceutics-15-02114" ref-type="bibr">300</xref>,<xref rid="B301-pharmaceutics-15-02114" ref-type="bibr">301</xref>,<xref rid="B302-pharmaceutics-15-02114" ref-type="bibr">302</xref>]. Nucleotide-based adjuvants (e.g., synthetic double-stranded RNA polyriboinosinic acid-polyribocytidylic acid [poly (I:C)], cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN), and cyclic guanosine monophosphate-adenosine monophosphate (2&#8242;3&#8242;-cGAMP or cGAMP)) are, on the other hand, target-specific molecules. For instance, poly (1:C), CpG ODN, and cGAMP specifically interact with Toll-like receptor (TLR) 3, TLR9, and stimulator of interferon genes (STING) receptors, respectively, activating inflammatory cytokines and type 1 interferon, eventually stimulating both innate and adaptive immune responses [<xref rid="B301-pharmaceutics-15-02114" ref-type="bibr">301</xref>,<xref rid="B302-pharmaceutics-15-02114" ref-type="bibr">302</xref>,<xref rid="B303-pharmaceutics-15-02114" ref-type="bibr">303</xref>,<xref rid="B304-pharmaceutics-15-02114" ref-type="bibr">304</xref>,<xref rid="B305-pharmaceutics-15-02114" ref-type="bibr">305</xref>,<xref rid="B306-pharmaceutics-15-02114" ref-type="bibr">306</xref>].</p><p>Lipid-based adjuvants (e.g., liposomes, lipid nanoparticles, emulsions, and immune-stimulating complexes (ISCOMs)) are often employed as vaccine carriers with adjuvanticity, capable of incorporating other additives, as well as facilitating interactions between vaccines and dendritic cells (DCs) [<xref rid="B307-pharmaceutics-15-02114" ref-type="bibr">307</xref>]. Protein-based adjuvants (e.g., flagellin, poly(&#947;-glutamic acid), and proteosome), meanwhile, function as ligands for receptors (TLR5, TLR4, and TLR2, respectively) [<xref rid="B308-pharmaceutics-15-02114" ref-type="bibr">308</xref>,<xref rid="B309-pharmaceutics-15-02114" ref-type="bibr">309</xref>,<xref rid="B310-pharmaceutics-15-02114" ref-type="bibr">310</xref>]. Their interactions activate helper T cells and cytotoxic T cells, thus stimulating adaptive immunity [<xref rid="B311-pharmaceutics-15-02114" ref-type="bibr">311</xref>].</p><p>Despite the advantages offered by adjuvants, only a few have received FDA approval, including aluminum salts, adjuvant System 04 (AS04), oil-in-water emulsion, CpG 1018, and Quillaja saponaria 21 (QS-21) [<xref rid="B312-pharmaceutics-15-02114" ref-type="bibr">312</xref>]. This delayed progress in developing vaccine adjuvants is primarily attributed to their reactogenicity and potential interactions with vaccines [<xref rid="B313-pharmaceutics-15-02114" ref-type="bibr">313</xref>]. Consequently, in order to advance the development of vaccine adjuvants, extensive research into their interaction mechanisms with vaccines and the human body is essential, along with thorough preclinical and clinical studies aimed at establishing the safety profiles of emerging adjuvants.</p></sec><sec id="sec3dot5-pharmaceutics-15-02114"><title>3.5. Future Perspectives</title><p>Researchers have highlighted the numerous advantages of non-invasive vaccines compared to their invasive counterparts. One significant advantage is the potential to increase vaccination rates by eliminating needle-related fears and phobias that affect a substantial portion of children, adolescents (20&#8211;50%), and young adults (20&#8211;30%) [<xref rid="B314-pharmaceutics-15-02114" ref-type="bibr">314</xref>]. Additionally, non-invasive vaccines are cost-effective by eliminating the need for cold chain systems, specialized facilities, and experienced personnel. Furthermore, disease-specific immunization can be achieved by developing and commercializing non-invasive vaccines. As shown in <xref rid="pharmaceutics-15-02114-t002" ref-type="table">Table 2</xref>, <xref rid="pharmaceutics-15-02114-t003" ref-type="table">Table 3</xref> and <xref rid="pharmaceutics-15-02114-t004" ref-type="table">Table 4</xref>, each administration method targets different diseases: intestine diseases (oral vaccines), respiratory diseases (intranasal vaccines), and outmost skin diseases (transcutaneous). Such an approach concentrates and maximizes immune responses at targeted sites. Additionally, in this sense, combination treatments of different non-invasive vaccines hold the potential for multi-site targeting. However, there is still a scarcity of approved non-invasive vaccines, as well as pre-clinical and clinical trials focused on non-invasive vaccines [<xref rid="B24-pharmaceutics-15-02114" ref-type="bibr">24</xref>,<xref rid="B29-pharmaceutics-15-02114" ref-type="bibr">29</xref>,<xref rid="B77-pharmaceutics-15-02114" ref-type="bibr">77</xref>,<xref rid="B315-pharmaceutics-15-02114" ref-type="bibr">315</xref>]. Therefore, further research endeavors should be directed towards addressing the challenges of non-invasive vaccines, optimizing their formulations and administration methods, in order to expand their usage and pave the way for effective global immunization against future disease outbreaks.</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceutics-15-02114"><title>4. Conclusions</title><p>Despite the evident benefits of non-invasive vaccines, their commercialization has encountered physiological barriers that impede the efficient delivery of vaccines to immunological cells, such as antigen-presenting cells (APCs). Each non-invasive vaccine faces specific challenges that restrict their bioavailability. For example, oral administration is hindered by gastrointestinal fluids and mucosal layers, intranasal administration is hindered by mucosal layers, and transcutaneous administration is hindered by the stratum corneum. Therefore, to enhance the immunogenicity of non-invasive vaccines, the formulation of the vaccine should carefully consider limitations associated with each route of administration. Additionally, various supplementary materials can be employed in vaccine formulation to enhance bioavailability, such as pH-sensitive polymers, mucus-penetrating polymers, and microneedles for addressing gastrointestinal fluids, mucosal layers, and the stratum corneum, respectively.</p><p>To optimize the immunogenicity of vaccines and minimize their immune-toxicity, careful selection of vaccine types and adjuvants is also essential, as different combinations of these components can lead to varying immune responses and clinical outcomes. For instance, for non-invasive administration with low immunogenicity, adjuvants are often combined with whole-particle-based vaccines to boost their effectiveness. On the other hand, in the case of invasive administration, whole-particle-based vaccines are typically not paired with adjuvants due to their inherent high immunogenicity, whereas adjuvants are mostly used with subunit vaccines due to their lower immunogenicity.</p><p>Adjuvants serve not only as immune enhancers but also as carriers for vaccines. These carriers can be further functionalized with other types of adjuvants to bolster immune responses or coupled with anchor proteins and stabilizers for improved performance. Nevertheless, careful consideration must be given to the selection of adjuvants to be paired with vaccines, and their toxicity should be thoroughly assessed through pre-clinical and clinical tests prior to clinical application. Only with such precautions in practice will the development of effective, safe non-invasive vaccines be achieved.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>S.H., P.L. and H.-J.C. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-15-02114"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lloyd</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lydon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ouhichi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zaffran</surname><given-names>M.</given-names></name></person-group><article-title>Reducing the loss of vaccines from accidental freezing in the cold chain: The experience of continuous temperature monitoring in Tunisia</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>902</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.10.080</pub-id><pub-id pub-id-type="pmid">25444810</pub-id><pub-id pub-id-type="pmcid">PMC4319682</pub-id></element-citation></ref><ref id="B2-pharmaceutics-15-02114"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Criscuolo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Diotti</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Sautto</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Kirchenbaum</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Clementi</surname><given-names>N.</given-names></name></person-group><article-title>Alternative methods of vaccine delivery: An overview of edible and intradermal vaccines</article-title><source>J. Immunol. Res.</source><year>2019</year><volume>2019</volume><fpage>8303648</fpage><pub-id pub-id-type="doi">10.1155/2019/8303648</pub-id><pub-id pub-id-type="pmid">30949518</pub-id><pub-id pub-id-type="pmcid">PMC6425294</pub-id></element-citation></ref><ref id="B3-pharmaceutics-15-02114"><label>3.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>COVID-19 Vaccination: Supply and Logistics Guidance</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/who-2019-ncov-vaccine-deployment-logistics-2021-1" ext-link-type="uri">https://www.who.int/publications/i/item/who-2019-ncov-vaccine-deployment-logistics-2021-1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-01-13">(accessed on 13 January 2023)</date-in-citation></element-citation></ref><ref id="B4-pharmaceutics-15-02114"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crommelin</surname><given-names>D.J.A.</given-names></name><name name-style="western"><surname>Anchordoquy</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Volkin</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mastrobattista</surname><given-names>E.</given-names></name></person-group><article-title>Addressing the cold reality of mRNA vaccine stability</article-title><source>J. Pharm. Sci.</source><year>2021</year><volume>110</volume><fpage>997</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2020.12.006</pub-id><pub-id pub-id-type="pmid">33321139</pub-id><pub-id pub-id-type="pmcid">PMC7834447</pub-id></element-citation></ref><ref id="B5-pharmaceutics-15-02114"><label>5.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group><article-title>Vaccine Administration</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html" ext-link-type="uri">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-05">(accessed on 5 February 2023)</date-in-citation></element-citation></ref><ref id="B6-pharmaceutics-15-02114"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deisenhammer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Radon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reichert</surname><given-names>J.</given-names></name></person-group><article-title>Needlestick injuries during medical training</article-title><source>J. Hosp. Infect.</source><year>2006</year><volume>63</volume><fpage>263</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2006.01.019</pub-id><pub-id pub-id-type="pmid">16650505</pub-id></element-citation></ref><ref id="B7-pharmaceutics-15-02114"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>SARS-CoV-2 vaccines in development</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>516</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2798-3</pub-id><pub-id pub-id-type="pmid">32967006</pub-id></element-citation></ref><ref id="B8-pharmaceutics-15-02114"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.K.</given-names></name></person-group><article-title>Delivery routes for COVID-19 vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>524</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9050524</pub-id><pub-id pub-id-type="pmid">34069359</pub-id><pub-id pub-id-type="pmcid">PMC8158705</pub-id></element-citation></ref><ref id="B9-pharmaceutics-15-02114"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>X.</given-names></name><name name-style="western"><surname>Martinez-Paniagua</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rezvan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sefat</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Fathi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pourpak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2</article-title><source>iScience</source><year>2021</year><volume>24</volume><fpage>103037</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2021.103037</pub-id><pub-id pub-id-type="pmid">34462731</pub-id><pub-id pub-id-type="pmcid">PMC8388188</pub-id></element-citation></ref><ref id="B10-pharmaceutics-15-02114"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Krebs</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Haigwood</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>H.S.</given-names></name></person-group><article-title>Vaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunity</article-title><source>Pharm. Res.</source><year>2014</year><volume>31</volume><fpage>2393</fpage><lpage>2403</lpage><pub-id pub-id-type="doi">10.1007/s11095-014-1335-1</pub-id><pub-id pub-id-type="pmid">24623480</pub-id><pub-id pub-id-type="pmcid">PMC4163144</pub-id></element-citation></ref><ref id="B11-pharmaceutics-15-02114"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>K.A.</given-names></name></person-group><article-title>Louis Pasteur, the father of immunology?</article-title><source>Front. Immunol.</source><year>2012</year><volume>3</volume><fpage>68</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2012.00068</pub-id><pub-id pub-id-type="pmid">22566949</pub-id><pub-id pub-id-type="pmcid">PMC3342039</pub-id></element-citation></ref><ref id="B12-pharmaceutics-15-02114"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trovato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sartorius</surname><given-names>R.</given-names></name><name name-style="western"><surname>D&#8217;Apice</surname><given-names>L.</given-names></name><name name-style="western"><surname>Manco</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Berardinis</surname><given-names>P.</given-names></name></person-group><article-title>Viral emerging diseases: Challenges in developing vaccination strategies</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>2130</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.02130</pub-id><pub-id pub-id-type="pmid">33013898</pub-id><pub-id pub-id-type="pmcid">PMC7494754</pub-id></element-citation></ref><ref id="B13-pharmaceutics-15-02114"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellamkonda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>U.P.</given-names></name><name name-style="western"><surname>Sawant</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nandi</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>D.</given-names></name></person-group><article-title>Immune Response to SARS-CoV-2 Vaccines</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>1464</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10071464</pub-id><pub-id pub-id-type="pmid">35884770</pub-id><pub-id pub-id-type="pmcid">PMC9312515</pub-id></element-citation></ref><ref id="B14-pharmaceutics-15-02114"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutzler</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D.B.</given-names></name></person-group><article-title>DNA vaccines: Ready for prime time?</article-title><source>Nat. Rev. Genet.</source><year>2008</year><volume>9</volume><fpage>776</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1038/nrg2432</pub-id><pub-id pub-id-type="pmid">18781156</pub-id><pub-id pub-id-type="pmcid">PMC4317294</pub-id></element-citation></ref><ref id="B15-pharmaceutics-15-02114"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maruggi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Advances in mRNA vaccines for infectious diseases</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>594</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00594</pub-id><pub-id pub-id-type="pmid">30972078</pub-id><pub-id pub-id-type="pmcid">PMC6446947</pub-id></element-citation></ref><ref id="B16-pharmaceutics-15-02114"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#8217;kovski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kratzel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stalder</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thiel</surname><given-names>V.</given-names></name></person-group><article-title>Coronavirus biology and replication: Implications for SARS-CoV-2</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>155</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-00468-6</pub-id><pub-id pub-id-type="pmid">33116300</pub-id><pub-id pub-id-type="pmcid">PMC7592455</pub-id></element-citation></ref><ref id="B17-pharmaceutics-15-02114"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert-Guroff</surname><given-names>M.</given-names></name></person-group><article-title>Replicating and non-replicating viral vectors for vaccine development</article-title><source>Curr. Opin. Biotechnol.</source><year>2007</year><volume>18</volume><fpage>546</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2007.10.010</pub-id><pub-id pub-id-type="pmid">18063357</pub-id><pub-id pub-id-type="pmcid">PMC2245896</pub-id></element-citation></ref><ref id="B18-pharmaceutics-15-02114"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.A.</given-names></name></person-group><article-title>DNA vaccines: A review</article-title><source>J. Intern. Med.</source><year>2003</year><volume>253</volume><fpage>402</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2796.2003.01140.x</pub-id><pub-id pub-id-type="pmid">12653868</pub-id></element-citation></ref><ref id="B19-pharmaceutics-15-02114"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollard</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bijker</surname><given-names>E.M.</given-names></name></person-group><article-title>A guide to vaccinology: From basic principles to new developments</article-title><source>Nat. Rev. Immunol.</source><year>2021</year><volume>21</volume><fpage>83</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00479-7</pub-id><pub-id pub-id-type="pmid">33353987</pub-id><pub-id pub-id-type="pmcid">PMC7754704</pub-id></element-citation></ref><ref id="B20-pharmaceutics-15-02114"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>A.</given-names></name></person-group><article-title>Th1 and Th2 responses: What are they?</article-title><source>BMJ</source><year>2000</year><volume>321</volume><fpage>424</fpage><pub-id pub-id-type="doi">10.1136/bmj.321.7258.424</pub-id><pub-id pub-id-type="pmid">10938051</pub-id><pub-id pub-id-type="pmcid">PMC27457</pub-id></element-citation></ref><ref id="B21-pharmaceutics-15-02114"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanagawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Iwabuchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ono&#233;</surname><given-names>K.</given-names></name></person-group><article-title>Co-operative action of interleukin-10 and interferon-&#947; to regulate dendritic cell functions</article-title><source>Immunology</source><year>2009</year><volume>127</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2008.02986.x</pub-id><pub-id pub-id-type="pmid">19191915</pub-id><pub-id pub-id-type="pmcid">PMC2712103</pub-id></element-citation></ref><ref id="B22-pharmaceutics-15-02114"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shirouzu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshimura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ushigome</surname><given-names>H.</given-names></name></person-group><article-title>The role of major histocompatibility complex in organ transplantation-donor specific anti-major histocompatibility complex antibodies analysis goes to the next stage</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>4544</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20184544</pub-id><pub-id pub-id-type="pmid">31540289</pub-id><pub-id pub-id-type="pmcid">PMC6769817</pub-id></element-citation></ref><ref id="B23-pharmaceutics-15-02114"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Ritz</surname><given-names>S.A.</given-names></name></person-group><article-title>The immune system in health and disease</article-title><source>Clinical Immunology</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2004</year><volume>Volume 6</volume><fpage>393</fpage><lpage>416</lpage></element-citation></ref><ref id="B24-pharmaceutics-15-02114"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebert</surname><given-names>D.</given-names></name></person-group><article-title>Experimental evolution of parasites</article-title><source>Science</source><year>1998</year><volume>282</volume><fpage>1432</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1126/science.282.5393.1432</pub-id><pub-id pub-id-type="pmid">9822369</pub-id></element-citation></ref><ref id="B25-pharmaceutics-15-02114"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Datey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chakravortty</surname><given-names>D.</given-names></name></person-group><article-title>Attenuation Methods for Live Vaccines</article-title><source>Methods Mol. Biol.</source><year>2021</year><volume>2183</volume><fpage>331</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">32959252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-0716-0795-4_17</pub-id></element-citation></ref><ref id="B26-pharmaceutics-15-02114"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutherland</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Shiels</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C.G.D.</given-names></name><name name-style="western"><surname>Preston</surname><given-names>P.M.</given-names></name></person-group><article-title><italic toggle="yes">Theileria annulata</italic>: Altered Gene Expression and Clonal Selection during Continuousin VitroCulture</article-title><source>Exp. Parasitol.</source><year>1996</year><volume>83</volume><fpage>125</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1006/expr.1996.0056</pub-id><pub-id pub-id-type="pmid">8654541</pub-id></element-citation></ref><ref id="B27-pharmaceutics-15-02114"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavan</surname><given-names>O.H.</given-names></name><name name-style="western"><surname>Boucias</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Pendland</surname><given-names>J.C.</given-names></name></person-group><article-title>The effects of serial passage of a nucleopolyhedrosis virus through an alternate host system</article-title><source>Entomophaga</source><year>1981</year><volume>26</volume><fpage>99</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1007/BF02371838</pub-id></element-citation></ref><ref id="B28-pharmaceutics-15-02114"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu&#241;oz-L&#243;pez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-P&#233;rez</surname><given-names>J.L.</given-names></name></person-group><article-title>DNA transposons: Nature and applications in genomics</article-title><source>Curr. Genom.</source><year>2010</year><volume>11</volume><fpage>115</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.2174/138920210790886871</pub-id><pub-id pub-id-type="pmid">20885819</pub-id><pub-id pub-id-type="pmcid">PMC2874221</pub-id></element-citation></ref><ref id="B29-pharmaceutics-15-02114"><label>29.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>B.</given-names></name><name name-style="western"><surname>Koldijk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schuitemaker</surname><given-names>H.</given-names></name></person-group><article-title>Inactivated viral vaccines</article-title><source>Vaccine Analysis: Strategies, Principles, and Control</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2015</year></element-citation></ref><ref id="B30-pharmaceutics-15-02114"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lauring</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Andino</surname><given-names>R.</given-names></name></person-group><article-title>Rationalizing the development of live attenuated virus vaccines</article-title><source>Nat. Biotechnol.</source><year>2010</year><volume>28</volume><fpage>573</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1038/nbt.1635</pub-id><pub-id pub-id-type="pmid">20531338</pub-id><pub-id pub-id-type="pmcid">PMC2883798</pub-id></element-citation></ref><ref id="B31-pharmaceutics-15-02114"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burns</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>J.</given-names></name><name name-style="western"><surname>Campagnoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jorba</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>A.</given-names></name><name name-style="western"><surname>Quay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kew</surname><given-names>O.</given-names></name></person-group><article-title>Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>3259</fpage><lpage>3272</lpage><pub-id pub-id-type="doi">10.1128/JVI.80.7.3259-3272.2006</pub-id><pub-id pub-id-type="pmid">16537593</pub-id><pub-id pub-id-type="pmcid">PMC1440415</pub-id></element-citation></ref><ref id="B32-pharmaceutics-15-02114"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delrue</surname><given-names>I.</given-names></name><name name-style="western"><surname>Verzele</surname><given-names>D.</given-names></name><name name-style="western"><surname>Madder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nauwynck</surname><given-names>H.J.</given-names></name></person-group><article-title>Inactivated virus vaccines from chemistry to prophylaxis: Merits, risks and challenges</article-title><source>Expert Rev. Vaccines</source><year>2012</year><volume>11</volume><fpage>695</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1586/erv.12.38</pub-id><pub-id pub-id-type="pmid">22873127</pub-id></element-citation></ref><ref id="B33-pharmaceutics-15-02114"><label>33.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><article-title>Emergency Use Authorization</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization" ext-link-type="uri">https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-25">(accessed on 25 April 2023)</date-in-citation></element-citation></ref><ref id="B34-pharmaceutics-15-02114"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>A.</given-names></name></person-group><article-title>Covaxin: An overview of its immunogenicity and safety trials in India</article-title><source>Bioinformation</source><year>2021</year><volume>17</volume><fpage>840</fpage><pub-id pub-id-type="pmid">35574502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6026/97320630017840</pub-id><pub-id pub-id-type="pmcid">PMC9070630</pub-id></element-citation></ref><ref id="B35-pharmaceutics-15-02114"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanriover</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Do&#287;anay</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#252;ner</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Azap</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akhan</surname><given-names>S.</given-names></name><name name-style="western"><surname>K&#246;se</surname><given-names>&#350;.</given-names></name><name name-style="western"><surname>Erdin&#231;</surname><given-names>F.&#350;.</given-names></name><name name-style="western"><surname>Akal&#305;n</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Tabak</surname><given-names>&#214;.F.</given-names></name></person-group><article-title>Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01429-X</pub-id><pub-id pub-id-type="pmid">34246358</pub-id><pub-id pub-id-type="pmcid">PMC8266301</pub-id></element-citation></ref><ref id="B36-pharmaceutics-15-02114"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tregoning</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Cheeseman</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Flight</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Higham</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Lemm</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Stirling</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>K.M.</given-names></name></person-group><article-title>Vaccines for COVID-19</article-title><source>Clin. Exp. Immunol.</source><year>2020</year><volume>202</volume><fpage>162</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1111/cei.13517</pub-id><pub-id pub-id-type="pmid">32935331</pub-id><pub-id pub-id-type="pmcid">PMC7597597</pub-id></element-citation></ref><ref id="B37-pharmaceutics-15-02114"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;nchez-Ram&#243;n</surname><given-names>S.</given-names></name><name name-style="western"><surname>Conejero</surname><given-names>L.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Sancho</surname><given-names>D.</given-names></name><name name-style="western"><surname>Palomares</surname><given-names>&#211;.</given-names></name><name name-style="western"><surname>Subiza</surname><given-names>J.L.</given-names></name></person-group><article-title>Trained immunity-based vaccines: A new paradigm for the development of broad-spectrum anti-infectious formulations</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2936</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02936</pub-id><pub-id pub-id-type="pmid">30619296</pub-id><pub-id pub-id-type="pmcid">PMC6304371</pub-id></element-citation></ref><ref id="B38-pharmaceutics-15-02114"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Travieso</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahesh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mello</surname><given-names>J.D.F.R.E.</given-names></name><name name-style="western"><surname>Blasi</surname><given-names>M.</given-names></name></person-group><article-title>The use of viral vectors in vaccine development</article-title><source>NPJ Vaccines</source><year>2022</year><volume>7</volume><fpage>75</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00503-y</pub-id><pub-id pub-id-type="pmid">35787629</pub-id><pub-id pub-id-type="pmcid">PMC9253346</pub-id></element-citation></ref><ref id="B39-pharmaceutics-15-02114"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chavda</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Bezbaruah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Athalye</surname><given-names>M.</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Chhipa</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V.</given-names></name></person-group><article-title>Replicating viral vector-based vaccines for COVID-19: Potential avenue in vaccination arena</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>759</elocation-id><pub-id pub-id-type="doi">10.3390/v14040759</pub-id><pub-id pub-id-type="pmid">35458489</pub-id><pub-id pub-id-type="pmcid">PMC9025561</pub-id></element-citation></ref><ref id="B40-pharmaceutics-15-02114"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sm Wold</surname><given-names>W.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>K.</given-names></name></person-group><article-title>Adenovirus vectors for gene therapy, vaccination and cancer gene therapy</article-title><source>Curr. Gene Ther.</source><year>2013</year><volume>13</volume><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.2174/1566523213666131125095046</pub-id><pub-id pub-id-type="pmid">24279313</pub-id><pub-id pub-id-type="pmcid">PMC4507798</pub-id></element-citation></ref><ref id="B41-pharmaceutics-15-02114"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geisbert</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Asiedu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Geisbert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Honko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mulangu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pau</surname><given-names>M.G.</given-names></name></person-group><article-title>Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>4222</fpage><lpage>4233</lpage><pub-id pub-id-type="doi">10.1128/JVI.02407-10</pub-id><pub-id pub-id-type="pmid">21325402</pub-id><pub-id pub-id-type="pmcid">PMC3126236</pub-id></element-citation></ref><ref id="B42-pharmaceutics-15-02114"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negri</surname><given-names>D.R.M.</given-names></name><name name-style="western"><surname>Michelini</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bona</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blasi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Filati</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leone</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cara</surname><given-names>A.</given-names></name></person-group><article-title>Integrase-defective lentiviral-vector-based vaccine: A new vector for induction of T cell immunity</article-title><source>Expert Opin. Biol. Ther.</source><year>2011</year><volume>11</volume><fpage>739</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1517/14712598.2011.571670</pub-id><pub-id pub-id-type="pmid">21434847</pub-id></element-citation></ref><ref id="B43-pharmaceutics-15-02114"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schakowski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gorschl&#252;ter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Junghans</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schroff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Buttgereit</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ziske</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sch&#246;ttker</surname><given-names>B.</given-names></name><name name-style="western"><surname>K&#246;nig-Merediz</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sauerbruch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wittig</surname><given-names>B.</given-names></name></person-group><article-title>A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA</article-title><source>Mol. Ther.</source><year>2001</year><volume>3</volume><fpage>793</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1006/mthe.2001.0322</pub-id><pub-id pub-id-type="pmid">11356084</pub-id></element-citation></ref><ref id="B44-pharmaceutics-15-02114"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>Self-replicating RNA viruses for vaccine development against infectious diseases and cancer</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1187</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9101187</pub-id><pub-id pub-id-type="pmid">34696295</pub-id><pub-id pub-id-type="pmcid">PMC8541504</pub-id></element-citation></ref><ref id="B45-pharmaceutics-15-02114"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafaati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saidijam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soleimani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hazrati</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mirzaei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amirheidari</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tanzadehpanah</surname><given-names>H.</given-names></name><name name-style="western"><surname>Karampoor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kazemi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yavari</surname><given-names>B.</given-names></name></person-group><article-title>A brief review on DNA vaccines in the era of COVID-19</article-title><source>Future Virol.</source><year>2022</year><volume>17</volume><fpage>49</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.2217/fvl-2021-0170</pub-id><pub-id pub-id-type="pmid">34858516</pub-id><pub-id pub-id-type="pmcid">PMC8629371</pub-id></element-citation></ref><ref id="B46-pharmaceutics-15-02114"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carnes</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.A.</given-names></name></person-group><article-title>Inducible <italic toggle="yes">Escherichia coli</italic> fermentation for increased plasmid DNA production</article-title><source>Biotechnol. Appl. Biochem.</source><year>2006</year><volume>45</volume><fpage>155</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">16819941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BA20050223</pub-id></element-citation></ref><ref id="B47-pharmaceutics-15-02114"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tubulekas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Berglund</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fleeton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liljestr&#246;m</surname><given-names>P.</given-names></name></person-group><article-title>Alphavirus expression vectors and their use as recombinant vaccines: A minireview</article-title><source>Gene</source><year>1997</year><volume>190</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/S0378-1119(96)00679-8</pub-id><pub-id pub-id-type="pmid">9185866</pub-id></element-citation></ref><ref id="B48-pharmaceutics-15-02114"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leitner</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>H.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>DNA and RNA-based vaccines: Principles, progress and prospects</article-title><source>Vaccine</source><year>1999</year><volume>18</volume><fpage>765</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00271-6</pub-id><pub-id pub-id-type="pmid">10580187</pub-id><pub-id pub-id-type="pmcid">PMC1986720</pub-id></element-citation></ref><ref id="B49-pharmaceutics-15-02114"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franck</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Fanslau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bistrovic Popov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tyagi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fruk</surname><given-names>L.</given-names></name></person-group><article-title>Biopolymer-based carriers for DNA vaccine design</article-title><source>Angew. Chem. Int. Ed.</source><year>2021</year><volume>60</volume><fpage>13225</fpage><lpage>13243</lpage><pub-id pub-id-type="doi">10.1002/anie.202010282</pub-id><pub-id pub-id-type="pmcid">PMC8247987</pub-id><pub-id pub-id-type="pmid">32893932</pub-id></element-citation></ref><ref id="B50-pharmaceutics-15-02114"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takeshita</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>K.-Q.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>N.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name></person-group><article-title>Adjuvant formulations and delivery systems for DNA vaccines</article-title><source>Methods</source><year>2003</year><volume>31</volume><fpage>243</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/S1046-2023(03)00140-3</pub-id><pub-id pub-id-type="pmid">14511957</pub-id></element-citation></ref><ref id="B51-pharmaceutics-15-02114"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Queiroz</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>&#194;.</given-names></name></person-group><article-title>Minicircle DNA: The future for DNA-based vectors?</article-title><source>Trends Biotechnol.</source><year>2020</year><volume>38</volume><fpage>1047</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2020.04.008</pub-id><pub-id pub-id-type="pmid">32409109</pub-id></element-citation></ref><ref id="B52-pharmaceutics-15-02114"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eus&#233;bio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Maia</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Queiroz</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>&#194;.</given-names></name></person-group><article-title>The performance of minicircle DNA versus parental plasmid in p53 gene delivery into HPV-18-Infected cervical cancer cells</article-title><source>Nucleic Acid Ther.</source><year>2021</year><volume>31</volume><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1089/nat.2020.0904</pub-id><pub-id pub-id-type="pmid">33252302</pub-id></element-citation></ref><ref id="B53-pharmaceutics-15-02114"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ar&#233;valo-Soliz</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Hardee</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Fogg</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Corman</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Noorbakhsh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zechiedrich</surname><given-names>L.</given-names></name></person-group><article-title>Improving therapeutic potential of non-viral minimized DNA vectors</article-title><source>Cell Gene Ther. Insights</source><year>2020</year><volume>6</volume><fpage>1489</fpage><pub-id pub-id-type="doi">10.18609/cgti.2020.163</pub-id><pub-id pub-id-type="pmid">33953961</pub-id><pub-id pub-id-type="pmcid">PMC8095377</pub-id></element-citation></ref><ref id="B54-pharmaceutics-15-02114"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardee</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Ar&#233;valo-Soliz</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Hornstein</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Zechiedrich</surname><given-names>L.</given-names></name></person-group><article-title>Advances in non-viral DNA vectors for gene therapy</article-title><source>Genes</source><year>2017</year><volume>8</volume><elocation-id>65</elocation-id><pub-id pub-id-type="doi">10.3390/genes8020065</pub-id><pub-id pub-id-type="pmid">28208635</pub-id><pub-id pub-id-type="pmcid">PMC5333054</pub-id></element-citation></ref><ref id="B55-pharmaceutics-15-02114"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schakowski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gorschl&#252;ter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Buttgereit</surname><given-names>P.</given-names></name><name name-style="western"><surname>M&#228;rten</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lilienfeld-Toal</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Junghans</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schroff</surname><given-names>M.</given-names></name><name name-style="western"><surname>K&#246;nig-Merediz</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ziske</surname><given-names>C.</given-names></name><name name-style="western"><surname>Strehl</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Minimal Size MIDGE Vectors Improve Transgene Expression <italic toggle="yes">In Vivo</italic></article-title><source>In Vivo</source><year>2007</year><volume>21</volume><fpage>17</fpage><pub-id pub-id-type="pmid">17354609</pub-id></element-citation></ref><ref id="B56-pharmaceutics-15-02114"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.-S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.-J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>C.K.C.</given-names></name><name name-style="western"><surname>Giesy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.-Y.</given-names></name></person-group><article-title>A Novel Micro-Linear Vector for In Vitro and In Vivo Gene Delivery and Its Application for EBV Positive Tumors</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e47159</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0047159</pub-id><pub-id pub-id-type="pmid">23077563</pub-id><pub-id pub-id-type="pmcid">PMC3471901</pub-id></element-citation></ref><ref id="B57-pharmaceutics-15-02114"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karda</surname><given-names>R.</given-names></name><name name-style="western"><surname>Counsell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Karbowniczek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Caproni</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Tite</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Waddington</surname><given-names>S.N.</given-names></name></person-group><article-title>Production of lentiviral vectors using novel, enzymatically produced, linear DNA</article-title><source>Gene Ther.</source><year>2019</year><volume>26</volume><fpage>86</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1038/s41434-018-0056-1</pub-id><pub-id pub-id-type="pmid">30643205</pub-id><pub-id pub-id-type="pmcid">PMC6760675</pub-id></element-citation></ref><ref id="B58-pharmaceutics-15-02114"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>D.O.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Ragwan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sardesai</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Rothwell</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Extance</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Caproni</surname><given-names>L.J.</given-names></name></person-group><article-title>Novel synthetic plasmid and Doggybone&#8482; DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice</article-title><source>Hum. Vaccines Immunother.</source><year>2015</year><volume>11</volume><fpage>1972</fpage><lpage>1982</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1022008</pub-id><pub-id pub-id-type="pmcid">PMC4635705</pub-id><pub-id pub-id-type="pmid">26091432</pub-id></element-citation></ref><ref id="B59-pharmaceutics-15-02114"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grunwald</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ulbert</surname><given-names>S.</given-names></name></person-group><article-title>Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: Vaccine-platforms for the battle against infectious diseases</article-title><source>Clin. Exp. Vaccine Res.</source><year>2015</year><volume>4</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.7774/cevr.2015.4.1.1</pub-id><pub-id pub-id-type="pmid">25648133</pub-id><pub-id pub-id-type="pmcid">PMC4313101</pub-id></element-citation></ref><ref id="B60-pharmaceutics-15-02114"><label>60.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Chellasamy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kiriyanthan</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Govindaraju</surname><given-names>S.</given-names></name><name name-style="western"><surname>Radha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>K.</given-names></name></person-group><article-title>Recent trends in the development of vaccine technologies to combat pandemic outbreaks and challenges</article-title><source>Pandemic Outbreaks in the 21st Century</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2021</year><fpage>235</fpage><lpage>243</lpage></element-citation></ref><ref id="B61-pharmaceutics-15-02114"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tews</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Meyers</surname><given-names>G.</given-names></name></person-group><article-title>Self-Replicating RNA vaccines</article-title><source>Methods Mol. Biol.</source><year>2017</year><volume>1499</volume><fpage>15</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">27987141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-6481-9_2</pub-id><pub-id pub-id-type="pmcid">PMC7122455</pub-id></element-citation></ref><ref id="B62-pharmaceutics-15-02114"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosa</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Prazeres</surname><given-names>D.M.F.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>M.P.C.</given-names></name></person-group><article-title>mRNA vaccines manufacturing: Challenges and bottlenecks</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>2190</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.038</pub-id><pub-id pub-id-type="pmid">33771389</pub-id><pub-id pub-id-type="pmcid">PMC7987532</pub-id></element-citation></ref><ref id="B63-pharmaceutics-15-02114"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>N.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>K.A.</given-names></name></person-group><article-title>mRNA vaccines for infectious diseases: Principles, delivery and clinical translation</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>817</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00283-5</pub-id><pub-id pub-id-type="pmid">34433919</pub-id><pub-id pub-id-type="pmcid">PMC8386155</pub-id></element-citation></ref><ref id="B64-pharmaceutics-15-02114"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Sekhon</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>W.-R.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>B.-K.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.-H.</given-names></name></person-group><article-title>Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency</article-title><source>Mol. Cell. Toxicol.</source><year>2022</year><volume>18</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s13273-021-00171-4</pub-id><pub-id pub-id-type="pmid">34567201</pub-id><pub-id pub-id-type="pmcid">PMC8450916</pub-id></element-citation></ref><ref id="B65-pharmaceutics-15-02114"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccines&#8212;A new era in vaccinology</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation></ref><ref id="B66-pharmaceutics-15-02114"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloom</surname><given-names>K.</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>F.</given-names></name><name name-style="western"><surname>Arbuthnot</surname><given-names>P.</given-names></name></person-group><article-title>Self-amplifying RNA vaccines for infectious diseases</article-title><source>Gene Ther.</source><year>2021</year><volume>28</volume><fpage>117</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/s41434-020-00204-y</pub-id><pub-id pub-id-type="pmid">33093657</pub-id><pub-id pub-id-type="pmcid">PMC7580817</pub-id></element-citation></ref><ref id="B67-pharmaceutics-15-02114"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Greer</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Thudium</surname><given-names>K.</given-names></name><name name-style="western"><surname>Doe</surname><given-names>B.</given-names></name><name name-style="western"><surname>Legg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dubensky</surname><given-names>T.W.</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>10394</fpage><lpage>10403</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.19.10394-10403.2003</pub-id><pub-id pub-id-type="pmid">12970424</pub-id><pub-id pub-id-type="pmcid">PMC228391</pub-id></element-citation></ref><ref id="B68-pharmaceutics-15-02114"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajj</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>K.A.</given-names></name></person-group><article-title>Tools for translation: Non-viral materials for therapeutic mRNA delivery</article-title><source>Nat. Rev. Mater.</source><year>2017</year><volume>2</volume><fpage>17056</fpage><pub-id pub-id-type="doi">10.1038/natrevmats.2017.56</pub-id></element-citation></ref><ref id="B69-pharmaceutics-15-02114"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caillaud</surname><given-names>M.-C.</given-names></name></person-group><article-title>Anionic lipids: A pipeline connecting key players of plant cell division</article-title><source>Front. Plant Sci.</source><year>2019</year><volume>10</volume><fpage>419</fpage><pub-id pub-id-type="doi">10.3389/fpls.2019.00419</pub-id><pub-id pub-id-type="pmid">31110508</pub-id><pub-id pub-id-type="pmcid">PMC6499208</pub-id></element-citation></ref><ref id="B70-pharmaceutics-15-02114"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowalski</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Rudra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.G.</given-names></name></person-group><article-title>Delivering the messenger: Advances in technologies for therapeutic mRNA delivery</article-title><source>Mol. Ther.</source><year>2019</year><volume>27</volume><fpage>710</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.02.012</pub-id><pub-id pub-id-type="pmid">30846391</pub-id><pub-id pub-id-type="pmcid">PMC6453548</pub-id></element-citation></ref><ref id="B71-pharmaceutics-15-02114"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Butowska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Swingle</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Alameh</surname><given-names>M.-G.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>M.J.</given-names></name></person-group><article-title>An ionizable lipid toolbox for RNA delivery</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>7233</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-27493-0</pub-id><pub-id pub-id-type="pmid">34903741</pub-id><pub-id pub-id-type="pmcid">PMC8668901</pub-id></element-citation></ref><ref id="B72-pharmaceutics-15-02114"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name></person-group><article-title>Lipid nanoparticles for mRNA delivery</article-title><source>Nat. Rev. Mater.</source><year>2021</year><volume>6</volume><fpage>1078</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/s41578-021-00358-0</pub-id><pub-id pub-id-type="pmid">34394960</pub-id><pub-id pub-id-type="pmcid">PMC8353930</pub-id></element-citation></ref><ref id="B73-pharmaceutics-15-02114"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>J.C.-T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name></person-group><article-title>Modification of lipid-based nanoparticles: An efficient delivery system for nucleic acid-based immunotherapy</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>1943</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27061943</pub-id><pub-id pub-id-type="pmid">35335310</pub-id><pub-id pub-id-type="pmcid">PMC8949521</pub-id></element-citation></ref><ref id="B74-pharmaceutics-15-02114"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lynn</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name></person-group><article-title>Degradable poly (&#946;-amino esters): Synthesis, characterization, and self-assembly with plasmid DNA</article-title><source>J. Am. Chem. Soc.</source><year>2000</year><volume>122</volume><fpage>10761</fpage><lpage>10768</lpage><pub-id pub-id-type="doi">10.1021/ja0015388</pub-id></element-citation></ref><ref id="B75-pharmaceutics-15-02114"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Kale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hartner</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Papahadjopoulos-Sternberg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V.P.</given-names></name></person-group><article-title>Self-assembling micelle-like nanoparticles based on phospholipid&#8211;polyethyleneimine conjugates for systemic gene delivery</article-title><source>J. Control. Release</source><year>2009</year><volume>133</volume><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2008.09.079</pub-id><pub-id pub-id-type="pmid">18929605</pub-id><pub-id pub-id-type="pmcid">PMC3183824</pub-id></element-citation></ref><ref id="B76-pharmaceutics-15-02114"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>B.</given-names></name></person-group><article-title>Chitosan microspheres in novel drug delivery systems</article-title><source>Indian J. Pharm. Sci.</source><year>2011</year><volume>73</volume><fpage>355</fpage><pub-id pub-id-type="pmid">22707817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0250-474X.95607</pub-id><pub-id pub-id-type="pmcid">PMC3374549</pub-id></element-citation></ref><ref id="B77-pharmaceutics-15-02114"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramirez</surname><given-names>J.E.V.</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Peppas</surname><given-names>N.A.</given-names></name></person-group><article-title>Current state and challenges in developing oral vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><year>2017</year><volume>114</volume><fpage>116</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2017.04.008</pub-id><pub-id pub-id-type="pmid">28438674</pub-id><pub-id pub-id-type="pmcid">PMC6132247</pub-id></element-citation></ref><ref id="B78-pharmaceutics-15-02114"><label>78.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cecil</surname><given-names>R.L.F.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>A.I.</given-names></name></person-group><source>Goldman&#8217;s Cecil Medicine, Expert Consult Premium Edition&#8212;Enhanced Online Features and Print, Single Volume, 24: Goldman&#8217;s Cecil Medicine</source><publisher-name>Elsevier Health Sciences</publisher-name><publisher-loc>Philadelphia, PA, USA</publisher-loc><year>2012</year><volume>Volume 1</volume></element-citation></ref><ref id="B79-pharmaceutics-15-02114"><label>79.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Rich</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Fleisher</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Shearer</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>H.W.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Frew</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Weyand</surname><given-names>C.M.</given-names></name></person-group><source>Clinical Immunology E-Book: Principles and Practice</source><publisher-name>Elsevier Health Sciences</publisher-name><publisher-loc>Philadelphia, PA, USA</publisher-loc><year>2012</year></element-citation></ref><ref id="B80-pharmaceutics-15-02114"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eliakim-Raz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leibovici</surname><given-names>L.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>M.</given-names></name></person-group><article-title>Conjugated pneumococcal vaccine versus polysaccharide pneumococcal vaccine for prevention of pneumonia and invasive pneumococcal disease in immunocompetent and immunocompromised adults and children</article-title><source>Cochrane Database Syst. Rev.</source><year>2019</year><volume>2019</volume><fpage>CD012306</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD012306.pub2</pub-id></element-citation></ref><ref id="B81-pharmaceutics-15-02114"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pichichero</surname><given-names>M.E.</given-names></name></person-group><article-title>Protein carriers of conjugate vaccines: Characteristics, development, and clinical trials</article-title><source>Hum. Vaccines Immunother.</source><year>2013</year><volume>9</volume><fpage>2505</fpage><lpage>2523</lpage><pub-id pub-id-type="doi">10.4161/hv.26109</pub-id><pub-id pub-id-type="pmid">23955057</pub-id><pub-id pub-id-type="pmcid">PMC4162048</pub-id></element-citation></ref><ref id="B82-pharmaceutics-15-02114"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giannini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ratti</surname><given-names>G.</given-names></name></person-group><article-title>The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197</article-title><source>Nucleic Acids Res.</source><year>1984</year><volume>12</volume><fpage>4063</fpage><lpage>4069</lpage><pub-id pub-id-type="doi">10.1093/nar/12.10.4063</pub-id><pub-id pub-id-type="pmid">6427753</pub-id><pub-id pub-id-type="pmcid">PMC318816</pub-id></element-citation></ref><ref id="B83-pharmaceutics-15-02114"><label>83.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sahu</surname><given-names>U.</given-names></name><name name-style="western"><surname>Khare</surname><given-names>P.</given-names></name></person-group><article-title>Chapter 2&#8212;Evolution and development of vaccines against major human infections</article-title><source>System Vaccinology</source><person-group person-group-type="editor"><name name-style="western"><surname>Prajapati</surname><given-names>V.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2022</year><fpage>17</fpage><lpage>30</lpage></element-citation></ref><ref id="B84-pharmaceutics-15-02114"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>P.</given-names></name></person-group><article-title>Meningococcal group A, C, Y and W-135 conjugate vaccine</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>429</fpage><pub-id pub-id-type="doi">10.1038/nrd3194</pub-id><pub-id pub-id-type="pmid">20514064</pub-id></element-citation></ref><ref id="B85-pharmaceutics-15-02114"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruan</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Akkoyunlu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grubb</surname><given-names>A.</given-names></name><name name-style="western"><surname>Forsgren</surname><given-names>A.</given-names></name></person-group><article-title>Protein D of <italic toggle="yes">Haemophilus influenzae</italic>. A novel bacterial surface protein with affinity for human IgD</article-title><source>J. Immunol.</source><year>1990</year><volume>145</volume><fpage>3379</fpage><lpage>3384</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.145.10.3379</pub-id><pub-id pub-id-type="pmid">2230124</pub-id></element-citation></ref><ref id="B86-pharmaceutics-15-02114"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brisse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vrba</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>H.</given-names></name></person-group><article-title>Emerging concepts and technologies in vaccine development</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>583077</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.583077</pub-id><pub-id pub-id-type="pmid">33101309</pub-id><pub-id pub-id-type="pmcid">PMC7554600</pub-id></element-citation></ref><ref id="B87-pharmaceutics-15-02114"><label>87.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Donaldson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Al-Barwani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Young</surname><given-names>V.</given-names></name><name name-style="western"><surname>Scullion</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>V.</given-names></name><name name-style="western"><surname>Young</surname><given-names>S.</given-names></name></person-group><article-title>Virus-like particles, a versatile subunit vaccine platform</article-title><source>Subunit Vaccine Delivery</source><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2015</year><fpage>159</fpage><lpage>180</lpage></element-citation></ref><ref id="B88-pharmaceutics-15-02114"><label>88.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khurana</surname><given-names>S.M.</given-names></name></person-group><source>Vaccines: Present Status and Application</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2013</year><fpage>491</fpage><lpage>508</lpage></element-citation></ref><ref id="B89-pharmaceutics-15-02114"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>R.G.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rigsby</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sesardic</surname><given-names>D.</given-names></name></person-group><article-title>An improved method for development of toxoid vaccines and antitoxins</article-title><source>J. Immunol. Methods</source><year>2008</year><volume>337</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2008.05.009</pub-id><pub-id pub-id-type="pmid">18571196</pub-id></element-citation></ref><ref id="B90-pharmaceutics-15-02114"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huisman</surname><given-names>W.</given-names></name><name name-style="western"><surname>Martina</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Rimmelzwaan</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Gruters</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.</given-names></name></person-group><article-title>Vaccine-induced enhancement of viral infections</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>505</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.10.087</pub-id><pub-id pub-id-type="pmid">19022319</pub-id><pub-id pub-id-type="pmcid">PMC7131326</pub-id></element-citation></ref><ref id="B91-pharmaceutics-15-02114"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>1107</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00127-4</pub-id><pub-id pub-id-type="pmid">33773111</pub-id><pub-id pub-id-type="pmcid">PMC7990482</pub-id></element-citation></ref><ref id="B92-pharmaceutics-15-02114"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: Implication for vaccine design</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>5757</fpage><lpage>5767</lpage><pub-id pub-id-type="doi">10.1128/JVI.00083-06</pub-id><pub-id pub-id-type="pmid">16731915</pub-id><pub-id pub-id-type="pmcid">PMC1472569</pub-id></element-citation></ref><ref id="B93-pharmaceutics-15-02114"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ulitzky</surname><given-names>L.</given-names></name><name name-style="western"><surname>Silberstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Viscidi</surname><given-names>R.</given-names></name></person-group><article-title>Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates</article-title><source>Viral Immunol.</source><year>2013</year><volume>26</volume><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1089/vim.2012.0076</pub-id><pub-id pub-id-type="pmid">23573979</pub-id><pub-id pub-id-type="pmcid">PMC3624630</pub-id></element-citation></ref><ref id="B94-pharmaceutics-15-02114"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>S.-S.</given-names></name><name name-style="western"><surname>Webby Richard</surname><given-names>J.</given-names></name></person-group><article-title>Traditional and new influenza vaccines</article-title><source>Clin. Microbiol. Rev.</source><year>2013</year><volume>26</volume><fpage>476</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1128/CMR.00097-12</pub-id><pub-id pub-id-type="pmid">23824369</pub-id><pub-id pub-id-type="pmcid">PMC3719499</pub-id></element-citation></ref><ref id="B95-pharmaceutics-15-02114"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.-J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Advancements in the development of subunit influenza vaccines</article-title><source>Microbes Infect.</source><year>2015</year><volume>17</volume><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2014.12.006</pub-id><pub-id pub-id-type="pmid">25529753</pub-id><pub-id pub-id-type="pmcid">PMC4336774</pub-id></element-citation></ref><ref id="B96-pharmaceutics-15-02114"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nobusawa</surname><given-names>E.</given-names></name></person-group><article-title>Structure and function of the hemagglutinin of influenza viruses</article-title><source>Nihon Rinsho Jpn. J. Clin. Med.</source><year>1997</year><volume>55</volume><fpage>2562</fpage><lpage>2569</lpage><pub-id pub-id-type="pmid">9360372</pub-id></element-citation></ref><ref id="B97-pharmaceutics-15-02114"><label>97.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>H.-J.</given-names></name></person-group><article-title>Chapter four&#8212;perspective of peptide vaccine composed of epitope peptide, CpG-DNA, and liposome complex without carriers</article-title><source>Advances in Protein Chemistry and Structural Biology</source><person-group person-group-type="editor"><name name-style="western"><surname>Donev</surname><given-names>R.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2015</year><volume>Volume 99</volume><fpage>75</fpage><lpage>97</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.apcsb.2015.03.004</pub-id><pub-id pub-id-type="pmid">26067817</pub-id></element-citation></ref><ref id="B98-pharmaceutics-15-02114"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van der Weken</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>E.</given-names></name><name name-style="western"><surname>Devriendt</surname><given-names>B.</given-names></name></person-group><article-title>Advances in oral subunit vaccine design</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9010001</pub-id><pub-id pub-id-type="pmid">33375151</pub-id><pub-id pub-id-type="pmcid">PMC7822154</pub-id></element-citation></ref><ref id="B99-pharmaceutics-15-02114"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>F.</given-names></name></person-group><article-title>A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: Development, characterization, stability and in vivo evaluation</article-title><source>Int. J. Pharm.</source><year>2014</year><volume>468</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.04.003</pub-id><pub-id pub-id-type="pmid">24704309</pub-id></element-citation></ref><ref id="B100-pharmaceutics-15-02114"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Chon</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Sangwai</surname><given-names>J.S.</given-names></name></person-group><article-title>Thermal stability of oil-in-water Pickering emulsion in the presence of nanoparticle, surfactant, and polymer</article-title><source>J. Ind. Eng. Chem.</source><year>2015</year><volume>22</volume><fpage>324</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.jiec.2014.07.026</pub-id></element-citation></ref><ref id="B101-pharmaceutics-15-02114"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siva</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Kow</surname><given-names>K.-W.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>Y.K.</given-names></name></person-group><article-title>Prediction of droplet sizes for oil-in-water emulsion systems assisted by ultrasound cavitation: Transient scaling law based on dynamic breakup potential</article-title><source>Ultrason. Sonochem.</source><year>2019</year><volume>55</volume><fpage>348</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.ultsonch.2018.12.040</pub-id><pub-id pub-id-type="pmid">30871878</pub-id></element-citation></ref><ref id="B102-pharmaceutics-15-02114"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lenzo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holden</surname><given-names>J.</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Brien-Simpson</surname><given-names>N.</given-names></name></person-group><article-title>The potential of calcium phosphate nanoparticles as adjuvants and vaccine delivery vehicles</article-title><source>Front. Mater.</source><year>2021</year><volume>8</volume><fpage>788373</fpage><pub-id pub-id-type="doi">10.3389/fmats.2021.788373</pub-id></element-citation></ref><ref id="B103-pharmaceutics-15-02114"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrando</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Lay</surname><given-names>L.</given-names></name><name name-style="western"><surname>Polito</surname><given-names>L.</given-names></name></person-group><article-title>Gold nanoparticle-based platforms for vaccine development</article-title><source>Drug Discov. Today Technol.</source><year>2020</year><volume>38</volume><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2021.02.001</pub-id><pub-id pub-id-type="pmid">34895641</pub-id></element-citation></ref><ref id="B104-pharmaceutics-15-02114"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name></person-group><article-title>Biodegradable inorganic nanoparticles for cancer theranostics: Insights into the degradation behavior</article-title><source>Bioconjug Chem.</source><year>2020</year><volume>31</volume><fpage>315</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.9b00699</pub-id><pub-id pub-id-type="pmid">31765561</pub-id></element-citation></ref><ref id="B105-pharmaceutics-15-02114"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duewell</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kisser</surname><given-names>U.</given-names></name><name name-style="western"><surname>Heckelsmiller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hoves</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stoitzner</surname><given-names>P.</given-names></name><name name-style="western"><surname>Koernig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morelli</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Clausen</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Dauer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eigler</surname><given-names>A.</given-names></name></person-group><article-title>ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells</article-title><source>J. Immunol.</source><year>2011</year><volume>187</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1004114</pub-id><pub-id pub-id-type="pmid">21613613</pub-id><pub-id pub-id-type="pmcid">PMC4285562</pub-id></element-citation></ref><ref id="B106-pharmaceutics-15-02114"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#246;vgren Bengtsson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name></person-group><article-title>ISCOM technology-based Matrix M&#8482; adjuvant: Success in future vaccines relies on formulation</article-title><source>Expert Rev. Vaccines</source><year>2011</year><volume>10</volume><fpage>401</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1586/erv.11.25</pub-id><pub-id pub-id-type="pmid">21506635</pub-id></element-citation></ref><ref id="B107-pharmaceutics-15-02114"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levast</surname><given-names>B.</given-names></name><name name-style="western"><surname>Awate</surname><given-names>S.</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mutwiri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gerdts</surname><given-names>V.</given-names></name><name name-style="western"><surname>van Drunen Littel-van den Hurk</surname><given-names>S.</given-names></name></person-group><article-title>Vaccine potentiation by combination adjuvants</article-title><source>Vaccines</source><year>2014</year><volume>2</volume><fpage>297</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.3390/vaccines2020297</pub-id><pub-id pub-id-type="pmid">26344621</pub-id><pub-id pub-id-type="pmcid">PMC4494260</pub-id></element-citation></ref><ref id="B108-pharmaceutics-15-02114"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brewer</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Tetley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liew</surname><given-names>F.Y.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>J.</given-names></name></person-group><article-title>Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen</article-title><source>J. Immunol.</source><year>1998</year><volume>161</volume><fpage>4000</fpage><lpage>4007</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.161.8.4000</pub-id><pub-id pub-id-type="pmid">9780169</pub-id></element-citation></ref><ref id="B109-pharmaceutics-15-02114"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attia</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Essa</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Elebyary</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Faheem</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Elkordy</surname><given-names>A.A.</given-names></name></person-group><article-title>Brief on recent application of liposomal vaccines for lower respiratory tract viral infections: From influenza to COVID-19 vaccines</article-title><source>Pharmaceuticals</source><year>2021</year><volume>14</volume><elocation-id>1173</elocation-id><pub-id pub-id-type="doi">10.3390/ph14111173</pub-id><pub-id pub-id-type="pmid">34832955</pub-id><pub-id pub-id-type="pmcid">PMC8619292</pub-id></element-citation></ref><ref id="B110-pharmaceutics-15-02114"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregoriadis</surname><given-names>G.</given-names></name></person-group><article-title>Liposomes and mRNA: Two technologies together create a COVID-19 vaccine</article-title><source>Med. Drug Discov.</source><year>2021</year><volume>12</volume><fpage>100104</fpage><pub-id pub-id-type="doi">10.1016/j.medidd.2021.100104</pub-id></element-citation></ref><ref id="B111-pharmaceutics-15-02114"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mann</surname><given-names>J.F.S.</given-names></name><name name-style="western"><surname>Shakir</surname><given-names>E.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Mullen</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferro</surname><given-names>V.A.</given-names></name></person-group><article-title>Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>3643</fpage><lpage>3649</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.03.040</pub-id><pub-id pub-id-type="pmid">19464545</pub-id></element-citation></ref><ref id="B112-pharmaceutics-15-02114"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corth&#233;sy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bioley</surname><given-names>G.</given-names></name></person-group><article-title>Lipid-based particles: Versatile delivery systems for mucosal vaccination against infection</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>431</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00431</pub-id><pub-id pub-id-type="pmid">29563912</pub-id><pub-id pub-id-type="pmcid">PMC5845866</pub-id></element-citation></ref><ref id="B113-pharmaceutics-15-02114"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zafar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alruwaili</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Imam</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Alotaibi</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Alharbi</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Afzal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alshehri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alzarea</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Elmowafy</surname><given-names>M.</given-names></name></person-group><article-title>Bioactive Apigenin loaded oral nano bilosomes: Formulation optimization to preclinical assessment</article-title><source>Saudi Pharm. J.</source><year>2021</year><volume>29</volume><fpage>269</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2021.02.003</pub-id><pub-id pub-id-type="pmid">33981176</pub-id><pub-id pub-id-type="pmcid">PMC8085606</pub-id></element-citation></ref><ref id="B114-pharmaceutics-15-02114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamiak</surname><given-names>N.</given-names></name><name name-style="western"><surname>Krawczyk</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Locht</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kowalewicz-Kulbat</surname><given-names>M.</given-names></name></person-group><article-title>Archaeosomes and gas vesicles as tools for vaccine development</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>746235</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.746235</pub-id><pub-id pub-id-type="pmid">34567012</pub-id><pub-id pub-id-type="pmcid">PMC8462270</pub-id></element-citation></ref><ref id="B115-pharmaceutics-15-02114"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dicaire</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Sprott</surname><given-names>G.D.</given-names></name></person-group><article-title>Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: Comparison to conventional liposomes and alum</article-title><source>Infect. Immun.</source><year>2000</year><volume>68</volume><fpage>54</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.1.54-63.2000</pub-id><pub-id pub-id-type="pmid">10603368</pub-id><pub-id pub-id-type="pmcid">PMC97101</pub-id></element-citation></ref><ref id="B116-pharmaceutics-15-02114"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCluskie</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Deschatelets</surname><given-names>L.</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>L.</given-names></name></person-group><article-title>Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity</article-title><source>Hum. Vaccines Immunother.</source><year>2017</year><volume>13</volume><fpage>2772</fpage><lpage>2779</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1316912</pub-id><pub-id pub-id-type="pmid">28537465</pub-id><pub-id pub-id-type="pmcid">PMC5718820</pub-id></element-citation></ref><ref id="B117-pharmaceutics-15-02114"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name></person-group><article-title>Influenza vaccines: The virosome concept</article-title><source>Immunol. Lett.</source><year>2009</year><volume>122</volume><fpage>118</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2008.11.006</pub-id><pub-id pub-id-type="pmid">19100779</pub-id></element-citation></ref><ref id="B118-pharmaceutics-15-02114"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name></person-group><article-title>Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment</article-title><source>Acta Pharm.</source><year>2015</year><volume>65</volume><fpage>105</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1515/acph-2015-0019</pub-id><pub-id pub-id-type="pmid">26011928</pub-id></element-citation></ref><ref id="B119-pharmaceutics-15-02114"><label>119.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Patravale</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dandekar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.</given-names></name></person-group><source>Nanoparticulate Drug Delivery: Perspectives on the Transition from Laboratory to Market</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2012</year></element-citation></ref><ref id="B120-pharmaceutics-15-02114"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asadi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gholami</surname><given-names>A.</given-names></name></person-group><article-title>Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review</article-title><source>Int. J. Biol. Macromol.</source><year>2021</year><volume>182</volume><fpage>648</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.04.005</pub-id><pub-id pub-id-type="pmid">33862071</pub-id><pub-id pub-id-type="pmcid">PMC8049750</pub-id></element-citation></ref><ref id="B121-pharmaceutics-15-02114"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourquin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zwiorek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lanz</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weigel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wurzenberger</surname><given-names>C.</given-names></name><name name-style="western"><surname>von der Borch</surname><given-names>P.</given-names></name><name name-style="western"><surname>Golic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moder</surname><given-names>S.</given-names></name></person-group><article-title>Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity</article-title><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>2990</fpage><lpage>2998</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.5.2990</pub-id><pub-id pub-id-type="pmid">18713969</pub-id></element-citation></ref><ref id="B122-pharmaceutics-15-02114"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sudheesh</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Vyas</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Kohli</surname><given-names>D.V.</given-names></name></person-group><article-title>Nanoparticle-based immunopotentiation via tetanus toxoid-loaded gelatin and aminated gelatin nanoparticles</article-title><source>Drug Deliv.</source><year>2011</year><volume>18</volume><fpage>320</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.3109/10717544.2010.549525</pub-id><pub-id pub-id-type="pmid">21351824</pub-id></element-citation></ref><ref id="B123-pharmaceutics-15-02114"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.H.</given-names></name></person-group><article-title>Protein-based nanoparticles as drug delivery systems</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>604</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12070604</pub-id><pub-id pub-id-type="pmid">32610448</pub-id><pub-id pub-id-type="pmcid">PMC7407889</pub-id></element-citation></ref><ref id="B124-pharmaceutics-15-02114"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahoo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sahoo</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Guha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuotsu</surname><given-names>K.</given-names></name></person-group><article-title>Recent advancement of gelatin nanoparticles in drug and vaccine delivery</article-title><source>Int. J. Biol. Macromol.</source><year>2015</year><volume>81</volume><fpage>317</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2015.08.006</pub-id><pub-id pub-id-type="pmid">26277745</pub-id></element-citation></ref><ref id="B125-pharmaceutics-15-02114"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lynn</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Q.</given-names></name></person-group><article-title>Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>1954</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-02191-y</pub-id><pub-id pub-id-type="pmid">29203865</pub-id><pub-id pub-id-type="pmcid">PMC5715147</pub-id></element-citation></ref><ref id="B126-pharmaceutics-15-02114"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Du</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Albumin-biomineralized nanoparticles to synergize phototherapy and immunotherapy against melanoma</article-title><source>J. Control. Release</source><year>2020</year><volume>322</volume><fpage>300</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.03.045</pub-id><pub-id pub-id-type="pmid">32240675</pub-id></element-citation></ref><ref id="B127-pharmaceutics-15-02114"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassanin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Elzoghby</surname><given-names>A.</given-names></name></person-group><article-title>Albumin-based nanoparticles: A promising strategy to overcome cancer drug resistance</article-title><source>Cancer Drug Resist.</source><year>2020</year><volume>3</volume><fpage>930</fpage><pub-id pub-id-type="doi">10.20517/cdr.2020.68</pub-id><pub-id pub-id-type="pmid">35582218</pub-id><pub-id pub-id-type="pmcid">PMC8992568</pub-id></element-citation></ref><ref id="B128-pharmaceutics-15-02114"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>The effect of size, dose, and administration route on zein nanoparticle immunogenicity in BALB/c mice</article-title><source>Int. J. Nanomed.</source><year>2019</year><volume>14</volume><fpage>9917</fpage><lpage>9928</lpage><pub-id pub-id-type="doi">10.2147/IJN.S226466</pub-id><pub-id pub-id-type="pmcid">PMC6927268</pub-id><pub-id pub-id-type="pmid">31908449</pub-id></element-citation></ref><ref id="B129-pharmaceutics-15-02114"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name></person-group><article-title>Development of a nanoparticle delivery system based on zein/polysaccharide complexes</article-title><source>J. Food Sci.</source><year>2020</year><volume>85</volume><fpage>4108</fpage><lpage>4117</lpage><pub-id pub-id-type="doi">10.1111/1750-3841.15535</pub-id><pub-id pub-id-type="pmid">33249573</pub-id></element-citation></ref><ref id="B130-pharmaceutics-15-02114"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>E.-J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.-M.</given-names></name></person-group><article-title>Immunology and efficacy of MF59-adjuvanted vaccines</article-title><source>Hum. Vaccines Immunother.</source><year>2018</year><volume>14</volume><fpage>3041</fpage><lpage>3045</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1495301</pub-id><pub-id pub-id-type="pmcid">PMC6343625</pub-id><pub-id pub-id-type="pmid">30015572</pub-id></element-citation></ref><ref id="B131-pharmaceutics-15-02114"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grigoryan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Vanderheiden</surname><given-names>A.</given-names></name><name name-style="western"><surname>Floyd</surname><given-names>K.</given-names></name></person-group><article-title>Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice</article-title><source>NPJ Vaccines</source><year>2022</year><volume>7</volume><fpage>55</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00472-2</pub-id><pub-id pub-id-type="pmid">35606518</pub-id><pub-id pub-id-type="pmcid">PMC9126867</pub-id></element-citation></ref><ref id="B132-pharmaceutics-15-02114"><label>132.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lodaya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amiji</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.</given-names></name></person-group><article-title>Overview of Vaccine Adjuvants</article-title><source>Practical Aspects of Vaccine Development</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2021</year><fpage>9</fpage><lpage>25</lpage></element-citation></ref><ref id="B133-pharmaceutics-15-02114"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Rosa</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Bonaparte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gerard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goepfert</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Larocque</surname><given-names>D.</given-names></name><name name-style="western"><surname>McElrath</surname><given-names>M.J.</given-names></name></person-group><article-title>Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate</article-title><source>Clin. Transl. Immunol.</source><year>2022</year><volume>11</volume><fpage>e1360</fpage><pub-id pub-id-type="doi">10.1002/cti2.1360</pub-id><pub-id pub-id-type="pmcid">PMC8752373</pub-id><pub-id pub-id-type="pmid">35035955</pub-id></element-citation></ref><ref id="B134-pharmaceutics-15-02114"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klucker</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Dalen&#231;on</surname><given-names>F.</given-names></name><name name-style="western"><surname>Probeck</surname><given-names>P.</given-names></name><name name-style="western"><surname>Haensler</surname><given-names>J.</given-names></name></person-group><article-title>AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method</article-title><source>J. Pharm. Sci.</source><year>2012</year><volume>101</volume><fpage>4490</fpage><lpage>4500</lpage><pub-id pub-id-type="doi">10.1002/jps.23311</pub-id><pub-id pub-id-type="pmid">22941944</pub-id></element-citation></ref><ref id="B135-pharmaceutics-15-02114"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>T.</given-names></name></person-group><article-title>Poly lactic-co-glycolic acid-based nanoparticles as delivery systems for enhanced cancer immunotherapy</article-title><source>Front. Chem.</source><year>2022</year><volume>10</volume><fpage>973666</fpage><pub-id pub-id-type="doi">10.3389/fchem.2022.973666</pub-id><pub-id pub-id-type="pmid">36046731</pub-id><pub-id pub-id-type="pmcid">PMC9420966</pub-id></element-citation></ref><ref id="B136-pharmaceutics-15-02114"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennewitz</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Babensee</surname><given-names>J.E.</given-names></name></person-group><article-title>The effect of the physical form of poly (lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen</article-title><source>Biomaterials</source><year>2005</year><volume>26</volume><fpage>2991</fpage><lpage>2999</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2004.08.023</pub-id><pub-id pub-id-type="pmid">15603794</pub-id></element-citation></ref><ref id="B137-pharmaceutics-15-02114"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broaders</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Beaudette</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Bachelder</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Fr&#233;chet</surname><given-names>J.M.J.</given-names></name></person-group><article-title>Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>5497</fpage><lpage>5502</lpage><pub-id pub-id-type="doi">10.1073/pnas.0901592106</pub-id><pub-id pub-id-type="pmid">19321415</pub-id><pub-id pub-id-type="pmcid">PMC2666992</pub-id></element-citation></ref><ref id="B138-pharmaceutics-15-02114"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gallovic</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>E.Q.</given-names></name><name name-style="western"><surname>Bachelder</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>K.M.</given-names></name></person-group><article-title>Degradation of acetalated dextran can be broadly tuned based on cyclic acetal coverage and molecular weight</article-title><source>Int. J. Pharm.</source><year>2016</year><volume>512</volume><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.08.031</pub-id><pub-id pub-id-type="pmid">27543351</pub-id></element-citation></ref><ref id="B139-pharmaceutics-15-02114"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peres</surname><given-names>C.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Conniot</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sainz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zupan&#269;i&#269;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Graca</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gaspar</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Preat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Florindo</surname><given-names>H.F.</given-names></name></person-group><article-title>Poly (lactic acid)-based particulate systems are promising tools for immune modulation</article-title><source>Acta Biomater.</source><year>2017</year><volume>48</volume><fpage>41</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2016.11.012</pub-id><pub-id pub-id-type="pmid">27826003</pub-id></element-citation></ref><ref id="B140-pharmaceutics-15-02114"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baek</surname><given-names>S.-W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.-S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Han</surname><given-names>D.K.</given-names></name></person-group><article-title>Enhanced Mechanical Properties and Anti&#8211;Inflammation of Poly (L&#8211;Lactic Acid) by Stereocomplexes of PLLA/PDLA and Surface&#8211;Modified Magnesium Hydroxide Nanoparticles</article-title><source>Polymers</source><year>2022</year><volume>14</volume><elocation-id>3790</elocation-id><pub-id pub-id-type="doi">10.3390/polym14183790</pub-id><pub-id pub-id-type="pmid">36145934</pub-id><pub-id pub-id-type="pmcid">PMC9504497</pub-id></element-citation></ref><ref id="B141-pharmaceutics-15-02114"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>Z.-S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.-T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.-R.</given-names></name></person-group><article-title>Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice</article-title><source>Mar. Drugs</source><year>2011</year><volume>9</volume><fpage>1038</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.3390/md9061038</pub-id><pub-id pub-id-type="pmid">21747747</pub-id><pub-id pub-id-type="pmcid">PMC3131560</pub-id></element-citation></ref><ref id="B142-pharmaceutics-15-02114"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemke</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Geary</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Zamba</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lubaroff</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>A.K.</given-names></name></person-group><article-title>Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines</article-title><source>Mol. Pharm.</source><year>2011</year><volume>8</volume><fpage>1652</fpage><lpage>1661</lpage><pub-id pub-id-type="doi">10.1021/mp100464y</pub-id><pub-id pub-id-type="pmid">21780831</pub-id><pub-id pub-id-type="pmcid">PMC3562499</pub-id></element-citation></ref><ref id="B143-pharmaceutics-15-02114"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name></person-group><article-title>Calcium phosphate nanoparticles as a new generation vaccine adjuvant</article-title><source>Expert Rev. Vaccines</source><year>2017</year><volume>16</volume><fpage>895</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1080/14760584.2017.1355733</pub-id><pub-id pub-id-type="pmid">28712326</pub-id></element-citation></ref><ref id="B144-pharmaceutics-15-02114"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yoshiyuki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sogo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>A.</given-names></name></person-group><article-title>Comprehensive mechanism analysis of mesoporous-silica-nanoparticle-induced cancer immunotherapy</article-title><source>Adv. Healthc. Mater.</source><year>2016</year><volume>5</volume><fpage>1169</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1002/adhm.201501013</pub-id><pub-id pub-id-type="pmid">26987867</pub-id></element-citation></ref><ref id="B145-pharmaceutics-15-02114"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bharti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nagaich</surname><given-names>U.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Gulati</surname><given-names>N.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles in target drug delivery system: A review</article-title><source>Int. J. Pharm. Investig.</source><year>2015</year><volume>5</volume><fpage>124</fpage><pub-id pub-id-type="doi">10.4103/2230-973X.160844</pub-id><pub-id pub-id-type="pmid">26258053</pub-id><pub-id pub-id-type="pmcid">PMC4522861</pub-id></element-citation></ref><ref id="B146-pharmaceutics-15-02114"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anselmo</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Mitragotri</surname><given-names>S.</given-names></name></person-group><article-title>Nanoparticles in the clinic</article-title><source>Bioeng. Transl. Med.</source><year>2016</year><volume>1</volume><fpage>10</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1002/btm2.10003</pub-id><pub-id pub-id-type="pmid">29313004</pub-id><pub-id pub-id-type="pmcid">PMC5689513</pub-id></element-citation></ref><ref id="B147-pharmaceutics-15-02114"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>L.</given-names></name></person-group><article-title>Different-sized gold nanoparticle activator/antigen increases dendritic cells accumulation in liver-draining lymph nodes and CD8+ T cell responses</article-title><source>ACS Nano</source><year>2016</year><volume>10</volume><fpage>2678</fpage><lpage>2692</lpage><pub-id pub-id-type="doi">10.1021/acsnano.5b07716</pub-id><pub-id pub-id-type="pmid">26771692</pub-id></element-citation></ref><ref id="B148-pharmaceutics-15-02114"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Gonon</surname><given-names>A.</given-names></name><name name-style="western"><surname>P&#233;cheur</surname><given-names>E.-I.</given-names></name><name name-style="western"><surname>Pezet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villiers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marche</surname><given-names>P.N.</given-names></name></person-group><article-title>Impact of gold nanoparticles on the functions of macrophages and dendritic cells</article-title><source>Cells</source><year>2021</year><volume>10</volume><elocation-id>96</elocation-id><pub-id pub-id-type="doi">10.3390/cells10010096</pub-id><pub-id pub-id-type="pmid">33430453</pub-id><pub-id pub-id-type="pmcid">PMC7826823</pub-id></element-citation></ref><ref id="B149-pharmaceutics-15-02114"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balfourier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Luciani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lelong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ersen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Khelfa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alloyeau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gazeau</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carn</surname><given-names>F.</given-names></name></person-group><article-title>Unexpected intracellular biodegradation and recrystallization of gold nanoparticles</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>103</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1073/pnas.1911734116</pub-id><pub-id pub-id-type="pmid">31852822</pub-id><pub-id pub-id-type="pmcid">PMC6955300</pub-id></element-citation></ref><ref id="B150-pharmaceutics-15-02114"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tolia</surname><given-names>N.H.</given-names></name></person-group><article-title>Protein-based antigen presentation platforms for nanoparticle vaccines</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>70</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00330-7</pub-id><pub-id pub-id-type="pmid">33986287</pub-id><pub-id pub-id-type="pmcid">PMC8119681</pub-id></element-citation></ref><ref id="B151-pharmaceutics-15-02114"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kianfar</surname><given-names>E.</given-names></name></person-group><article-title>Protein nanoparticles in drug delivery: Animal protein, plant proteins and protein cages, albumin nanoparticles</article-title><source>J. Nanobiotechnol.</source><year>2021</year><volume>19</volume><fpage>159</fpage><pub-id pub-id-type="doi">10.1186/s12951-021-00896-3</pub-id><pub-id pub-id-type="pmid">34051806</pub-id><pub-id pub-id-type="pmcid">PMC8164776</pub-id></element-citation></ref><ref id="B152-pharmaceutics-15-02114"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>Controlled delivery of hollow corn protein nanoparticles via non-toxic crosslinking: In vivo and drug loading study</article-title><source>Biomed. Microdevices</source><year>2015</year><volume>17</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1007/s10544-014-9926-5</pub-id><pub-id pub-id-type="pmid">25666984</pub-id></element-citation></ref><ref id="B153-pharmaceutics-15-02114"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gulati</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nagaich</surname><given-names>U.</given-names></name></person-group><article-title>Protein based nanostructures for drug delivery</article-title><source>J. Pharm.</source><year>2018</year><volume>2018</volume><fpage>9285854</fpage><pub-id pub-id-type="doi">10.1155/2018/9285854</pub-id><pub-id pub-id-type="pmcid">PMC5976961</pub-id><pub-id pub-id-type="pmid">29862118</pub-id></element-citation></ref><ref id="B154-pharmaceutics-15-02114"><label>154.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Marasini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ghaffar</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name></person-group><article-title>Chapter twelve&#8212;Liposomes as a vaccine delivery system</article-title><source>Micro and Nanotechnology in Vaccine Development</source><person-group person-group-type="editor"><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name></person-group><publisher-name>William Andrew Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2017</year><fpage>221</fpage><lpage>239</lpage></element-citation></ref><ref id="B155-pharmaceutics-15-02114"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kisakova</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Apartsin</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Nizolenko</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Karpenko</surname><given-names>L.I.</given-names></name></person-group><article-title>Dendrimer-mediated delivery of DNA and RNA vaccines</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>1106</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15041106</pub-id><pub-id pub-id-type="pmid">37111593</pub-id><pub-id pub-id-type="pmcid">PMC10145063</pub-id></element-citation></ref><ref id="B156-pharmaceutics-15-02114"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutjahr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Phelip</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coolen</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Monge</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boisgard</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Verrier</surname><given-names>B.</given-names></name></person-group><article-title>Biodegradable polymeric nanoparticles-based vaccine adjuvants for lymph nodes targeting</article-title><source>Vaccines</source><year>2016</year><volume>4</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines4040034</pub-id><pub-id pub-id-type="pmid">27754314</pub-id><pub-id pub-id-type="pmcid">PMC5192354</pub-id></element-citation></ref><ref id="B157-pharmaceutics-15-02114"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaid</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yildirim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pasquinelli</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>King</surname><given-names>M.W.</given-names></name></person-group><article-title>Hydrolytic degradation of polylactic acid fibers as a function of pH and exposure time</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>7554</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26247554</pub-id><pub-id pub-id-type="pmid">34946629</pub-id><pub-id pub-id-type="pmcid">PMC8706057</pub-id></element-citation></ref><ref id="B158-pharmaceutics-15-02114"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.A.</given-names></name></person-group><article-title>Organic and inorganic nanoparticle vaccines for prevention of infectious diseases</article-title><source>Nano Express</source><year>2020</year><volume>1</volume><fpage>012001</fpage><pub-id pub-id-type="doi">10.1088/2632-959X/ab8075</pub-id></element-citation></ref><ref id="B159-pharmaceutics-15-02114"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name></person-group><article-title>Carbohydrate conjugates in vaccine developments</article-title><source>Front. Chem.</source><year>2020</year><volume>8</volume><fpage>284</fpage><pub-id pub-id-type="doi">10.3389/fchem.2020.00284</pub-id><pub-id pub-id-type="pmid">32351942</pub-id><pub-id pub-id-type="pmcid">PMC7174737</pub-id></element-citation></ref><ref id="B160-pharmaceutics-15-02114"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Carvalho Lima</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Justo</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Castilho Piqueira</surname><given-names>J.R.</given-names></name></person-group><article-title>Advances and perspectives in the use of carbon nanotubes in vaccine development</article-title><source>Int. J. Nanomed.</source><year>2021</year><volume>16</volume><fpage>5411</fpage><lpage>5435</lpage><pub-id pub-id-type="doi">10.2147/IJN.S314308</pub-id><pub-id pub-id-type="pmcid">PMC8367085</pub-id><pub-id pub-id-type="pmid">34408416</pub-id></element-citation></ref><ref id="B161-pharmaceutics-15-02114"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bamrungsap</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system</article-title><source>Nanomedicine</source><year>2012</year><volume>7</volume><fpage>1253</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.2217/nnm.12.87</pub-id><pub-id pub-id-type="pmid">22931450</pub-id></element-citation></ref><ref id="B162-pharmaceutics-15-02114"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy</article-title><source>Nat. Nanotechnol.</source><year>2022</year><volume>17</volume><fpage>531</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1038/s41565-022-01098-0</pub-id><pub-id pub-id-type="pmid">35410368</pub-id></element-citation></ref><ref id="B163-pharmaceutics-15-02114"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>N.</given-names></name></person-group><article-title>Nanovaccine: An emerging strategy</article-title><source>Expert Rev. Vaccines</source><year>2021</year><volume>20</volume><fpage>1273</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1080/14760584.2021.1984890</pub-id><pub-id pub-id-type="pmid">34550859</pub-id></element-citation></ref><ref id="B164-pharmaceutics-15-02114"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maina</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Grego</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Boggiatto</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Sacco</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>McGill</surname><given-names>J.L.</given-names></name></person-group><article-title>Applications of Nanovaccines for Disease Prevention in Cattle</article-title><source>Front. Bioeng. Biotechnol.</source><year>2020</year><volume>8</volume><fpage>608050</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2020.608050</pub-id><pub-id pub-id-type="pmid">33363134</pub-id><pub-id pub-id-type="pmcid">PMC7759628</pub-id></element-citation></ref><ref id="B165-pharmaceutics-15-02114"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azharuddin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hinkula</surname><given-names>J.</given-names></name><name name-style="western"><surname>Slater</surname><given-names>N.K.H.</given-names></name><name name-style="western"><surname>Patra</surname><given-names>H.K.</given-names></name></person-group><article-title>Nano toolbox in immune modulation and nanovaccines</article-title><source>Trends Biotechnol.</source><year>2022</year><volume>40</volume><fpage>1195</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2022.03.011</pub-id><pub-id pub-id-type="pmid">35450779</pub-id><pub-id pub-id-type="pmcid">PMC10439010</pub-id></element-citation></ref><ref id="B166-pharmaceutics-15-02114"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Trager</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Brandl</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Sandefer</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Doll</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Liebowitz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>S.N.</given-names></name></person-group><article-title>Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>37295</fpage><pub-id pub-id-type="doi">10.1038/srep37295</pub-id><pub-id pub-id-type="pmid">27881837</pub-id><pub-id pub-id-type="pmcid">PMC5121599</pub-id></element-citation></ref><ref id="B167-pharmaceutics-15-02114"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mudie</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>G.E.</given-names></name></person-group><article-title>Physiological parameters for oral delivery and in vitro testing</article-title><source>Mol. Pharm.</source><year>2010</year><volume>7</volume><fpage>1388</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1021/mp100149j</pub-id><pub-id pub-id-type="pmid">20822152</pub-id><pub-id pub-id-type="pmcid">PMC3025274</pub-id></element-citation></ref><ref id="B168-pharmaceutics-15-02114"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Talton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eppler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Large intestine&#8211;targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection</article-title><source>Nat. Med.</source><year>2012</year><volume>18</volume><fpage>1291</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1038/nm.2866</pub-id><pub-id pub-id-type="pmid">22797811</pub-id><pub-id pub-id-type="pmcid">PMC3475749</pub-id></element-citation></ref><ref id="B169-pharmaceutics-15-02114"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mangal</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>A.P.</given-names></name></person-group><article-title>Oral drug delivery for immunoengineering</article-title><source>Bioeng. Transl. Med.</source><year>2022</year><volume>7</volume><fpage>e10243</fpage><pub-id pub-id-type="doi">10.1002/btm2.10243</pub-id><pub-id pub-id-type="pmid">35111945</pub-id><pub-id pub-id-type="pmcid">PMC8780903</pub-id></element-citation></ref><ref id="B170-pharmaceutics-15-02114"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahadian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Finbloom</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Mofidfar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diltemiz</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Nasrollahi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Davoodi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mylonaki</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sangabathuni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montazerian</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Micro and nanoscale technologies in oral drug delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>157</volume><fpage>37</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.07.012</pub-id><pub-id pub-id-type="pmid">32707147</pub-id><pub-id pub-id-type="pmcid">PMC7374157</pub-id></element-citation></ref><ref id="B171-pharmaceutics-15-02114"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffey</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Gaiha</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Traverso</surname><given-names>G.</given-names></name></person-group><article-title>Oral biologic delivery: Advances toward oral subunit, DNA, and mRNA vaccines and the potential for mass vaccination during pandemics</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2021</year><volume>61</volume><fpage>517</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-030320-092348</pub-id><pub-id pub-id-type="pmid">32466690</pub-id><pub-id pub-id-type="pmcid">PMC8057107</pub-id></element-citation></ref><ref id="B172-pharmaceutics-15-02114"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Santa Barbara</surname><given-names>P.</given-names></name><name name-style="western"><surname>van den Brink</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>D.J.</given-names></name></person-group><article-title>Development and differentiation of the intestinal epithelium</article-title><source>Cell. Mol. Life Sci. CMLS</source><year>2003</year><volume>60</volume><fpage>1322</fpage><lpage>1332</lpage><pub-id pub-id-type="doi">10.1007/s00018-003-2289-3</pub-id><pub-id pub-id-type="pmid">12943221</pub-id><pub-id pub-id-type="pmcid">PMC2435618</pub-id></element-citation></ref><ref id="B173-pharmaceutics-15-02114"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roopenian</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Akilesh</surname><given-names>S.</given-names></name></person-group><article-title>FcRn: The neonatal Fc receptor comes of age</article-title><source>Nat. Rev. Immunol.</source><year>2007</year><volume>7</volume><fpage>715</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1038/nri2155</pub-id><pub-id pub-id-type="pmid">17703228</pub-id></element-citation></ref><ref id="B174-pharmaceutics-15-02114"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name></person-group><article-title>Role of goblet cells in intestinal barrier and mucosal imunity</article-title><source>J. Inflamm. Res.</source><year>2021</year><volume>14</volume><fpage>3171</fpage><lpage>3183</lpage><pub-id pub-id-type="doi">10.2147/JIR.S318327</pub-id><pub-id pub-id-type="pmid">34285541</pub-id><pub-id pub-id-type="pmcid">PMC8286120</pub-id></element-citation></ref><ref id="B175-pharmaceutics-15-02114"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hugot</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Barreau</surname><given-names>F.</given-names></name></person-group><article-title>Peyer&#8217;s patches: The immune sensors of the intestine</article-title><source>Int. J. Inflamm.</source><year>2010</year><volume>2010</volume><fpage>823710</fpage><pub-id pub-id-type="doi">10.4061/2010/823710</pub-id><pub-id pub-id-type="pmid">21188221</pub-id><pub-id pub-id-type="pmcid">PMC3004000</pub-id></element-citation></ref><ref id="B176-pharmaceutics-15-02114"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Homayun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.-J.</given-names></name></person-group><article-title>Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>129</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11030129</pub-id><pub-id pub-id-type="pmid">30893852</pub-id><pub-id pub-id-type="pmcid">PMC6471246</pub-id></element-citation></ref><ref id="B177-pharmaceutics-15-02114"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Smet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Allais</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cuvelier</surname><given-names>C.A.</given-names></name></person-group><article-title>Recent advances in oral vaccine development: Yeast-derived &#946;-glucan particles</article-title><source>Hum. Vaccines Immunother.</source><year>2014</year><volume>10</volume><fpage>1309</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.4161/hv.28166</pub-id><pub-id pub-id-type="pmid">24553259</pub-id><pub-id pub-id-type="pmcid">PMC4896516</pub-id></element-citation></ref><ref id="B178-pharmaceutics-15-02114"><label>178.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mastropietro</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Omidian</surname><given-names>H.</given-names></name></person-group><source>Polymers in Oral Drug Delivery</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2017</year><fpage>430</fpage><lpage>444</lpage></element-citation></ref><ref id="B179-pharmaceutics-15-02114"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>dos Santos</surname><given-names>J.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Velho</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>R.C.</given-names></name></person-group><article-title>Eudragit<sup>&#174;</sup>: A versatile family of polymers for hot melt extrusion and 3D printing processes in pharmaceutics</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1424</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13091424</pub-id><pub-id pub-id-type="pmid">34575500</pub-id><pub-id pub-id-type="pmcid">PMC8471576</pub-id></element-citation></ref><ref id="B180-pharmaceutics-15-02114"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franco</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>I.</given-names></name></person-group><article-title>Eudragit: A Novel Carrier for Controlled Drug Delivery in Supercritical Antisolvent Coprecipitation</article-title><source>Polymers</source><year>2020</year><volume>12</volume><elocation-id>234</elocation-id><pub-id pub-id-type="doi">10.3390/polym12010234</pub-id><pub-id pub-id-type="pmid">31963638</pub-id><pub-id pub-id-type="pmcid">PMC7023534</pub-id></element-citation></ref><ref id="B181-pharmaceutics-15-02114"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snejdrova Eva</surname><given-names>D.M.</given-names></name></person-group><article-title>Pharmaceutical applications of plasticized polymers</article-title><source>Recent Adv. Plast.</source><year>2012</year><volume>21</volume><fpage>23</fpage><lpage>34</lpage></element-citation></ref><ref id="B182-pharmaceutics-15-02114"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidal-Romero</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rocha-P&#233;rez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zambrano-Zaragoza</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Del Real</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Acevedo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Galindo-P&#233;rez</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Quintanar-Guerrero</surname><given-names>D.</given-names></name></person-group><article-title>Development and characterization of pH-dependent cellulose acetate phthalate nanofibers by electrospinning technique</article-title><source>Nanomaterials</source><year>2021</year><volume>11</volume><elocation-id>3202</elocation-id><pub-id pub-id-type="doi">10.3390/nano11123202</pub-id><pub-id pub-id-type="pmid">34947551</pub-id><pub-id pub-id-type="pmcid">PMC8706738</pub-id></element-citation></ref><ref id="B183-pharmaceutics-15-02114"><label>183.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Obara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanno</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Sarode</surname><given-names>A.</given-names></name></person-group><article-title>Properties and applications of hypromellose acetate succinate (HPMCAS) for solubility enhancement using melt extrusion</article-title><source>Melt Extrusion: Materials, Technology and Drug Product Design</source><person-group person-group-type="editor"><name name-style="western"><surname>Repka</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>N.</given-names></name><name name-style="western"><surname>DiNunzio</surname><given-names>J.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2013</year><fpage>107</fpage><lpage>121</lpage></element-citation></ref><ref id="B184-pharmaceutics-15-02114"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagre</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N.K.</given-names></name></person-group><article-title>Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: In vitro and in vivo assessment</article-title><source>Int. J. Pharm.</source><year>2013</year><volume>456</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.08.037</pub-id><pub-id pub-id-type="pmid">23994363</pub-id></element-citation></ref><ref id="B185-pharmaceutics-15-02114"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>D.J.</given-names></name></person-group><article-title>Alginate: Properties and biomedical applications</article-title><source>Prog. Polym. Sci.</source><year>2012</year><volume>37</volume><fpage>106</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.progpolymsci.2011.06.003</pub-id><pub-id pub-id-type="pmid">22125349</pub-id><pub-id pub-id-type="pmcid">PMC3223967</pub-id></element-citation></ref><ref id="B186-pharmaceutics-15-02114"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subramanian</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Traverso</surname><given-names>G.</given-names></name></person-group><article-title>Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems</article-title><source>J. Nanobiotechnol.</source><year>2022</year><volume>20</volume><fpage>362</fpage><pub-id pub-id-type="doi">10.1186/s12951-022-01539-x</pub-id><pub-id pub-id-type="pmid">35933341</pub-id><pub-id pub-id-type="pmcid">PMC9356434</pub-id></element-citation></ref><ref id="B187-pharmaceutics-15-02114"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernkop-Schn&#252;rch</surname><given-names>A.</given-names></name></person-group><article-title>Mucoadhesive systems in oral drug delivery</article-title><source>Drug Discov. Today Technol.</source><year>2005</year><volume>2</volume><fpage>83</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2005.05.001</pub-id><pub-id pub-id-type="pmid">24981759</pub-id></element-citation></ref><ref id="B188-pharmaceutics-15-02114"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boddupalli</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>Z.N.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Banji</surname><given-names>D.</given-names></name></person-group><article-title>Mucoadhesive drug delivery system: An overview</article-title><source>J. Adv. Pharm. Technol. Res.</source><year>2010</year><volume>1</volume><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.4103/0110-5558.76436</pub-id><pub-id pub-id-type="pmid">22247877</pub-id><pub-id pub-id-type="pmcid">PMC3255397</pub-id></element-citation></ref><ref id="B189-pharmaceutics-15-02114"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>C.-S.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S.-K.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>M.-J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.-G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.-K.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>D.-B.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-J.</given-names></name></person-group><article-title>Mucosal vaccine delivery using mucoadhesive polymer particulate systems</article-title><source>Tissue Eng. Regen. Med.</source><year>2021</year><volume>18</volume><fpage>693</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1007/s13770-021-00373-w</pub-id><pub-id pub-id-type="pmid">34304387</pub-id><pub-id pub-id-type="pmcid">PMC8310561</pub-id></element-citation></ref><ref id="B190-pharmaceutics-15-02114"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaikh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>T.R.R.</given-names></name><name name-style="western"><surname>Garland</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Woolfson</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name></person-group><article-title>Mucoadhesive drug delivery systems</article-title><source>J. Pharm. Bioallied Sci.</source><year>2011</year><volume>3</volume><fpage>89</fpage><pub-id pub-id-type="pmid">21430958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0975-7406.76478</pub-id><pub-id pub-id-type="pmcid">PMC3053525</pub-id></element-citation></ref><ref id="B191-pharmaceutics-15-02114"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;rez-Gonz&#225;lez</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Villarreal-G&#243;mez</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Serrano-Medina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Torres-Mart&#237;nez</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Cornejo-Bravo</surname><given-names>J.M.</given-names></name></person-group><article-title>Mucoadhesive electrospun nanofibers for drug delivery systems: Applications of polymers and the parameters&#8217; roles</article-title><source>Int. J. Nanomed.</source><year>2019</year><volume>14</volume><fpage>5271</fpage><lpage>5285</lpage><pub-id pub-id-type="doi">10.2147/IJN.S193328</pub-id><pub-id pub-id-type="pmid">31409989</pub-id><pub-id pub-id-type="pmcid">PMC6643962</pub-id></element-citation></ref><ref id="B192-pharmaceutics-15-02114"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vu</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.-S.</given-names></name></person-group><article-title>Application of chitosan/alginate nanoparticle in oral drug delivery systems: Prospects and challenges</article-title><source>Drug Deliv.</source><year>2022</year><volume>29</volume><fpage>1142</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1080/10717544.2022.2058646</pub-id><pub-id pub-id-type="pmid">35384787</pub-id><pub-id pub-id-type="pmcid">PMC9004504</pub-id></element-citation></ref><ref id="B193-pharmaceutics-15-02114"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z.</given-names></name></person-group><article-title>Preparation of alginate coated chitosan microparticles for vaccine delivery</article-title><source>BMC Biotechnol.</source><year>2008</year><volume>8</volume><elocation-id>89</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6750-8-89</pub-id><pub-id pub-id-type="pmid">19019229</pub-id><pub-id pub-id-type="pmcid">PMC2603011</pub-id></element-citation></ref><ref id="B194-pharmaceutics-15-02114"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Forier</surname><given-names>K.</given-names></name><name name-style="western"><surname>Steukers</surname><given-names>L.</given-names></name><name name-style="western"><surname>Van Vlierberghe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dubruel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Braeckmans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Glorieux</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nauwynck</surname><given-names>H.J.</given-names></name></person-group><article-title>Immobilization of pseudorabies virus in porcine tracheal respiratory mucus revealed by single particle tacking</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e51054</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0051054</pub-id><pub-id pub-id-type="pmid">23236432</pub-id><pub-id pub-id-type="pmcid">PMC3517622</pub-id></element-citation></ref><ref id="B195-pharmaceutics-15-02114"><label>195.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grewal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jyoti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>U.K.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>J.</given-names></name></person-group><article-title>Oral controlled and sustained drug delivery systems: Concepts, advances, preclinical, and clinical status</article-title><source>Drug Targeting and Stimuli Sensitive Drug Delivery Systems</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2018</year><fpage>567</fpage><lpage>626</lpage></element-citation></ref><ref id="B196-pharmaceutics-15-02114"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cevher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taha</surname><given-names>M.A.M.</given-names></name><name name-style="western"><surname>Orlu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Araman</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation of mechanical and mucoadhesive properties of clomiphene citrate gel formulations containing carbomers and their thiolated derivatives</article-title><source>Drug Deliv.</source><year>2008</year><volume>15</volume><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1080/10717540701829234</pub-id><pub-id pub-id-type="pmid">18197525</pub-id></element-citation></ref><ref id="B197-pharmaceutics-15-02114"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Hanes</surname><given-names>J.</given-names></name></person-group><article-title>Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues</article-title><source>Adv. Drug Deliv. Rev.</source><year>2009</year><volume>61</volume><fpage>158</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2008.11.002</pub-id><pub-id pub-id-type="pmid">19133304</pub-id><pub-id pub-id-type="pmcid">PMC2667119</pub-id></element-citation></ref><ref id="B198-pharmaceutics-15-02114"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snook</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Chesson</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Peniche</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Dann</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Paulucci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pinchuk</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Rudra</surname><given-names>J.S.</given-names></name></person-group><article-title>Peptide nanofiber&#8211;CaCO<sub>3</sub> composite microparticles as adjuvant-free oral vaccine delivery vehicles</article-title><source>J. Mater. Chem. B</source><year>2016</year><volume>4</volume><fpage>1640</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1039/C5TB01623A</pub-id><pub-id pub-id-type="pmid">32263017</pub-id></element-citation></ref><ref id="B199-pharmaceutics-15-02114"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Comparative study of mucoadhesive and mucus-penetrative nanoparticles based on phospholipid complex to overcome the mucus barrier for inhaled delivery of baicalein</article-title><source>Acta Pharm. Sin. B</source><year>2020</year><volume>10</volume><fpage>1576</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2019.10.002</pub-id><pub-id pub-id-type="pmid">32963951</pub-id><pub-id pub-id-type="pmcid">PMC7488487</pub-id></element-citation></ref><ref id="B200-pharmaceutics-15-02114"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamson</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fein</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>K.A.</given-names></name></person-group><article-title>Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability</article-title><source>Nat. Biomed. Eng.</source><year>2020</year><volume>4</volume><fpage>84</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/s41551-019-0465-5</pub-id><pub-id pub-id-type="pmid">31686002</pub-id><pub-id pub-id-type="pmcid">PMC7461704</pub-id></element-citation></ref><ref id="B201-pharmaceutics-15-02114"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Cone</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wirtz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hanes</surname><given-names>J.</given-names></name></person-group><article-title>Altering Mucus Rheology to &#8220;Solidify&#8221; Human Mucus at the Nanoscale</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e4294</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0004294</pub-id><pub-id pub-id-type="pmid">19173002</pub-id><pub-id pub-id-type="pmcid">PMC2627937</pub-id></element-citation></ref><ref id="B202-pharmaceutics-15-02114"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Boylan</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Suk</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Nance</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>McDonnell</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Cone</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Duh</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Hanes</surname><given-names>J.</given-names></name></person-group><article-title>Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo</article-title><source>J. Control. Release</source><year>2013</year><volume>167</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2013.01.018</pub-id><pub-id pub-id-type="pmid">23369761</pub-id><pub-id pub-id-type="pmcid">PMC3693951</pub-id></element-citation></ref><ref id="B203-pharmaceutics-15-02114"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Suk</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Pace</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cone</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hanes</surname><given-names>J.</given-names></name></person-group><article-title>Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2008</year><volume>47</volume><fpage>9726</fpage><lpage>9729</lpage><pub-id pub-id-type="doi">10.1002/anie.200803526</pub-id><pub-id pub-id-type="pmid">18979480</pub-id><pub-id pub-id-type="pmcid">PMC2666733</pub-id></element-citation></ref><ref id="B204-pharmaceutics-15-02114"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name></person-group><article-title>Developments of mucus penetrating nanoparticles</article-title><source>Asian J. Pharm. Sci.</source><year>2015</year><volume>10</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.ajps.2014.12.007</pub-id></element-citation></ref><ref id="B205-pharmaceutics-15-02114"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensign</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mert</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hanes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cone</surname><given-names>R.</given-names></name></person-group><article-title>Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus</article-title><source>Biomacromolecules</source><year>2014</year><volume>15</volume><fpage>4403</fpage><lpage>4409</lpage><pub-id pub-id-type="doi">10.1021/bm501419z</pub-id><pub-id pub-id-type="pmid">25347518</pub-id><pub-id pub-id-type="pmcid">PMC4261994</pub-id></element-citation></ref><ref id="B206-pharmaceutics-15-02114"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#252;nnhaupt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kammona</surname><given-names>O.</given-names></name><name name-style="western"><surname>Waldner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kiparissides</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bernkop-Schn&#252;rch</surname><given-names>A.</given-names></name></person-group><article-title>Nano-carrier systems: Strategies to overcome the mucus gel barrier</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2015</year><volume>96</volume><fpage>447</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2015.01.022</pub-id><pub-id pub-id-type="pmid">25712487</pub-id></element-citation></ref><ref id="B207-pharmaceutics-15-02114"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samuni</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>M.</given-names></name></person-group><article-title>The chemistry and biological activities of N-acetylcysteine</article-title><source>Biochim. Biophys. Acta Gen. Subj.</source><year>2013</year><volume>1830</volume><fpage>4117</fpage><lpage>4129</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2013.04.016</pub-id><pub-id pub-id-type="pmid">23618697</pub-id></element-citation></ref><ref id="B208-pharmaceutics-15-02114"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name></person-group><article-title>Intranasal vaccines: Forthcoming challenges</article-title><source>Pharm. Sci. Technol. Today</source><year>2000</year><volume>3</volume><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/S1461-5347(00)00281-9</pub-id><pub-id pub-id-type="pmid">10916147</pub-id></element-citation></ref><ref id="B209-pharmaceutics-15-02114"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hufnagel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name></person-group><article-title>Intranasal vaccine: Factors to consider in research and development</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>609</volume><fpage>121180</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121180</pub-id><pub-id pub-id-type="pmid">34637935</pub-id></element-citation></ref><ref id="B210-pharmaceutics-15-02114"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ichimiya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seya</surname><given-names>T.</given-names></name></person-group><article-title>Mucosal immune response in nasal-associated lymphoid tissue upon intranasal administration by adjuvants</article-title><source>J. Innate Immun.</source><year>2018</year><volume>10</volume><fpage>515</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1159/000489405</pub-id><pub-id pub-id-type="pmid">29860261</pub-id><pub-id pub-id-type="pmcid">PMC6784108</pub-id></element-citation></ref><ref id="B211-pharmaceutics-15-02114"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scherlie&#223;</surname><given-names>R.</given-names></name></person-group><article-title>Nasal formulations for drug administration and characterization of nasal preparations in drug delivery</article-title><source>Ther. Deliv.</source><year>2020</year><volume>11</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.4155/tde-2019-0086</pub-id><pub-id pub-id-type="pmid">32046624</pub-id></element-citation></ref><ref id="B212-pharmaceutics-15-02114"><label>212.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Ramvikas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arumugam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chakrabarti</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Jaganathan</surname><given-names>K.S.</given-names></name></person-group><article-title>Nasal vaccine delivery</article-title><source>Micro and Nanotechnology in Vaccine Development</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2017</year><fpage>279</fpage><lpage>301</lpage></element-citation></ref><ref id="B213-pharmaceutics-15-02114"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jadhav</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Gambhire</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Shaikh</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Kadam</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Pisal</surname><given-names>S.S.</given-names></name></person-group><article-title>Nasal drug delivery system-factors affecting and applications</article-title><source>Curr. Drug Ther.</source><year>2007</year><volume>2</volume><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.2174/157488507779422374</pub-id></element-citation></ref><ref id="B214-pharmaceutics-15-02114"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tirucherai</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Pezron</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>A.K.</given-names></name></person-group><article-title>Novel approaches to nasal delivery of peptides and proteins</article-title><source>STP Pharma Sci.</source><year>2002</year><volume>12</volume><fpage>3</fpage><lpage>12</lpage></element-citation></ref><ref id="B215-pharmaceutics-15-02114"><label>215.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Marx</surname><given-names>D.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.</given-names></name><name name-style="western"><surname>Birkhoff</surname><given-names>M.</given-names></name></person-group><article-title>Intranasal drug administration&#8212;An attractive delivery route for some drugs</article-title><source>Drug Discovery and Development</source><publisher-name>IntechOpen</publisher-name><publisher-loc>Rijeka, Croatia</publisher-loc><year>2015</year><fpage>299</fpage><lpage>320</lpage></element-citation></ref><ref id="B216-pharmaceutics-15-02114"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>U.M.</given-names></name><name name-style="western"><surname>Chotai</surname><given-names>N.P.</given-names></name></person-group><article-title>Intranasal drug delivery system-A glimpse to become maestro</article-title><source>J. Appl. Pharm. Sci.</source><year>2011</year><volume>1</volume><fpage>34</fpage><lpage>44</lpage></element-citation></ref><ref id="B217-pharmaceutics-15-02114"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>K.</given-names></name><name name-style="western"><surname>Woghiren</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Priefer</surname><given-names>R.</given-names></name></person-group><article-title>Surface tension examination of various liquid oral, nasal, and ophthalmic dosage forms</article-title><source>Chem. Cent. J.</source><year>2016</year><volume>10</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/s13065-016-0176-x</pub-id><pub-id pub-id-type="pmid">27162532</pub-id><pub-id pub-id-type="pmcid">PMC4860758</pub-id></element-citation></ref><ref id="B218-pharmaceutics-15-02114"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>S.</given-names></name></person-group><article-title>Factors influencing drug deposition in the nasal cavity upon delivery via nasal sprays</article-title><source>J. Pharm. Investig.</source><year>2020</year><volume>50</volume><fpage>251</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1007/s40005-020-00482-z</pub-id></element-citation></ref><ref id="B219-pharmaceutics-15-02114"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djupesland</surname><given-names>P.G.</given-names></name></person-group><article-title>Nasal drug delivery devices: Characteristics and performance in a clinical perspective&#8212;A review</article-title><source>Drug Deliv. Transl. Res.</source><year>2013</year><volume>3</volume><fpage>42</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s13346-012-0108-9</pub-id><pub-id pub-id-type="pmid">23316447</pub-id><pub-id pub-id-type="pmcid">PMC3539067</pub-id></element-citation></ref><ref id="B220-pharmaceutics-15-02114"><label>220.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><article-title>FluMist Quadrivalent</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/vaccines-blood-biologics/vaccines/flumist-quadrivalent" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/vaccines/flumist-quadrivalent</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-24">(accessed on 24 April 2023)</date-in-citation></element-citation></ref><ref id="B221-pharmaceutics-15-02114"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardoso</surname><given-names>F.M.C.</given-names></name><name name-style="western"><surname>Petrovajov&#225;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hor&#328;&#225;kov&#225;</surname><given-names>T.</given-names></name></person-group><article-title>Viral vaccine stabilizers: Status and trends</article-title><source>Acta Virol.</source><year>2017</year><volume>61</volume><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.4149/av_2017_301</pub-id><pub-id pub-id-type="pmid">28854787</pub-id></element-citation></ref><ref id="B222-pharmaceutics-15-02114"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chavda</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Vora</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Pandya</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Patravale</surname><given-names>V.B.</given-names></name></person-group><article-title>Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management</article-title><source>Drug Discov. Today</source><year>2021</year><volume>26</volume><fpage>2619</fpage><lpage>2636</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2021.07.021</pub-id><pub-id pub-id-type="pmid">34332100</pub-id><pub-id pub-id-type="pmcid">PMC8319039</pub-id></element-citation></ref><ref id="B223-pharmaceutics-15-02114"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraan</surname><given-names>H.</given-names></name><name name-style="western"><surname>van Herpen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.</given-names></name><name name-style="western"><surname>Amorij</surname><given-names>J.-P.</given-names></name></person-group><article-title>Development of thermostable lyophilized inactivated polio vaccine</article-title><source>Pharm. Res.</source><year>2014</year><volume>31</volume><fpage>2618</fpage><lpage>2629</lpage><pub-id pub-id-type="doi">10.1007/s11095-014-1359-6</pub-id><pub-id pub-id-type="pmid">24760448</pub-id><pub-id pub-id-type="pmcid">PMC4197379</pub-id></element-citation></ref><ref id="B224-pharmaceutics-15-02114"><label>224.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Herdis</surname><given-names>H.</given-names></name><name name-style="western"><surname>Surachman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Darmawan</surname><given-names>I.W.A.</given-names></name><name name-style="western"><surname>Afifah</surname><given-names>A.</given-names></name></person-group><article-title>The role of sucrose as extracellular cryoprotectant in maintaining the Garut rams&#8217; frozen semen quality</article-title><source>AIP Conference Proceedings</source><publisher-name>AIP Publishing</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2019</year></element-citation></ref><ref id="B225-pharmaceutics-15-02114"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henriques</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fortuna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doktorovov&#225;</surname><given-names>S.</given-names></name></person-group><article-title>Spray dried powders for nasal delivery: Process and formulation considerations</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2022</year><volume>176</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2022.05.002</pub-id><pub-id pub-id-type="pmid">35568256</pub-id></element-citation></ref><ref id="B226-pharmaceutics-15-02114"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanojia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Have</surname><given-names>R.t.</given-names></name><name name-style="western"><surname>Soema</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Frijlink</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amorij</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.</given-names></name></person-group><article-title>Developments in the formulation and delivery of spray dried vaccines</article-title><source>Hum. Vaccines Immunother.</source><year>2017</year><volume>13</volume><fpage>2364</fpage><lpage>2378</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1356952</pub-id><pub-id pub-id-type="pmcid">PMC5647985</pub-id><pub-id pub-id-type="pmid">28925794</pub-id></element-citation></ref><ref id="B227-pharmaceutics-15-02114"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahamondez-Canas</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name></person-group><article-title>Intranasal immunization with dry powder vaccines</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2018</year><volume>122</volume><fpage>167</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2017.11.001</pub-id><pub-id pub-id-type="pmid">29122735</pub-id><pub-id pub-id-type="pmcid">PMC5776719</pub-id></element-citation></ref><ref id="B228-pharmaceutics-15-02114"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni&#382;i&#263; Nodilo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ugrina</surname><given-names>I.</given-names></name><name name-style="western"><surname>&#352;poljari&#263;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Amid&#382;i&#263; Klari&#263;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jakobu&#353;i&#263; Brala</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perku&#353;i&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pepi&#263;</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lovri&#263;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sar&#353;on</surname><given-names>V.</given-names></name><name name-style="western"><surname>Safund&#382;i&#263; Ku&#269;uk</surname><given-names>M.</given-names></name></person-group><article-title>A dry powder platform for nose-to-brain delivery of dexamethasone: Formulation development and nasal deposition studies</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>795</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13060795</pub-id><pub-id pub-id-type="pmid">34073500</pub-id><pub-id pub-id-type="pmcid">PMC8229415</pub-id></element-citation></ref><ref id="B229-pharmaceutics-15-02114"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.-J.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>L.-T.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.-H.</given-names></name><name name-style="western"><surname>Si</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.-P.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.</given-names></name></person-group><article-title>The Optimal Concentration of Formaldehyde is Key to Stabilizing the Pre-Fusion Conformation of Respiratory Syncytial Virus Fusion Protein</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>628</elocation-id><pub-id pub-id-type="doi">10.3390/v11070628</pub-id><pub-id pub-id-type="pmid">31288455</pub-id><pub-id pub-id-type="pmcid">PMC6669674</pub-id></element-citation></ref><ref id="B230-pharmaceutics-15-02114"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gockel</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beagley</surname><given-names>K.W.</given-names></name></person-group><article-title>Transcutaneous immunization induces mucosal and systemic immunity: A potent method for targeting immunity to the female reproductive tract</article-title><source>Mol. Immunol.</source><year>2000</year><volume>37</volume><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/S0161-5890(00)00074-2</pub-id><pub-id pub-id-type="pmid">11163403</pub-id></element-citation></ref><ref id="B231-pharmaceutics-15-02114"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karande</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mitragotri</surname><given-names>S.</given-names></name></person-group><article-title>Transcutaneous immunization: An overview of advantages, disease targets, vaccines, and delivery technologies</article-title><source>Annu. Rev. Chem. Biomol. Eng.</source><year>2010</year><volume>1</volume><fpage>175</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1146/annurev-chembioeng-073009-100948</pub-id><pub-id pub-id-type="pmid">22432578</pub-id></element-citation></ref><ref id="B232-pharmaceutics-15-02114"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hettinga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carlisle</surname><given-names>R.</given-names></name></person-group><article-title>Vaccination into the dermal compartment: Techniques, challenges, and prospects</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>534</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8030534</pub-id><pub-id pub-id-type="pmid">32947966</pub-id><pub-id pub-id-type="pmcid">PMC7564253</pub-id></element-citation></ref><ref id="B233-pharmaceutics-15-02114"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirobe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>S.</given-names></name></person-group><article-title>Transcutaneous vaccines&#8211;current and emerging strategies</article-title><source>Expert Opin. Drug Deliv.</source><year>2013</year><volume>10</volume><fpage>485</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1517/17425247.2013.760542</pub-id><pub-id pub-id-type="pmid">23316778</pub-id></element-citation></ref><ref id="B234-pharmaceutics-15-02114"><label>234.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Manikkath</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hegde</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Parekh</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Mutalik</surname><given-names>S.</given-names></name></person-group><article-title>Peptide dendrimers in delivery of bioactive molecules to skin</article-title><source>Nanoscience in Dermatology</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2016</year><fpage>89</fpage><lpage>97</lpage></element-citation></ref><ref id="B235-pharmaceutics-15-02114"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tezel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paliwal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Mitragotri</surname><given-names>S.</given-names></name></person-group><article-title>Low-frequency ultrasound as a transcutaneous immunization adjuvant</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>3800</fpage><lpage>3807</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.02.027</pub-id><pub-id pub-id-type="pmid">15893617</pub-id></element-citation></ref><ref id="B236-pharmaceutics-15-02114"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gehl</surname><given-names>J.</given-names></name></person-group><article-title>Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research</article-title><source>Acta Physiol. Scand.</source><year>2003</year><volume>177</volume><fpage>437</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1046/j.1365-201X.2003.01093.x</pub-id><pub-id pub-id-type="pmid">12648161</pub-id></element-citation></ref><ref id="B237-pharmaceutics-15-02114"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoppink</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rivas</surname><given-names>D.F.</given-names></name></person-group><article-title>Jet injectors: Perspectives for small volume delivery with lasers</article-title><source>Adv. Drug Deliv. Rev.</source><year>2022</year><volume>182</volume><fpage>114109</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.114109</pub-id><pub-id pub-id-type="pmid">34998902</pub-id></element-citation></ref><ref id="B238-pharmaceutics-15-02114"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trimzi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ham</surname><given-names>Y.-B.</given-names></name></person-group><article-title>A needle-free jet injection system for controlled release and repeated biopharmaceutical delivery</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1770</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13111770</pub-id><pub-id pub-id-type="pmid">34834185</pub-id><pub-id pub-id-type="pmcid">PMC8620904</pub-id></element-citation></ref><ref id="B239-pharmaceutics-15-02114"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Aljuffali</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.-Y.</given-names></name></person-group><article-title>Lasers as an approach for promoting drug delivery via skin</article-title><source>Expert Opin. Drug Deliv.</source><year>2014</year><volume>11</volume><fpage>599</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1517/17425247.2014.885501</pub-id><pub-id pub-id-type="pmid">24490743</pub-id></element-citation></ref><ref id="B240-pharmaceutics-15-02114"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kakar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Laser facilitates week-long sustained transdermal drug delivery at high doses</article-title><source>J. Control. Release</source><year>2020</year><volume>319</volume><fpage>428</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.01.011</pub-id><pub-id pub-id-type="pmid">31923535</pub-id><pub-id pub-id-type="pmcid">PMC7050411</pub-id></element-citation></ref><ref id="B241-pharmaceutics-15-02114"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menon</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bagwe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Bajaj</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gala</surname><given-names>R.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>D&#8217;souza</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Zughaier</surname><given-names>S.M.</given-names></name></person-group><article-title>Microneedles: A new generation vaccine delivery system</article-title><source>Micromachines</source><year>2021</year><volume>12</volume><elocation-id>435</elocation-id><pub-id pub-id-type="doi">10.3390/mi12040435</pub-id><pub-id pub-id-type="pmid">33919925</pub-id><pub-id pub-id-type="pmcid">PMC8070939</pub-id></element-citation></ref><ref id="B242-pharmaceutics-15-02114"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alimardani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Abolmaali</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Yousefi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rahiminezhad</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Abedi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tamaddon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahadian</surname><given-names>S.</given-names></name></person-group><article-title>Microneedle arrays combined with nanomedicine approaches for transdermal delivery of therapeutics</article-title><source>J. Clin. Med.</source><year>2021</year><volume>10</volume><elocation-id>181</elocation-id><pub-id pub-id-type="doi">10.3390/jcm10020181</pub-id><pub-id pub-id-type="pmid">33419118</pub-id><pub-id pub-id-type="pmcid">PMC7825522</pub-id></element-citation></ref><ref id="B243-pharmaceutics-15-02114"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.-Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C.-M.</given-names></name></person-group><article-title>Transdermal drug delivery systems for fighting common viral infectious diseases</article-title><source>Drug Deliv. Transl. Res.</source><year>2021</year><volume>11</volume><fpage>1498</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1007/s13346-021-01004-6</pub-id><pub-id pub-id-type="pmid">34024014</pub-id><pub-id pub-id-type="pmcid">PMC8140753</pub-id></element-citation></ref><ref id="B244-pharmaceutics-15-02114"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>C&#225;rcamo-Mart&#237;nez</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Mallon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dom&#237;nguez-Robles</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vora</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Anjani</surname><given-names>Q.K.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name></person-group><article-title>Hollow microneedles: A perspective in biomedical applications</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>599</volume><fpage>120455</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120455</pub-id><pub-id pub-id-type="pmid">33676993</pub-id></element-citation></ref><ref id="B245-pharmaceutics-15-02114"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name></person-group><article-title>Engineering microneedle patches for vaccination and drug delivery to skin</article-title><source>Annu. Rev. Chem. Biomol. Eng.</source><year>2017</year><volume>8</volume><fpage>177</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1146/annurev-chembioeng-060816-101514</pub-id><pub-id pub-id-type="pmid">28375775</pub-id></element-citation></ref><ref id="B246-pharmaceutics-15-02114"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tariq</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Tayyaba</surname><given-names>S.</given-names></name></person-group><article-title>A review on solid microneedles for biomedical applications</article-title><source>J. Pharm. Innov.</source><year>2022</year><volume>17</volume><fpage>1464</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1007/s12247-021-09586-x</pub-id></element-citation></ref><ref id="B247-pharmaceutics-15-02114"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S.G.</given-names></name></person-group><article-title>Microneedle for transdermal drug delivery: Current trends and fabrication</article-title><source>J. Pharm. Investig.</source><year>2021</year><volume>51</volume><fpage>503</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1007/s40005-021-00512-4</pub-id><pub-id pub-id-type="pmcid">PMC7931162</pub-id><pub-id pub-id-type="pmid">33686358</pub-id></element-citation></ref><ref id="B248-pharmaceutics-15-02114"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aldawood</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Andar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>S.</given-names></name></person-group><article-title>A comprehensive review of microneedles: Types, materials, processes, characterizations and applications</article-title><source>Polymers</source><year>2021</year><volume>13</volume><elocation-id>2815</elocation-id><pub-id pub-id-type="doi">10.3390/polym13162815</pub-id><pub-id pub-id-type="pmid">34451353</pub-id><pub-id pub-id-type="pmcid">PMC8400269</pub-id></element-citation></ref><ref id="B249-pharmaceutics-15-02114"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name></person-group><article-title>Microneedle system for transdermal drug and vaccine delivery: Devices, safety, and prospects</article-title><source>Dose-Response</source><year>2019</year><volume>17</volume><fpage>1559325819878585</fpage><pub-id pub-id-type="doi">10.1177/1559325819878585</pub-id><pub-id pub-id-type="pmid">31662709</pub-id><pub-id pub-id-type="pmcid">PMC6794664</pub-id></element-citation></ref><ref id="B250-pharmaceutics-15-02114"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leone</surname><given-names>M.</given-names></name><name name-style="western"><surname>M&#246;nk&#228;re</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bouwstra</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.</given-names></name></person-group><article-title>Dissolving microneedle patches for dermal vaccination</article-title><source>Pharm. Res.</source><year>2017</year><volume>34</volume><fpage>2223</fpage><lpage>2240</lpage><pub-id pub-id-type="doi">10.1007/s11095-017-2223-2</pub-id><pub-id pub-id-type="pmid">28718050</pub-id><pub-id pub-id-type="pmcid">PMC5643353</pub-id></element-citation></ref><ref id="B251-pharmaceutics-15-02114"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sartawi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Blackshields</surname><given-names>C.</given-names></name><name name-style="western"><surname>Faisal</surname><given-names>W.</given-names></name></person-group><article-title>Dissolving microneedles: Applications and growing therapeutic potential</article-title><source>J. Control. Release</source><year>2022</year><volume>348</volume><fpage>186</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.05.045</pub-id><pub-id pub-id-type="pmid">35662577</pub-id></element-citation></ref><ref id="B252-pharmaceutics-15-02114"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>White</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Estrela</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leese</surname><given-names>H.S.</given-names></name></person-group><article-title>Hydrogel-forming microneedles: Current advancements and future trends</article-title><source>Macromol. Biosci.</source><year>2021</year><volume>21</volume><fpage>2000307</fpage><pub-id pub-id-type="doi">10.1002/mabi.202000307</pub-id><pub-id pub-id-type="pmid">33241641</pub-id></element-citation></ref><ref id="B253-pharmaceutics-15-02114"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dardano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cali&#242;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Palma</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bevilacqua</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Di Matteo</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Stefano</surname><given-names>L.</given-names></name></person-group><article-title>A photolithographic approach to polymeric microneedles array fabrication</article-title><source>Materials</source><year>2015</year><volume>8</volume><fpage>8661</fpage><lpage>8673</lpage><pub-id pub-id-type="doi">10.3390/ma8125484</pub-id><pub-id pub-id-type="pmid">28793736</pub-id><pub-id pub-id-type="pmcid">PMC5458808</pub-id></element-citation></ref><ref id="B254-pharmaceutics-15-02114"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>L.</given-names></name></person-group><article-title>Application of microneedle-based vaccines in biosecurity</article-title><source>J. Biosaf. Biosecur.</source><year>2022</year><volume>4</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.jobb.2022.04.001</pub-id></element-citation></ref><ref id="B255-pharmaceutics-15-02114"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>McCrudden</surname><given-names>M.T.C.</given-names></name><name name-style="western"><surname>Zaid Alkilani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Larra&#241;eta</surname><given-names>E.</given-names></name><name name-style="western"><surname>McAlister</surname><given-names>E.</given-names></name><name name-style="western"><surname>Courtenay</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Kearney</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>T.R.R.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Kett</surname><given-names>V.L.</given-names></name></person-group><article-title>Hydrogel-forming microneedles prepared from &#8220;super swelling&#8221; polymers combined with lyophilised wafers for transdermal drug delivery</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e111547</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0111547</pub-id><pub-id pub-id-type="pmid">25360806</pub-id><pub-id pub-id-type="pmcid">PMC4216095</pub-id></element-citation></ref><ref id="B256-pharmaceutics-15-02114"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Microneedle-mediated transdermal delivery of drug-carrying nanoparticles</article-title><source>Front. Bioeng. Biotechnol.</source><year>2022</year><volume>10</volume><fpage>840395</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2022.840395</pub-id><pub-id pub-id-type="pmid">35223799</pub-id><pub-id pub-id-type="pmcid">PMC8874791</pub-id></element-citation></ref><ref id="B257-pharmaceutics-15-02114"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habibi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mauser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lahann</surname><given-names>J.</given-names></name></person-group><article-title>Protein nanoparticles: Uniting the power of proteins with engineering design approaches</article-title><source>Adv. Sci.</source><year>2022</year><volume>9</volume><fpage>2104012</fpage><pub-id pub-id-type="doi">10.1002/advs.202104012</pub-id><pub-id pub-id-type="pmcid">PMC8922121</pub-id><pub-id pub-id-type="pmid">35077010</pub-id></element-citation></ref><ref id="B258-pharmaceutics-15-02114"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karande</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mitragotri</surname><given-names>S.</given-names></name></person-group><article-title>Enhancement of transdermal drug delivery via synergistic action of chemicals</article-title><source>Biochim. Biophys. Acta-Biomembr.</source><year>2009</year><volume>1788</volume><fpage>2362</fpage><lpage>2373</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2009.08.015</pub-id><pub-id pub-id-type="pmid">19733150</pub-id></element-citation></ref><ref id="B259-pharmaceutics-15-02114"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barry</surname><given-names>B.W.</given-names></name></person-group><article-title>Lipid-protein-partitioning theory of skin penetration enhancement</article-title><source>J. Control. Release</source><year>1991</year><volume>15</volume><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/0168-3659(91)90115-T</pub-id><pub-id pub-id-type="pmid">2014203</pub-id></element-citation></ref><ref id="B260-pharmaceutics-15-02114"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Freytag</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>John</surname><given-names>V.T.</given-names></name></person-group><article-title>Hydration effects on skin microstructure as probed by high-resolution cryo-scanning electron microscopy and mechanistic implications to enhanced transcutaneous delivery of biomacromolecules</article-title><source>J. Pharm. Sci.</source><year>2010</year><volume>99</volume><fpage>730</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1002/jps.21863</pub-id><pub-id pub-id-type="pmid">19582754</pub-id><pub-id pub-id-type="pmcid">PMC2849273</pub-id></element-citation></ref><ref id="B261-pharmaceutics-15-02114"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alonso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meirelles</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Yushmanov</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Tabak</surname><given-names>M.</given-names></name></person-group><article-title>Water increases the fluidity of intercellular membranes of stratum corneum: Correlation with water permeability, elastic, and electrical resistance properties</article-title><source>J. Investig. Dermatol.</source><year>1996</year><volume>106</volume><fpage>1058</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1111/1523-1747.ep12338682</pub-id><pub-id pub-id-type="pmid">8618039</pub-id></element-citation></ref><ref id="B262-pharmaceutics-15-02114"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Notman</surname><given-names>R.</given-names></name><name name-style="western"><surname>den Otter</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Noro</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Briels</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Anwar</surname><given-names>J.</given-names></name></person-group><article-title>The permeability enhancing mechanism of DMSO in ceramide bilayers simulated by molecular dynamics</article-title><source>Biophys. J.</source><year>2007</year><volume>93</volume><fpage>2056</fpage><lpage>2068</lpage><pub-id pub-id-type="doi">10.1529/biophysj.107.104703</pub-id><pub-id pub-id-type="pmid">17513383</pub-id><pub-id pub-id-type="pmcid">PMC1959535</pub-id></element-citation></ref><ref id="B263-pharmaceutics-15-02114"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>B.W.</given-names></name></person-group><article-title>Terpenes and the lipid&#8211;protein&#8211;partitioning theory of skin penetration enhancement</article-title><source>Pharm. Res.</source><year>1991</year><volume>8</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1023/A:1015813803205</pub-id><pub-id pub-id-type="pmid">2014203</pub-id></element-citation></ref><ref id="B264-pharmaceutics-15-02114"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osborne</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Musakhanian</surname><given-names>J.</given-names></name></person-group><article-title>Skin penetration and permeation properties of Transcutol<sup>&#174;</sup>&#8212;Neat or diluted mixtures</article-title><source>AAPS PharmSciTech</source><year>2018</year><volume>19</volume><fpage>3512</fpage><lpage>3533</lpage><pub-id pub-id-type="doi">10.1208/s12249-018-1196-8</pub-id><pub-id pub-id-type="pmid">30421383</pub-id><pub-id pub-id-type="pmcid">PMC6848246</pub-id></element-citation></ref><ref id="B265-pharmaceutics-15-02114"><label>265.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><article-title>VAXCHORA</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxchora" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxchora</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-24">(accessed on 24 April 2023)</date-in-citation></element-citation></ref><ref id="B266-pharmaceutics-15-02114"><label>266.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><article-title>ROTARIX</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/vaccines-blood-biologics/vaccines/rotarix" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/vaccines/rotarix</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-24">(accessed on 24 April 2023)</date-in-citation></element-citation></ref><ref id="B267-pharmaceutics-15-02114"><label>267.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><article-title>RotaTeq</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/vaccines-blood-biologics/vaccines/rotateq" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/vaccines/rotateq</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-23">(accessed on 23 April 2023)</date-in-citation></element-citation></ref><ref id="B268-pharmaceutics-15-02114"><label>268.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><article-title>VIVOTIF</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/vaccines-blood-biologics/vaccines/vivotif" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/vaccines/vivotif</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-23">(accessed on 23 April 2023)</date-in-citation></element-citation></ref><ref id="B269-pharmaceutics-15-02114"><label>269.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><article-title>Adenovirus Type 4 and Type 7 Vaccine, Live, Oral</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/vaccines-blood-biologics/vaccines/adenovirus-type-4-and-type-7-vaccine-live-oral" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/vaccines/adenovirus-type-4-and-type-7-vaccine-live-oral</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-23">(accessed on 23 April 2023)</date-in-citation></element-citation></ref><ref id="B270-pharmaceutics-15-02114"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kool</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fierens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>B.N.</given-names></name></person-group><article-title>Alum adjuvant: Some of the tricks of the oldest adjuvant</article-title><source>J. Med. Microbiol.</source><year>2012</year><volume>61</volume><fpage>927</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.038943-0</pub-id><pub-id pub-id-type="pmid">22174375</pub-id></element-citation></ref><ref id="B271-pharmaceutics-15-02114"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>HogenEsch</surname><given-names>H.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><article-title>Optimizing the utilization of aluminum adjuvants in vaccines: You might just get what you want</article-title><source>NPJ Vaccines</source><year>2018</year><volume>3</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.1038/s41541-018-0089-x</pub-id><pub-id pub-id-type="pmid">30323958</pub-id><pub-id pub-id-type="pmcid">PMC6180056</pub-id></element-citation></ref><ref id="B272-pharmaceutics-15-02114"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Van Riet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Romeijn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.F.A.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bouwstra</surname><given-names>J.A.</given-names></name></person-group><article-title>Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment</article-title><source>Pharm. Res.</source><year>2009</year><volume>26</volume><fpage>1635</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1007/s11095-009-9874-6</pub-id><pub-id pub-id-type="pmid">19326190</pub-id><pub-id pub-id-type="pmcid">PMC2689355</pub-id></element-citation></ref><ref id="B273-pharmaceutics-15-02114"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stark</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Akache</surname><given-names>B.</given-names></name><name name-style="western"><surname>Deschatelets</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stuible</surname><given-names>M.</given-names></name><name name-style="western"><surname>Durocher</surname><given-names>Y.</given-names></name><name name-style="western"><surname>McCluskie</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Agbayani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dudani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>B.A.</given-names></name></person-group><article-title>Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>9772</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-13819-5</pub-id><pub-id pub-id-type="pmid">35697917</pub-id><pub-id pub-id-type="pmcid">PMC9191540</pub-id></element-citation></ref><ref id="B274-pharmaceutics-15-02114"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name></person-group><article-title>Advances in aluminum hydroxide-based adjuvant research and its mechanism</article-title><source>Hum. Vaccines Immunother.</source><year>2015</year><volume>11</volume><fpage>477</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1080/21645515.2014.1004026</pub-id><pub-id pub-id-type="pmcid">PMC4514166</pub-id><pub-id pub-id-type="pmid">25692535</pub-id></element-citation></ref><ref id="B275-pharmaceutics-15-02114"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotloff</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Wasserman</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>DiLorenzo</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>R.I.</given-names></name></person-group><article-title>Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection</article-title><source>Infect. Immun.</source><year>2001</year><volume>69</volume><fpage>3581</fpage><lpage>3590</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.6.3581-3590.2001</pub-id><pub-id pub-id-type="pmid">11349017</pub-id><pub-id pub-id-type="pmcid">PMC98341</pub-id></element-citation></ref><ref id="B276-pharmaceutics-15-02114"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bourgeois</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Sack</surname><given-names>D.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>R.</given-names></name><name name-style="western"><surname>DeNearing</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brubaker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fix</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dally</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>S.</given-names></name></person-group><article-title>Live attenuated enterotoxigenic <italic toggle="yes">Escherichia coli</italic> (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>1978</fpage><lpage>1986</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.02.025</pub-id><pub-id pub-id-type="pmid">30797634</pub-id><pub-id pub-id-type="pmcid">PMC6434318</pub-id></element-citation></ref><ref id="B277-pharmaceutics-15-02114"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qadri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Akhtar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bhuiyan</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rafique</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>S.I.A.</given-names></name><name name-style="western"><surname>Khanam</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lundgren</surname><given-names>A.</given-names></name></person-group><article-title>Safety and immunogenicity of the oral, inactivated, enterotoxigenic <italic toggle="yes">Escherichia coli</italic> vaccine ETVAX in Bangladeshi children and infants: A double-blind, randomised, placebo-controlled phase 1/2 trial</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>208</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30571-7</pub-id><pub-id pub-id-type="pmid">31757774</pub-id><pub-id pub-id-type="pmcid">PMC6990395</pub-id></element-citation></ref><ref id="B278-pharmaceutics-15-02114"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norton</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Freytag</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>J.D.</given-names></name></person-group><article-title>Characterization of a mutant <italic toggle="yes">Escherichia coli</italic> heat-labile toxin, LT (R192G/L211A), as a safe and effective oral adjuvant</article-title><source>Clin. Vaccine Immunol.</source><year>2011</year><volume>18</volume><fpage>546</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1128/CVI.00538-10</pub-id><pub-id pub-id-type="pmid">21288994</pub-id><pub-id pub-id-type="pmcid">PMC3122563</pub-id></element-citation></ref><ref id="B279-pharmaceutics-15-02114"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sj&#246;kvist Ottsj&#246;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Flach</surname><given-names>C.-F.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holmgren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>S.</given-names></name></person-group><article-title>A double mutant heat-labile toxin from <italic toggle="yes">Escherichia coli</italic>, LT (R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection</article-title><source>Infect. Immun.</source><year>2013</year><volume>81</volume><fpage>1532</fpage><lpage>1540</lpage><pub-id pub-id-type="doi">10.1128/IAI.01407-12</pub-id><pub-id pub-id-type="pmid">23439305</pub-id><pub-id pub-id-type="pmcid">PMC3647992</pub-id></element-citation></ref><ref id="B280-pharmaceutics-15-02114"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sj&#246;kvist Ottsj&#246;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jeverstam</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yrlid</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>A.U.</given-names></name><name name-style="western"><surname>Walduck</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>S.</given-names></name></person-group><article-title>Induction of mucosal immune responses against Helicobacter pylori infection after sublingual and intragastric route of immunization</article-title><source>Immunology</source><year>2017</year><volume>150</volume><fpage>172</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1111/imm.12676</pub-id><pub-id pub-id-type="pmid">27676456</pub-id><pub-id pub-id-type="pmcid">PMC5216441</pub-id></element-citation></ref><ref id="B281-pharmaceutics-15-02114"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maldarelli</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Matz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hamza</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yfantis</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Donnenberg</surname><given-names>M.S.</given-names></name></person-group><article-title>Pilin vaccination stimulates weak antibody responses and provides no protection in a C57Bl/6 murine model of acute Clostridium difficile infection</article-title><source>J. Vaccines Vaccin.</source><year>2016</year><volume>7</volume><fpage>321</fpage><pub-id pub-id-type="doi">10.4172/2157-7560.1000321</pub-id><pub-id pub-id-type="pmid">27375958</pub-id><pub-id pub-id-type="pmcid">PMC4927082</pub-id></element-citation></ref><ref id="B282-pharmaceutics-15-02114"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Streatfield</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lamphear</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Fake</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Keener</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Tizard</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>J.A.</given-names></name></person-group><article-title>Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>2937</fpage><lpage>2942</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.02.072</pub-id><pub-id pub-id-type="pmid">22406456</pub-id><pub-id pub-id-type="pmcid">PMC3322283</pub-id></element-citation></ref><ref id="B283-pharmaceutics-15-02114"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lalsiamthara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name></person-group><article-title>Immunization with Salmonella Enteritidis secreting mucosal adjuvant labile toxin confers protection against wild type challenge via augmentation of CD3+ CD4+ T-cell proliferation and enhancement of IFN-&#947;, IL-6 and IL-10 expressions in chicken</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>767</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.12.042</pub-id><pub-id pub-id-type="pmid">28063704</pub-id></element-citation></ref><ref id="B284-pharmaceutics-15-02114"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holmgren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nordqvist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blomquist</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jeverstam</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lebens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>S.</given-names></name></person-group><article-title>Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>6223</fpage><lpage>6230</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.07.073</pub-id><pub-id pub-id-type="pmid">30119923</pub-id></element-citation></ref><ref id="B285-pharmaceutics-15-02114"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Terrinoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Larena</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gustafsson-Hedberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>K&#228;llg&#229;rd</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nygren</surname><given-names>E.</given-names></name><name name-style="western"><surname>Holmgren</surname><given-names>J.</given-names></name></person-group><article-title>Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>2121</fpage><lpage>2128</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.03.002</pub-id><pub-id pub-id-type="pmid">26973069</pub-id></element-citation></ref><ref id="B286-pharmaceutics-15-02114"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stratmann</surname><given-names>T.</given-names></name></person-group><article-title>Cholera toxin subunit B as adjuvant&#8211;&#8211;An accelerator in protective immunity and a break in autoimmunity</article-title><source>Vaccines</source><year>2015</year><volume>3</volume><fpage>579</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.3390/vaccines3030579</pub-id><pub-id pub-id-type="pmid">26350596</pub-id><pub-id pub-id-type="pmcid">PMC4586468</pub-id></element-citation></ref><ref id="B287-pharmaceutics-15-02114"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name></person-group><article-title>Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against <italic toggle="yes">H. pylori</italic> infection in BALB/c mice</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>7664</fpage><lpage>7673</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.08.034</pub-id><pub-id pub-id-type="pmid">17913305</pub-id></element-citation></ref><ref id="B288-pharmaceutics-15-02114"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schussek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bernasconi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>U.A.</given-names></name><name name-style="western"><surname>Str&#246;mberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gribonika</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sch&#246;n</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lycke</surname><given-names>N.Y.</given-names></name></person-group><article-title>The CTA1-DD adjuvant strongly potentiates follicular dendritic cell function and germinal center formation, which results in improved neonatal immunization</article-title><source>Mucosal Immunol.</source><year>2020</year><volume>13</volume><fpage>545</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1038/s41385-020-0253-2</pub-id><pub-id pub-id-type="pmid">31959882</pub-id><pub-id pub-id-type="pmcid">PMC7223721</pub-id></element-citation></ref><ref id="B289-pharmaceutics-15-02114"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Mucosal adjuvant activity of chitosan encapsulated nanoparticles as helicobacter pylori epitope vaccine carrier</article-title><source>Nanosci. Nanotechnol. Lett.</source><year>2016</year><volume>8</volume><fpage>1106</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1166/nnl.2016.2234</pub-id></element-citation></ref><ref id="B290-pharmaceutics-15-02114"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laue</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>Y.</given-names></name><name name-style="western"><surname>van Erp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Papazova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Soeth</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pannenbeckers</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stolte</surname><given-names>E.</given-names></name><name name-style="western"><surname>B&#246;hm</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gall</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Falourd</surname><given-names>X.</given-names></name></person-group><article-title>Adjuvant effect of orally applied preparations containing non-digestible polysaccharides on influenza vaccination in healthy seniors: A double-blind, randomised, controlled pilot trial</article-title><source>Nutrients</source><year>2021</year><volume>13</volume><elocation-id>2683</elocation-id><pub-id pub-id-type="doi">10.3390/nu13082683</pub-id><pub-id pub-id-type="pmid">34444843</pub-id><pub-id pub-id-type="pmcid">PMC8400163</pub-id></element-citation></ref><ref id="B291-pharmaceutics-15-02114"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rachmawati</surname><given-names>H.</given-names></name><name name-style="western"><surname>Winarsih</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prawiro</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Barlianto</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sanarto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Djunaedi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Endharti</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Sardjono</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Khotimah</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nugraheni</surname><given-names>R.W.</given-names></name></person-group><article-title>AdhO36 liposomes from Salmonella Typhi in combination with &#946;-Glucan Immuno-adjuvant From Candida albicans cell wall as oral vaccine against typhoid fever in mice model</article-title><source>Open Access Maced. J. Med. Sci.</source><year>2020</year><volume>8</volume><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.3889/oamjms.2020.4422</pub-id></element-citation></ref><ref id="B292-pharmaceutics-15-02114"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kournikakis</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mandeville</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brousseau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ostroff</surname><given-names>G.</given-names></name></person-group><article-title>Anthrax-protective effects of yeast beta 1, 3 glucans</article-title><source>MedGenMed</source><year>2003</year><volume>5</volume><fpage>1</fpage><pub-id pub-id-type="pmid">12827062</pub-id></element-citation></ref><ref id="B293-pharmaceutics-15-02114"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courtney</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Nehete</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Nehete</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Thapa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sastry</surname><given-names>K.J.</given-names></name></person-group><article-title>Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>3335</fpage><lpage>3341</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.083</pub-id><pub-id pub-id-type="pmid">19200849</pub-id><pub-id pub-id-type="pmcid">PMC5798449</pub-id></element-citation></ref><ref id="B294-pharmaceutics-15-02114"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davitt</surname><given-names>C.J.H.</given-names></name><name name-style="western"><surname>Longet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Albutti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aversa</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nordqvist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>B.</given-names></name><name name-style="western"><surname>McEntee</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coulter</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Lebens</surname><given-names>M.</given-names></name></person-group><article-title>Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines</article-title><source>Mucosal Immunol.</source><year>2019</year><volume>12</volume><fpage>1055</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1038/s41385-019-0159-z</pub-id><pub-id pub-id-type="pmid">30953000</pub-id><pub-id pub-id-type="pmcid">PMC7746523</pub-id></element-citation></ref><ref id="B295-pharmaceutics-15-02114"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Longet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abautret-Daly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davitt</surname><given-names>C.J.H.</given-names></name><name name-style="western"><surname>McEntee</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Aversa</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coulter</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Holmgren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>E.C.</given-names></name></person-group><article-title>An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R-and IL-17R-dependent Th1 responses</article-title><source>NPJ Vaccines</source><year>2019</year><volume>4</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1038/s41541-019-0139-z</pub-id><pub-id pub-id-type="pmid">31666991</pub-id><pub-id pub-id-type="pmcid">PMC6814776</pub-id></element-citation></ref><ref id="B296-pharmaceutics-15-02114"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clements</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>E.B.</given-names></name></person-group><article-title>The mucosal vaccine adjuvant LT (R192G/L211A) or dmLT</article-title><source>mSphere</source><year>2018</year><volume>3</volume><fpage>e00215</fpage><lpage>e00218</lpage><pub-id pub-id-type="doi">10.1128/mSphere.00215-18</pub-id><pub-id pub-id-type="pmid">30045966</pub-id><pub-id pub-id-type="pmcid">PMC6060342</pub-id></element-citation></ref><ref id="B297-pharmaceutics-15-02114"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elieh Ali Komi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dela Cruz</surname><given-names>C.S.</given-names></name></person-group><article-title>Chitin and its effects on inflammatory and immune responses</article-title><source>Clin. Rev. Allergy Immunol.</source><year>2018</year><volume>54</volume><fpage>213</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1007/s12016-017-8600-0</pub-id><pub-id pub-id-type="pmid">28251581</pub-id><pub-id pub-id-type="pmcid">PMC5680136</pub-id></element-citation></ref><ref id="B298-pharmaceutics-15-02114"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Saade</surname><given-names>F.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Advax&#8482;, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>5373</fpage><lpage>5381</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.06.021</pub-id><pub-id pub-id-type="pmid">22728225</pub-id><pub-id pub-id-type="pmcid">PMC3401346</pub-id></element-citation></ref><ref id="B299-pharmaceutics-15-02114"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name></person-group><article-title>Polyactin A is a novel and potent immunological adjuvant for peptide-based cancer vaccine</article-title><source>Int. Immunopharmacol.</source><year>2018</year><volume>54</volume><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2017.10.020</pub-id><pub-id pub-id-type="pmid">29112895</pub-id></element-citation></ref><ref id="B300-pharmaceutics-15-02114"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Musa</surname><given-names>H.</given-names></name></person-group><article-title>Cereal-derived arabinoxylans as biological response modifiers: Extraction, molecular features, and immune-stimulating properties</article-title><source>Crit. Rev. Food Sci. Nutr.</source><year>2015</year><volume>55</volume><fpage>1035</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1080/10408398.2012.705188</pub-id><pub-id pub-id-type="pmid">25314049</pub-id></element-citation></ref><ref id="B301-pharmaceutics-15-02114"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichinohe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>S.-i.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chiba</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kurata</surname><given-names>T.</given-names></name></person-group><article-title>Synthetic double-stranded RNA poly (I: C) combined with mucosal vaccine protects against influenza virus infection</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>2910</fpage><lpage>2919</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.5.2910-2919.2005</pub-id><pub-id pub-id-type="pmid">15709010</pub-id><pub-id pub-id-type="pmcid">PMC548446</pub-id></element-citation></ref><ref id="B302-pharmaceutics-15-02114"><label>302.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Vanpouille-Box</surname><given-names>C.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name></person-group><source>Nucleic Acid Sensing and Immunity-PART B</source><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2019</year></element-citation></ref><ref id="B303-pharmaceutics-15-02114"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohto</surname><given-names>U.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>T.</given-names></name></person-group><article-title>Structural aspects of nucleic acid-sensing Toll-like receptors</article-title><source>Biophys. Rev.</source><year>2016</year><volume>8</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1007/s12551-015-0187-1</pub-id><pub-id pub-id-type="pmcid">PMC5425962</pub-id><pub-id pub-id-type="pmid">28510149</pub-id></element-citation></ref><ref id="B304-pharmaceutics-15-02114"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group><article-title>Toll-like receptors and innate immunity</article-title><source>Nat. Rev. Immunol.</source><year>2001</year><volume>1</volume><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/35100529</pub-id><pub-id pub-id-type="pmid">11905821</pub-id></element-citation></ref><ref id="B305-pharmaceutics-15-02114"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morere</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hognon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Miclot</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dumont</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Monari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bignon</surname><given-names>E.</given-names></name></person-group><article-title>How Fragile We Are: Influence of Stimulator of Interferon Genes (STING) Variants on Pathogen Recognition and Immune Response Efficiency</article-title><source>J. Chem. Inf. Model.</source><year>2022</year><volume>62</volume><fpage>3096</fpage><lpage>3106</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.2c00315</pub-id><pub-id pub-id-type="pmid">35675714</pub-id></element-citation></ref><ref id="B306-pharmaceutics-15-02114"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNab</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mayer-Barber</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wack</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Garra</surname><given-names>A.</given-names></name></person-group><article-title>Type I interferons in infectious disease</article-title><source>Nat. Rev.</source><year>2015</year><volume>15</volume><fpage>87</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nri3787</pub-id><pub-id pub-id-type="pmid">25614319</pub-id><pub-id pub-id-type="pmcid">PMC7162685</pub-id></element-citation></ref><ref id="B307-pharmaceutics-15-02114"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tandrup Schmidt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Foged</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smith Korsholm</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rades</surname><given-names>T.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>D.</given-names></name></person-group><article-title>Liposome-based adjuvants for subunit vaccines: Formulation strategies for subunit antigens and immunostimulators</article-title><source>Pharmaceutics</source><year>2016</year><volume>8</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics8010007</pub-id><pub-id pub-id-type="pmid">26978390</pub-id><pub-id pub-id-type="pmcid">PMC4810083</pub-id></element-citation></ref><ref id="B308-pharmaceutics-15-02114"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Ozinsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hawn</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Goodlett</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Eng</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Underhill</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Aderem</surname><given-names>A.</given-names></name></person-group><article-title>The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5</article-title><source>Nature</source><year>2001</year><volume>410</volume><fpage>1099</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1038/35074106</pub-id><pub-id pub-id-type="pmid">11323673</pub-id></element-citation></ref><ref id="B309-pharmaceutics-15-02114"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>D.-G.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J.-W.</given-names></name></person-group><article-title>The antiviral activity of poly-&#947;-glutamic acid, a polypeptide secreted by Bacillus sp., through induction of CD14-dependent type I interferon responses</article-title><source>Biomaterials</source><year>2013</year><volume>34</volume><fpage>9700</fpage><lpage>9708</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.08.067</pub-id><pub-id pub-id-type="pmid">24016850</pub-id><pub-id pub-id-type="pmcid">PMC7112489</pub-id></element-citation></ref><ref id="B310-pharmaceutics-15-02114"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cyr</surname><given-names>S.</given-names></name><name name-style="western"><surname>Allard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bellerose</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>D.S.</given-names></name></person-group><article-title>Protollin&#8482;: A novel adjuvant for intranasal vaccines</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>3691</fpage><lpage>3697</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.03.035</pub-id><pub-id pub-id-type="pmid">15315848</pub-id></element-citation></ref><ref id="B311-pharmaceutics-15-02114"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az-Dinamarca</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Manubens</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vasquez</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M.I.</given-names></name></person-group><article-title>Protein-based adjuvants for vaccines as immunomodulators of the innate and adaptive immune response: Current knowledge, challenges, and future opportunities</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>1671</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14081671</pub-id><pub-id pub-id-type="pmid">36015297</pub-id><pub-id pub-id-type="pmcid">PMC9414397</pub-id></element-citation></ref><ref id="B312-pharmaceutics-15-02114"><label>312.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><article-title>Common Ingredients in U.S. Licensed Vaccines</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/common-ingredients-us-licensed-vaccines" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/common-ingredients-us-licensed-vaccines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-23">(accessed on 23 April 2023)</date-in-citation></element-citation></ref><ref id="B313-pharmaceutics-15-02114"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Comparative safety of vaccine adjuvants: A summary of current evidence and future needs</article-title><source>Drug Saf.</source><year>2015</year><volume>38</volume><fpage>1059</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1007/s40264-015-0350-4</pub-id><pub-id pub-id-type="pmid">26446142</pub-id><pub-id pub-id-type="pmcid">PMC4615573</pub-id></element-citation></ref><ref id="B314-pharmaceutics-15-02114"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLenon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>M.A.M.</given-names></name></person-group><article-title>The fear of needles: A systematic review and meta-analysis</article-title><source>J. Adv. Nurs.</source><year>2019</year><volume>75</volume><fpage>30</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1111/jan.13818</pub-id><pub-id pub-id-type="pmid">30109720</pub-id></element-citation></ref><ref id="B315-pharmaceutics-15-02114"><label>315.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Diaz-Ar&#233;valo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>M.</given-names></name></person-group><article-title>Noninvasive vaccination against infectious diseases</article-title><source>Hum. Vaccines Immunother.</source><year>2018</year><volume>14</volume><fpage>1717</fpage><lpage>1733</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1461296</pub-id><pub-id pub-id-type="pmcid">PMC6067898</pub-id><pub-id pub-id-type="pmid">29624470</pub-id></element-citation></ref><ref id="B316-pharmaceutics-15-02114"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bopp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Linder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Spyr</surname><given-names>C.</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>R.</given-names></name></person-group><article-title>Use of the inactivated intranasal influenza vaccine and the risk of Bell&#8217;s palsy in Switzerland</article-title><source>N. Engl. J. Med.</source><year>2004</year><volume>350</volume><fpage>896</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030595</pub-id><pub-id pub-id-type="pmid">14985487</pub-id></element-citation></ref><ref id="B317-pharmaceutics-15-02114"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephenson</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zambon</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Rudin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Colegate</surname><given-names>A.</given-names></name><name name-style="western"><surname>Podda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bugarini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></name><name name-style="western"><surname>Minutello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bonnington</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holmgren</surname><given-names>J.</given-names></name></person-group><article-title>Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic <italic toggle="yes">Escherichia coli</italic> enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>4962</fpage><lpage>4970</lpage><pub-id pub-id-type="doi">10.1128/JVI.80.10.4962-4970.2006</pub-id><pub-id pub-id-type="pmid">16641287</pub-id><pub-id pub-id-type="pmcid">PMC1472052</pub-id></element-citation></ref><ref id="B318-pharmaceutics-15-02114"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harriett</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Nowakowska</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Baudier</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Provosty</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>McSween</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>E.B.</given-names></name></person-group><article-title>LTA1 is a safe, intranasal enterotoxin-based adjuvant that improves vaccine protection against influenza in young, old and B-cell-depleted (&#956;MT) mice</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>15128</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-51356-w</pub-id><pub-id pub-id-type="pmid">31641151</pub-id><pub-id pub-id-type="pmcid">PMC6805908</pub-id></element-citation></ref><ref id="B319-pharmaceutics-15-02114"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>X.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Q.D.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.I.U.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.I.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Da Yan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kun</surname><given-names>Q.I.N.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>S.L.</given-names></name></person-group><article-title>Intranasal immunization using CTA1-DD as a mucosal adjuvant for an inactivated influenza vaccine</article-title><source>Biomed. Environ. Sci.</source><year>2019</year><volume>32</volume><fpage>531</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">31331437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3967/bes2019.070</pub-id></element-citation></ref><ref id="B320-pharmaceutics-15-02114"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name></person-group><article-title>Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>18641</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-97535-6</pub-id><pub-id pub-id-type="pmid">34545126</pub-id><pub-id pub-id-type="pmcid">PMC8452643</pub-id></element-citation></ref><ref id="B321-pharmaceutics-15-02114"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Agger</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Lycke</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>L&#246;vgren</surname><given-names>K.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P.</given-names></name></person-group><article-title>The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>408</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1128/IAI.01290-06</pub-id><pub-id pub-id-type="pmid">17074845</pub-id><pub-id pub-id-type="pmcid">PMC1828435</pub-id></element-citation></ref><ref id="B322-pharmaceutics-15-02114"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Filette</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Birkett</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lycke</surname><given-names>N.</given-names></name><name name-style="western"><surname>L&#246;wenadler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jou</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Saelens</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fiers</surname><given-names>W.</given-names></name></person-group><article-title>The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>544</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.08.061</pub-id><pub-id pub-id-type="pmid">16169634</pub-id></element-citation></ref><ref id="B323-pharmaceutics-15-02114"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asahi-Ozaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Itamura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ichinohe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Strong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>S.-i.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tashiro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sata</surname><given-names>T.</given-names></name></person-group><article-title>Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection</article-title><source>Microbes Infect.</source><year>2006</year><volume>8</volume><fpage>2706</fpage><lpage>2714</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2006.07.018</pub-id><pub-id pub-id-type="pmid">16968669</pub-id></element-citation></ref><ref id="B324-pharmaceutics-15-02114"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ar&#233;valo</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Posadas</surname><given-names>O.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>M.</given-names></name></person-group><article-title>Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses</article-title><source>Hum. Vaccines Immunother.</source><year>2014</year><volume>10</volume><fpage>1211</fpage><lpage>1220</lpage><pub-id pub-id-type="doi">10.4161/hv.28407</pub-id><pub-id pub-id-type="pmcid">PMC4896531</pub-id><pub-id pub-id-type="pmid">24632749</pub-id></element-citation></ref><ref id="B325-pharmaceutics-15-02114"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Intranasal vaccination against HIV-1 with adenoviral vector-based nanocomplex using synthetic TLR-4 agonist peptide as adjuvant</article-title><source>Mol. Pharm.</source><year>2016</year><volume>13</volume><fpage>885</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5b00802</pub-id><pub-id pub-id-type="pmid">26824411</pub-id></element-citation></ref><ref id="B326-pharmaceutics-15-02114"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>S.-T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.-M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.-F.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.-J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q.-Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.-J.</given-names></name></person-group><article-title>Intranasal immunization using mannatide as a novel adjuvant for an inactivated influenza vaccine and its adjuvant effect compared with MF59</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0169501</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0169501</pub-id><pub-id pub-id-type="pmid">28052136</pub-id><pub-id pub-id-type="pmcid">PMC5215226</pub-id></element-citation></ref><ref id="B327-pharmaceutics-15-02114"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luczo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bousse</surname><given-names>T.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>N.</given-names></name><name name-style="western"><surname>Neiswanger</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.-X.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wentworth</surname><given-names>D.E.</given-names></name></person-group><article-title>Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00320-9</pub-id><pub-id pub-id-type="pmid">33883559</pub-id><pub-id pub-id-type="pmcid">PMC8060263</pub-id></element-citation></ref><ref id="B328-pharmaceutics-15-02114"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doavi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mousavi</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Kamali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amani</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ramandi</surname><given-names>M.F.</given-names></name></person-group><article-title>Chitosan-based intranasal vaccine against <italic toggle="yes">Escherichia coli</italic> O157: H7</article-title><source>Iran. Biomed. J.</source><year>2016</year><volume>20</volume><fpage>97</fpage><pub-id pub-id-type="pmid">26724233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7508/ibj.2016.02.005</pub-id><pub-id pub-id-type="pmcid">PMC4726890</pub-id></element-citation></ref><ref id="B329-pharmaceutics-15-02114"><label>329.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mann</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Noulin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Catchpole</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stittelaar</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>De Waal</surname><given-names>L.</given-names></name><name name-style="western"><surname>Veldhuis Kroeze</surname><given-names>E.J.B.</given-names></name><name name-style="western"><surname>Hinchcliffe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.</given-names></name><name name-style="western"><surname>Montomoli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Piccirella</surname><given-names>S.</given-names></name></person-group><article-title>Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e93761</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0093761</pub-id><pub-id pub-id-type="pmid">24850536</pub-id><pub-id pub-id-type="pmcid">PMC4029577</pub-id></element-citation></ref><ref id="B330-pharmaceutics-15-02114"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Z.</given-names></name></person-group><article-title>Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization</article-title><source>Biomaterials</source><year>2012</year><volume>33</volume><fpage>2351</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.11.068</pub-id><pub-id pub-id-type="pmid">22192540</pub-id></element-citation></ref><ref id="B331-pharmaceutics-15-02114"><label>331.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svindland</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Jul-Larsen</surname><given-names>&#197;.</given-names></name><name name-style="western"><surname>Pathirana</surname><given-names>R.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Madhun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Montomoli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jabbal-Gill</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name></person-group><article-title>The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine</article-title><source>Influenza Other Respir. Viruses</source><year>2012</year><volume>6</volume><fpage>90</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1111/j.1750-2659.2011.00271.x</pub-id><pub-id pub-id-type="pmid">21749672</pub-id><pub-id pub-id-type="pmcid">PMC4942079</pub-id></element-citation></ref><ref id="B332-pharmaceutics-15-02114"><label>332.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.-B.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.-Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name></person-group><article-title>The mechanism of action of acid-soluble chitosan as an adjuvant in the formulation of nasally administered vaccine against HBV</article-title><source>RSC Adv.</source><year>2016</year><volume>6</volume><fpage>96785</fpage><lpage>96797</lpage><pub-id pub-id-type="doi">10.1039/C6RA14419E</pub-id></element-citation></ref><ref id="B333-pharmaceutics-15-02114"><label>333.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasegawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ichinohe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Strong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>S.i.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chiba</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kurata</surname><given-names>T.</given-names></name></person-group><article-title>Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant</article-title><source>J. Med. Virol.</source><year>2005</year><volume>75</volume><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1002/jmv.20247</pub-id><pub-id pub-id-type="pmid">15543590</pub-id></element-citation></ref><ref id="B334-pharmaceutics-15-02114"><label>334.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takenaka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Haredy</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Tanimoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gomi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akagi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Okuno</surname><given-names>Y.</given-names></name></person-group><article-title>Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection</article-title><source>Clin. Vaccine Immunol.</source><year>2012</year><volume>19</volume><fpage>979</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1128/CVI.00016-12</pub-id><pub-id pub-id-type="pmid">22552600</pub-id><pub-id pub-id-type="pmcid">PMC3393367</pub-id></element-citation></ref><ref id="B335-pharmaceutics-15-02114"><label>335.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kuramitsu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Momose</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kobiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aoshi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Mizukami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hamaguchi</surname><given-names>I.</given-names></name></person-group><article-title>A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>821</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.12.036</pub-id><pub-id pub-id-type="pmid">28063707</pub-id></element-citation></ref><ref id="B336-pharmaceutics-15-02114"><label>336.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.-M.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>S.-M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>P.-Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.-C.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>B.-L.</given-names></name></person-group><article-title>A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>10713</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-28281-5</pub-id><pub-id pub-id-type="pmid">30013088</pub-id><pub-id pub-id-type="pmcid">PMC6048030</pub-id></element-citation></ref><ref id="B337-pharmaceutics-15-02114"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>G.-Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.-K.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.-H.</given-names></name></person-group><article-title>Formulation of SARS-CoV-2 spike protein with CpG oligodeoxynucleotides and squalene nanoparticles modulates immunological aspects following intranasal delivery</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>2539</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14112539</pub-id><pub-id pub-id-type="pmid">36432730</pub-id><pub-id pub-id-type="pmcid">PMC9693849</pub-id></element-citation></ref><ref id="B338-pharmaceutics-15-02114"><label>338.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hamaoka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kainuma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katoh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>T.</given-names></name></person-group><article-title>The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia</article-title><source>Microbiol. Immunol.</source><year>2018</year><volume>62</volume><fpage>774</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1111/1348-0421.12658</pub-id><pub-id pub-id-type="pmid">30378708</pub-id></element-citation></ref><ref id="B339-pharmaceutics-15-02114"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poggio</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>La Torre</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Scodeller</surname><given-names>E.A.</given-names></name></person-group><article-title>Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic <italic toggle="yes">Escherichia coli</italic> challenge</article-title><source>Can. J. Microbiol.</source><year>2006</year><volume>52</volume><fpage>1093</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1139/w06-065</pub-id><pub-id pub-id-type="pmid">17215901</pub-id></element-citation></ref><ref id="B340-pharmaceutics-15-02114"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jearanaiwitayakul</surname><given-names>T.</given-names></name><name name-style="western"><surname>Limthongkul</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaofai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Apichirapokey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chawengkirttikul</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sapsutthipas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sunintaboon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ubol</surname><given-names>S.</given-names></name></person-group><article-title>The STING ligand and delivery system synergistically enhance the immunogenicity of an intranasal spike SARS-CoV-2 vaccine candidate</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>1142</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10051142</pub-id><pub-id pub-id-type="pmid">35625879</pub-id><pub-id pub-id-type="pmcid">PMC9138454</pub-id></element-citation></ref><ref id="B341-pharmaceutics-15-02114"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name></person-group><article-title>Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>2280</fpage><lpage>2287</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.006</pub-id><pub-id pub-id-type="pmid">33731271</pub-id><pub-id pub-id-type="pmcid">PMC7934688</pub-id></element-citation></ref><ref id="B342-pharmaceutics-15-02114"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falkeborn</surname><given-names>T.</given-names></name><name name-style="western"><surname>Asahara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hinkula</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maltais</surname><given-names>A.-K.</given-names></name></person-group><article-title>Comparison of the mucosal adjuvant Endocine&#8482; with two well-known adjuvants: Cholera toxin and alum</article-title><source>Jacobs J. Vaccine Vaccin.</source><year>2015</year><volume>1</volume><fpage>6</fpage></element-citation></ref><ref id="B343-pharmaceutics-15-02114"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.-Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name></person-group><article-title>A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern</article-title><source>Cell. Mol. Immunol.</source><year>2022</year><volume>19</volume><fpage>1279</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1038/s41423-022-00929-3</pub-id><pub-id pub-id-type="pmid">36220993</pub-id><pub-id pub-id-type="pmcid">PMC9552159</pub-id></element-citation></ref><ref id="B344-pharmaceutics-15-02114"><label>344.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Seong</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>G.-J.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Fujihashi</surname><given-names>K.</given-names></name></person-group><article-title>Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>466</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.10.058</pub-id><pub-id pub-id-type="pmid">22051136</pub-id></element-citation></ref><ref id="B345-pharmaceutics-15-02114"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Treanor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>C.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>D.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Linden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fries</surname><given-names>L.</given-names></name></person-group><article-title>Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>254</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.07.088</pub-id><pub-id pub-id-type="pmid">16129526</pub-id></element-citation></ref><ref id="B346-pharmaceutics-15-02114"><label>346.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novotny</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Bakaletz</surname><given-names>L.O.</given-names></name></person-group><article-title>Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable <italic toggle="yes">Haemophilus influenzae</italic></article-title><source>Mucosal Immunol.</source><year>2011</year><volume>4</volume><fpage>456</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1038/mi.2011.6</pub-id><pub-id pub-id-type="pmid">21326197</pub-id><pub-id pub-id-type="pmcid">PMC3118858</pub-id></element-citation></ref><ref id="B347-pharmaceutics-15-02114"><label>347.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riddle</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Maciel</surname><given-names>M.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Porter</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Poole</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Gormley</surname><given-names>R.</given-names></name><name name-style="western"><surname>Laird</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Sebeny</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Dori</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Greenleaf</surname><given-names>M.E.</given-names></name></person-group><article-title>A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic <italic toggle="yes">Escherichia coli</italic> fimbrial tip adhesin with heat-labile enterotoxin with mutation R192G</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>7040</fpage><lpage>7048</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.09.025</pub-id><pub-id pub-id-type="pmid">32978003</pub-id></element-citation></ref><ref id="B348-pharmaceutics-15-02114"><label>348.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stickings</surname><given-names>P.</given-names></name><name name-style="western"><surname>Peyre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coombes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></name><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Sesardic</surname><given-names>D.</given-names></name></person-group><article-title>Transcutaneous immunization with cross-reacting material CRM197 of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine</article-title><source>Infect. Immun.</source><year>2008</year><volume>76</volume><fpage>1766</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1128/IAI.00797-07</pub-id><pub-id pub-id-type="pmid">18227167</pub-id><pub-id pub-id-type="pmcid">PMC2292886</pub-id></element-citation></ref><ref id="B349-pharmaceutics-15-02114"><label>349.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tierney</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beignon</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sesardic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name></person-group><article-title>Transcutaneous immunization with tetanus toxoid and mutants of <italic toggle="yes">Escherichia coli</italic> heat-labile enterotoxin as adjuvants elicits strong protective antibody responses</article-title><source>J. Infect. Dis.</source><year>2003</year><volume>188</volume><fpage>753</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1086/377287</pub-id><pub-id pub-id-type="pmid">12934192</pub-id></element-citation></ref><ref id="B350-pharmaceutics-15-02114"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skountzou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>F.-S.</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>J.</given-names></name><name name-style="western"><surname>Compans</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.-M.</given-names></name></person-group><article-title>Transcutaneous immunization with inactivated influenza virus induces protective immune responses</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>6110</fpage><lpage>6119</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.05.014</pub-id><pub-id pub-id-type="pmid">16766095</pub-id></element-citation></ref><ref id="B351-pharmaceutics-15-02114"><label>351.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name></person-group><article-title>Effective transcutaneous immunization against hepatitis B virus by a combined approach of hydrogel patch formulation and microneedle arrays</article-title><source>Biomed. Microdevices</source><year>2013</year><volume>15</volume><fpage>1077</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1007/s10544-013-9799-z</pub-id><pub-id pub-id-type="pmid">23893014</pub-id></element-citation></ref><ref id="B352-pharmaceutics-15-02114"><label>352.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bal</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.F.A.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bouwstra</surname><given-names>J.A.</given-names></name></person-group><article-title>Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations</article-title><source>Pharm. Res.</source><year>2010</year><volume>27</volume><fpage>1837</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1007/s11095-010-0182-y</pub-id><pub-id pub-id-type="pmid">20559701</pub-id><pub-id pub-id-type="pmcid">PMC2920068</pub-id></element-citation></ref><ref id="B353-pharmaceutics-15-02114"><label>353.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weldon</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Zarnitsyn</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Esser</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Taherbhai</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Koutsonanos</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Vassilieva</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Skountzou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Compans</surname><given-names>R.W.</given-names></name></person-group><article-title>Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e41501</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0041501</pub-id><pub-id pub-id-type="pmid">22848514</pub-id><pub-id pub-id-type="pmcid">PMC3405087</pub-id></element-citation></ref><ref id="B354-pharmaceutics-15-02114"><label>354.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hashizume</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kurita-Ochiai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M.</given-names></name></person-group><article-title>CpG oligodeoxynucleotide is an effective adjuvant for transcutaneous immunization</article-title><source>Int. J. Oral-Med. Sci.</source><year>2007</year><volume>6</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.5466/ijoms.6.91</pub-id></element-citation></ref><ref id="B355-pharmaceutics-15-02114"><label>355.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berry</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Hickey</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Skelding</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rendina</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Hansbro</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Gockel</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Beagley</surname><given-names>K.W.</given-names></name></person-group><article-title>Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against <italic toggle="yes">Chlamydia muridarum</italic> genital tract infection</article-title><source>Infect. Immun.</source><year>2004</year><volume>72</volume><fpage>1019</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.2.1019-1028.2004</pub-id><pub-id pub-id-type="pmid">14742549</pub-id><pub-id pub-id-type="pmcid">PMC321610</pub-id></element-citation></ref><ref id="B356-pharmaceutics-15-02114"><label>356.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belyakov</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ahlers</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Berzofsky</surname><given-names>J.A.</given-names></name></person-group><article-title>Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells</article-title><source>J. Clin. Investig.</source><year>2004</year><volume>113</volume><fpage>998</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1172/JCI20261</pub-id><pub-id pub-id-type="pmid">15057306</pub-id><pub-id pub-id-type="pmcid">PMC379323</pub-id></element-citation></ref><ref id="B357-pharmaceutics-15-02114"><label>357.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beignon</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>F.</given-names></name><name name-style="western"><surname>Eftekhari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Briand</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name></person-group><article-title>A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses</article-title><source>Vet. Immunol. Immunopathol.</source><year>2005</year><volume>104</volume><fpage>273</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2004.12.008</pub-id><pub-id pub-id-type="pmid">15734548</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-15-02114-f001" orientation="portrait"><label>Figure 1</label><caption><p>Schematic illustration of limitations of invasive vaccines.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02114-g001.jpg"/></fig><fig position="float" id="pharmaceutics-15-02114-f002" orientation="portrait"><label>Figure 2</label><caption><p>Schematic illustration of immune responses upon vaccine administration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02114-g002.jpg"/></fig><fig position="float" id="pharmaceutics-15-02114-f003" orientation="portrait"><label>Figure 3</label><caption><p>Schematic illustration of DNA vaccine production methods. Production of circular DNA (<bold>A</bold>) and linear DNA (<bold>B</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02114-g003.jpg"/></fig><fig position="float" id="pharmaceutics-15-02114-f004" orientation="portrait"><label>Figure 4</label><caption><p>Representation of immune responses of an intestinal M cell.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02114-g004.jpg"/></fig><fig position="float" id="pharmaceutics-15-02114-f005" orientation="portrait"><label>Figure 5</label><caption><p>Schematic illustration of mucus-penetrating mechanisms. (<bold>A</bold>) Size-dependent penetration, (<bold>B</bold>) non-reactive coating treatment, and (<bold>C</bold>) permeation enhancer treatment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02114-g005.jpg"/></fig><table-wrap position="float" id="pharmaceutics-15-02114-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-02114-t001_Table 1</object-id><label>Table 1</label><caption><p>Nano- and micro-sized carriers with adjuvanticity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Carriers/Adjuvants</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immune Responses</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Limitations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Status</th></tr></thead><tbody><tr><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Lipid-based carriers</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immune-stimulating complexes (ISCOM)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells [<xref rid="B105-pharmaceutics-15-02114" ref-type="bibr">105</xref>]</p></list-item><list-item><p>Th1 and Th2 activation [<xref rid="B106-pharmaceutics-15-02114" ref-type="bibr">106</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>High dose of saponin is required to manufacture (immunoreactive) [<xref rid="B106-pharmaceutics-15-02114" ref-type="bibr">106</xref>]</p></list-item><list-item><p>Limitation in encapsulation of non-membrane-derived antigens [<xref rid="B106-pharmaceutics-15-02114" ref-type="bibr">106</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical stage [<xref rid="B107-pharmaceutics-15-02114" ref-type="bibr">107</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposome</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Th1 and Th2 activation [<xref rid="B108-pharmaceutics-15-02114" ref-type="bibr">108</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Limitations in the selection of lipid due to rigidity [<xref rid="B109-pharmaceutics-15-02114" ref-type="bibr">109</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In use in the vaccine industry; Pfizer/BioNTech and Moderna (SARS-CoV-2) [<xref rid="B110-pharmaceutics-15-02114" ref-type="bibr">110</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bilosome</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Th1 activation [<xref rid="B111-pharmaceutics-15-02114" ref-type="bibr">111</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>High stability but low immunogenicity [<xref rid="B112-pharmaceutics-15-02114" ref-type="bibr">112</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical stage [<xref rid="B113-pharmaceutics-15-02114" ref-type="bibr">113</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Archaeosomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells [<xref rid="B114-pharmaceutics-15-02114" ref-type="bibr">114</xref>]</p></list-item><list-item><p>Th1 and Th2 activation [<xref rid="B115-pharmaceutics-15-02114" ref-type="bibr">115</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Mechanism-of-action- and safety-related research should be performed [<xref rid="B115-pharmaceutics-15-02114" ref-type="bibr">115</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical stage [<xref rid="B116-pharmaceutics-15-02114" ref-type="bibr">116</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virosomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells [<xref rid="B114-pharmaceutics-15-02114" ref-type="bibr">114</xref>,<xref rid="B117-pharmaceutics-15-02114" ref-type="bibr">117</xref>]</p></list-item><list-item><p>Th1 and Th2 activation [<xref rid="B115-pharmaceutics-15-02114" ref-type="bibr">115</xref>,<xref rid="B117-pharmaceutics-15-02114" ref-type="bibr">117</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Rapid disintegration in the blood [<xref rid="B118-pharmaceutics-15-02114" ref-type="bibr">118</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In use in the vaccine industry; Epaxal<sup>&#174;</sup> and Inflexal<sup>&#174;</sup>V (influenza vaccine) [<xref rid="B119-pharmaceutics-15-02114" ref-type="bibr">119</xref>,<xref rid="B120-pharmaceutics-15-02114" ref-type="bibr">120</xref>]</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Protein-based carriers</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gelatin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells [<xref rid="B121-pharmaceutics-15-02114" ref-type="bibr">121</xref>]</p></list-item><list-item><p>Th1 and Th2 activation [<xref rid="B122-pharmaceutics-15-02114" ref-type="bibr">122</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Large particle size</p></list-item><list-item><p>Rapid degradation [<xref rid="B123-pharmaceutics-15-02114" ref-type="bibr">123</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical stage [<xref rid="B124-pharmaceutics-15-02114" ref-type="bibr">124</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Albumin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells [<xref rid="B125-pharmaceutics-15-02114" ref-type="bibr">125</xref>]</p></list-item><list-item><p>Th1 activation [<xref rid="B126-pharmaceutics-15-02114" ref-type="bibr">126</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Potential immunogenic reaction [<xref rid="B127-pharmaceutics-15-02114" ref-type="bibr">127</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA-approved [<xref rid="B123-pharmaceutics-15-02114" ref-type="bibr">123</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Th1 and Th2 activation [<xref rid="B128-pharmaceutics-15-02114" ref-type="bibr">128</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Low stability [<xref rid="B129-pharmaceutics-15-02114" ref-type="bibr">129</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical stage [<xref rid="B128-pharmaceutics-15-02114" ref-type="bibr">128</xref>]</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Emulsion</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MF59<break/>(oil-in-water emulsion)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells [<xref rid="B130-pharmaceutics-15-02114" ref-type="bibr">130</xref>]</p></list-item><list-item><p>Th2 activation [<xref rid="B130-pharmaceutics-15-02114" ref-type="bibr">130</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Limitation in drug release control</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In use in the vaccine industry; Fluad<sup>&#174;</sup>, Focetria<sup>&#174;</sup>, and Celtura<sup>&#174;</sup> (influenza vaccine) [<xref rid="B130-pharmaceutics-15-02114" ref-type="bibr">130</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AS03<break/>(oil-in-water emulsion)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Th1 and Th2 activation [<xref rid="B131-pharmaceutics-15-02114" ref-type="bibr">131</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Limitation in drug release control</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In use in the vaccine industry; Pandemrix and Arepanrix (influenza vaccin) [<xref rid="B132-pharmaceutics-15-02114" ref-type="bibr">132</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AF03<break/>(oil-in-water emulsion)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Th1 and Th2 activation [<xref rid="B133-pharmaceutics-15-02114" ref-type="bibr">133</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Lower immune response compared to AS03 [<xref rid="B133-pharmaceutics-15-02114" ref-type="bibr">133</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In use in the vaccine industry; Humenza&#8482; (influenza vaccine) [<xref rid="B134-pharmaceutics-15-02114" ref-type="bibr">134</xref>]</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Polymer</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poly(lactic-co-glycolic acid) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells [<xref rid="B135-pharmaceutics-15-02114" ref-type="bibr">135</xref>]</p></list-item><list-item><p>Th1 and Th2 activation (Th2 dominant) [<xref rid="B136-pharmaceutics-15-02114" ref-type="bibr">136</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Slow and non-tunable degradation rate [<xref rid="B137-pharmaceutics-15-02114" ref-type="bibr">137</xref>]</p></list-item><list-item><p>Degradation into acidic byproduct (inflammation) [<xref rid="B138-pharmaceutics-15-02114" ref-type="bibr">138</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA-approved</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poly(lactic acid) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells</p></list-item><list-item><p>Th1 and Th2 activation [<xref rid="B139-pharmaceutics-15-02114" ref-type="bibr">139</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Degradation into acidic byproduct (inflammation) [<xref rid="B140-pharmaceutics-15-02114" ref-type="bibr">140</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA-approved</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Th1 and Th2 activation [<xref rid="B141-pharmaceutics-15-02114" ref-type="bibr">141</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Reduction in CD8 T cell response [<xref rid="B142-pharmaceutics-15-02114" ref-type="bibr">142</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA-approved</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dextran (acetalated)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells [<xref rid="B137-pharmaceutics-15-02114" ref-type="bibr">137</xref>]</p></list-item><list-item><p>Th1 and Th2 activation [<xref rid="B137-pharmaceutics-15-02114" ref-type="bibr">137</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Fast and tunable degradation rate [<xref rid="B137-pharmaceutics-15-02114" ref-type="bibr">137</xref>]</p></list-item><list-item><p>Degradation into pH-neutral byproduct [<xref rid="B137-pharmaceutics-15-02114" ref-type="bibr">137</xref>,<xref rid="B138-pharmaceutics-15-02114" ref-type="bibr">138</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA-approved</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Inorganic</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Calcium phosphate nanoparticles</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells [<xref rid="B102-pharmaceutics-15-02114" ref-type="bibr">102</xref>]</p></list-item><list-item><p>Th1 and Th2 activation [<xref rid="B143-pharmaceutics-15-02114" ref-type="bibr">143</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Low antigen loading capacity and rapid aggregation [<xref rid="B102-pharmaceutics-15-02114" ref-type="bibr">102</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA-approved</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silica nanoparticles</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells [<xref rid="B144-pharmaceutics-15-02114" ref-type="bibr">144</xref>]</p></list-item><list-item><p>Th1 and Th2 activation [<xref rid="B144-pharmaceutics-15-02114" ref-type="bibr">144</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Hemolysis through interaction of silanol groups and the phospholipids of the red blood cells [<xref rid="B145-pharmaceutics-15-02114" ref-type="bibr">145</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical stage [<xref rid="B146-pharmaceutics-15-02114" ref-type="bibr">146</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold nanoparticles</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Activation of CD8 T cells [<xref rid="B147-pharmaceutics-15-02114" ref-type="bibr">147</xref>]</p></list-item><list-item><p>Th1 and Th2 activation [<xref rid="B148-pharmaceutics-15-02114" ref-type="bibr">148</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Poor biodegradability [<xref rid="B149-pharmaceutics-15-02114" ref-type="bibr">149</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA-approved</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-15-02114-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-02114-t002_Table 2</object-id><label>Table 2</label><caption><p>Adjuvants for oral vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Status</th></tr></thead><tbody><tr><td rowspan="13" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Toxin-based adjuvant</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heat-labile enterotoxin (LT) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine [<xref rid="B275-pharmaceutics-15-02114" ref-type="bibr">275</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Helicobacter pylori</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical</td></tr><tr><td rowspan="7" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Double-mutant heat-labile toxin (dmLT)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ETEC vaccine (ACE527) [<xref rid="B276-pharmaceutics-15-02114" ref-type="bibr">276</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Live attenuated vaccine</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enterotoxigenic <italic toggle="yes">Escherichia coli</italic> (ETEC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ETVAX [<xref rid="B277-pharmaceutics-15-02114" ref-type="bibr">277</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enterotoxigenic <italic toggle="yes">Escherichia coli</italic> (ETEC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine [<xref rid="B278-pharmaceutics-15-02114" ref-type="bibr">278</xref>]</p></list-item><list-item><p>Subunit vaccine [<xref rid="B279-pharmaceutics-15-02114" ref-type="bibr">279</xref>,<xref rid="B280-pharmaceutics-15-02114" ref-type="bibr">280</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Helicobacter pylori</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Subunit vaccine [<xref rid="B281-pharmaceutics-15-02114" ref-type="bibr">281</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Clostridium difficile</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Subunit vaccine [<xref rid="B278-pharmaceutics-15-02114" ref-type="bibr">278</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Clostridium tetani</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Subunit vaccine [<xref rid="B282-pharmaceutics-15-02114" ref-type="bibr">282</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Live attenuated vaccine [<xref rid="B283-pharmaceutics-15-02114" ref-type="bibr">283</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Salmonella enteritidis</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Multiple-mutated cholera toxin (mmCT)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine [<xref rid="B284-pharmaceutics-15-02114" ref-type="bibr">284</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Helicobacter pylori</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated bacteria (Vibrio cholerae) [<xref rid="B285-pharmaceutics-15-02114" ref-type="bibr">285</xref>]</p></list-item><list-item><p>Subunit vaccine (influenza virus) [<xref rid="B285-pharmaceutics-15-02114" ref-type="bibr">285</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Vibrio cholerae</italic> and influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Recombinant cholera toxin B subunit (rCTB)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dukoral [<xref rid="B286-pharmaceutics-15-02114" ref-type="bibr">286</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Vibrio cholerae</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prequalified by WHO</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Live bacteria [<xref rid="B287-pharmaceutics-15-02114" ref-type="bibr">287</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Helicobacter pylori</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholera-toxin-derived adjuvant (CTA1DD) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTA1-3M2e-DD [<xref rid="B288-pharmaceutics-15-02114" ref-type="bibr">288</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Subunit vaccine</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="6" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Polysaccharide-based adjuvant</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine [<xref rid="B289-pharmaceutics-15-02114" ref-type="bibr">289</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Helicobacter pylori</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&#946;-glucans</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine [<xref rid="B290-pharmaceutics-15-02114" ref-type="bibr">290</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Subunit vaccine [<xref rid="B291-pharmaceutics-15-02114" ref-type="bibr">291</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Salmonella Typhi</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine [<xref rid="B292-pharmaceutics-15-02114" ref-type="bibr">292</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Bacillus anthracis</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arabinoxylan (AX) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine [<xref rid="B290-pharmaceutics-15-02114" ref-type="bibr">290</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacterial exopolysaccharide (EPS) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine [<xref rid="B290-pharmaceutics-15-02114" ref-type="bibr">290</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Lipid-based adjuvant</bold>
</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&#945;-galactosyl ceramide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Subunit vaccine [<xref rid="B293-pharmaceutics-15-02114" ref-type="bibr">293</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human immunodeficiency virus </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine [<xref rid="B294-pharmaceutics-15-02114" ref-type="bibr">294</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Vibrio cholerae</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Inactivated vaccine [<xref rid="B295-pharmaceutics-15-02114" ref-type="bibr">295</xref>]</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Helicobacter pylori</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-15-02114-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-02114-t003_Table 3</object-id><label>Table 3</label><caption><p>Adjuvants for intranasal vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Status</th></tr></thead><tbody><tr><td rowspan="9" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Toxin-based adjuvant</bold>
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Heat-labile enterotoxin (LT)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nasalflu (Berna Biotech) [<xref rid="B316-pharmaceutics-15-02114" ref-type="bibr">316</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B317-pharmaceutics-15-02114" ref-type="bibr">317</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enzymatic A1 domain of LT (LTA1) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B318-pharmaceutics-15-02114" ref-type="bibr">318</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Cholera-toxin-derived adjuvant (CTA1DD) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B319-pharmaceutics-15-02114" ref-type="bibr">319</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B320-pharmaceutics-15-02114" ref-type="bibr">320</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human respiratory syncytial virus (hRSV)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B321-pharmaceutics-15-02114" ref-type="bibr">321</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Mycobacterium tuberculosis</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B322-pharmaceutics-15-02114" ref-type="bibr">322</xref>,<xref rid="B323-pharmaceutics-15-02114" ref-type="bibr">323</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Cholera toxin B subunit (CTB)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated vaccine [<xref rid="B323-pharmaceutics-15-02114" ref-type="bibr">323</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B324-pharmaceutics-15-02114" ref-type="bibr">324</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="9" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Polysaccharide-based adjuvant</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RS09 (Ala-Pro-Pro-His-Ala-Leu-Ser) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral vector vaccine [<xref rid="B325-pharmaceutics-15-02114" ref-type="bibr">325</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human immunodeficiency virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mannatide (polyactin A)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B326-pharmaceutics-15-02114" ref-type="bibr">326</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advax&#8482;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated [<xref rid="B327-pharmaceutics-15-02114" ref-type="bibr">327</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Chitosan</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-viral vector vaccine [<xref rid="B328-pharmaceutics-15-02114" ref-type="bibr">328</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Enterohemorrhagic Escherichia coli</italic> (EHEC) O157:H7</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B329-pharmaceutics-15-02114" ref-type="bibr">329</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B330-pharmaceutics-15-02114" ref-type="bibr">330</xref>,<xref rid="B331-pharmaceutics-15-02114" ref-type="bibr">331</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B332-pharmaceutics-15-02114" ref-type="bibr">332</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Chitin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated [<xref rid="B323-pharmaceutics-15-02114" ref-type="bibr">323</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B333-pharmaceutics-15-02114" ref-type="bibr">333</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="8" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Nucleotide-based adjuvant, synthetic adjuvant</bold>
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Synthetic double-stranded RNA polyriboinosinic acid-polyribocytidylic acid [poly (I:C)]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated vaccine [<xref rid="B323-pharmaceutics-15-02114" ref-type="bibr">323</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B334-pharmaceutics-15-02114" ref-type="bibr">334</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B335-pharmaceutics-15-02114" ref-type="bibr">335</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B336-pharmaceutics-15-02114" ref-type="bibr">336</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enterovirus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B337-pharmaceutics-15-02114" ref-type="bibr">337</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-viral vector vaccine [<xref rid="B338-pharmaceutics-15-02114" ref-type="bibr">338</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pseudomonas aeruginosa</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-viral vector vaccine [<xref rid="B339-pharmaceutics-15-02114" ref-type="bibr">339</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Escherichia coli</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclic guanosine monophosphate-adenosine monophosphate (2&#8242;3&#8242;-cGAMP or cGAMP)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B340-pharmaceutics-15-02114" ref-type="bibr">340</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Aluminum-based adjuvant</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alhydrogel<sup>&#174;</sup> (aluminum oxyhydroxide gel)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B341-pharmaceutics-15-02114" ref-type="bibr">341</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Lipid-based adjuvant</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endocine&#8482; (lipids monoolein and oleic acid)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B342-pharmaceutics-15-02114" ref-type="bibr">342</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical </td></tr><tr><td rowspan="6" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Protein-based adjuvant</bold>
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Flagellin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B343-pharmaceutics-15-02114" ref-type="bibr">343</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B344-pharmaceutics-15-02114" ref-type="bibr">344</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poly(&#947;-glutamic acid)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B334-pharmaceutics-15-02114" ref-type="bibr">334</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Proteosome</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B273-pharmaceutics-15-02114" ref-type="bibr">273</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B345-pharmaceutics-15-02114" ref-type="bibr">345</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protollin<sup>TM</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B310-pharmaceutics-15-02114" ref-type="bibr">310</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-15-02114-t004" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-02114-t004_Table 4</object-id><label>Table 4</label><caption><p>Adjuvants for transcutaneous vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Administration Method</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Status</th></tr></thead><tbody><tr><td rowspan="7" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Toxin derivates</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Double-mutant heat-labile toxin (dmLT)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B346-pharmaceutics-15-02114" ref-type="bibr">346</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nontypeable Haemophilus influenzae (NTHI)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydration (sterile, pyrogen-free 0.9% sodium chloride)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Single-mutant heat-labile enterotoxin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B347-pharmaceutics-15-02114" ref-type="bibr">347</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enterotoxigenic Escherichia coli (ETEC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydration and abrasion (70% isopropyl alcohol, glycerol 10%, and 10 swipes of medical grade sandpaper)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B348-pharmaceutics-15-02114" ref-type="bibr">348</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Corynebacterium diphtheriae</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydration (sterile PBS)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B349-pharmaceutics-15-02114" ref-type="bibr">349</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Clostridium tetani</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydration</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Cholera toxin (CT)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B272-pharmaceutics-15-02114" ref-type="bibr">272</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Corynebacterium diphtheriae</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hollow microneedle (pre-treatment purpose)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine [<xref rid="B350-pharmaceutics-15-02114" ref-type="bibr">350</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydration (saline-soaked gauze)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholera toxin B subunit (CTB)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B351-pharmaceutics-15-02114" ref-type="bibr">351</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hepatitis B<break/>virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid microneedle and hydrogel patch</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Polysaccharide-based adjuvant</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Chitosan</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td><td align="left" valign="middle" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B352-pharmaceutics-15-02114" ref-type="bibr">352</xref>]</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Corynebacterium diphtheriae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Hollow microneedle (pre- or post-treatment purpose)</td><td align="left" valign="middle" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="6" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Nucleotide-based adjuvant, synthetic adjuvant</bold>
</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Synthetic double-stranded RNA polyriboinosinic acid-polyribocytidylic acid [poly (I:C)]</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B353-pharmaceutics-15-02114" ref-type="bibr">353</xref>]</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coated microneedle</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B354-pharmaceutics-15-02114" ref-type="bibr">354</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Clostridium tetani</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydration (PBS-drenched<break/>wound plaster)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B272-pharmaceutics-15-02114" ref-type="bibr">272</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Corynebacterium diphtheriae</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hollow microneedle (pre-treatment purpose)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-viral vector vaccine [<xref rid="B355-pharmaceutics-15-02114" ref-type="bibr">355</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Chlamydia muridarum</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydration (sterile PBS)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B356-pharmaceutics-15-02114" ref-type="bibr">356</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human immunodeficiency virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydration (saline-drenched gauze)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B357-pharmaceutics-15-02114" ref-type="bibr">357</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foot-and-mouth disease<break/>virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydration</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Immune-stimulating complexes (ISCOMs)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quil A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine [<xref rid="B272-pharmaceutics-15-02114" ref-type="bibr">272</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Corynebacterium diphtheriae</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hollow microneedle (pre-treatment purpose)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In preclinical</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>